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Abstract
a-Synuclein (aS) is a 14.5 kDa neuronal protein associated with Parkinson’s disease 
(PD) and related disorders. Aggregated protein inclusions called Lewy bodies found in 
the brain in PD contain aS. Rare inherited forms of early-onset PD are caused by 
autosomal dominant mutations in aS or by autosomal recessive mutations in parkin, a 
53kDa E3 ubiquitin ligase. aS and parkin have been reported to interact functionally, 
with parkin ubiquitinating a glycosylated, heavier 22-24 KDa form of aS  (aSp22).
ELISA assays were developed to investigate if  parkin interacts with a-synuclein in 
human blood plasma. Immunoprecipitation followed by immunoblotting techniques 
were utilised to first capture and then assess the molecular weight o f the complex. Ion 
exchange chromatography and gel-filtration chromatography allowed the complex to 
be further isolated and characterised.
ELISA assays detected the aS/parkin complex in plasma from patients with PD and 
controls. The aS/parkin complex was isolated from plasma by immunoprecipitation, 
and immunoblotting revealed the aS to be the normal 14.5 kDa form. Application o f 
plasma to an ion exchange column allowed isolation o f the complex.
Autopsy studies have shown that about 55% of patients with frontotemporal lobar 
degeneration (FTLD) and 25% of patients with Alzheimer’s disease (AD) harbour 
TDP-43 immunoreactive pathological changes in their brains. Again, ELISAs were 
developed to investigate whether TDP-43 wras present, or indeed increased amounts 
detected, in plasma. Elevated levels o f TDP-43 protein were detected in plasma of 
46% patients with FTLD with clinical frontotemporal dementia (FTD) and 22%
patients with AD, compared to 8% of control subjects. The proportions of patients 
with FTD and AD showing raised plasma TDP-43 levels correspond closely to those 
proportions known from autopsy studies to contain TDP-43 pathological changes in 
their brains. Raised TDP-43 plasma levels may thereby reflect TDP-43 pathology 
within the brain.
This study has confirmed that aS and parkin do interact in biological samples. 
However, the target for parkin does not appear to be the reported 22-24 kDa 
glycosylated isoform of aS, but the unmodified protein. For the first time, the 
existence of parkin and the complex has been demonstrated in human plasma. Plasma 
TDP-43 levels may be a biomarker that can provide a laboratory test capable of 
identifying the presence of TDP-43 brain pathology in neurodegenerative disease 
during life. These findings may prove to be useful in the diagnosis of 
neurodegenerative diseases.
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1.1 Abnormal protein aggregation and neurodegenerative disorders
The reasoning around neurodegenerative disorders has changed in recent years, as it 
became clear that most of them feature a degree of protein aggregation or abnormal 
protein misfolding (Ingelsson et al. 2005). For example, the protein tau is important 
both in the number of diseases in which it is implicated, and also by the number of 
individuals that it affects worldwide. Tau is an important component in cell 
cytoskeletal physiology forming the neurofibrillary tangles of Alzheimer's disease 
(AD), Pick's disease, progressive supranuclear palsy, frontotemporal dementia (FTD), 
corticobasal degeneration, postencephalitic parkinsonism, and others. The next most 
common protein in epidemiological terms is said to be p-amyloid (A|3), which fonns 
the amyloid plaques of AD and then a-synuclein which fonns the aggregates in 
Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy 
(MSA) and a few others (see table 1.1). a-synuclein and tau may interact to produce 
an increased risk of PD (Golbe et al. 2001). There is only a partial overlap between the 
cells in which the protein aggregates, and the cells that degenerate. The correlation 
between the amount of protein misfolding/aggregation and the severity of disease has 
not been established. Moreover, it is not known whether the protein aggregation 
actually results in neurodegeneration, or conversely results from it. However, it is 
most likely that inclusion bodies and other visible protein aggregates represent an end 
stage of a series of molecular mechanisms, and that earlier steps in the cascade may be 
more directly tied to pathogenesis than the inclusions themselves (Ross and Poirier 
2004). Variations in genetics in some diseases can help explain the pathogenesis of the 
more common sporadic forms.
Huntingtins disease (HD), a progressive neurodegenerative disorder, is caused by such 
a variation in genetics, a repeat CAG coding for polyglutamate in the amino terminus 
of the huntingtin protein. Polyglutamate lengths of 36 or more are responsible for
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causing the disease, and those of less than 36 do not (Scherzinger et al. 1999). There is 
a direct correlation between the number required for aggregation in vitro and those 
required for disease in humans and the longer the repeats, the earlier the onset of 
disease. HD is a progressive neurodegenerative disorder which is caused by a 
mutation in one gene. However, the picture is far from clear, as neurons with 
inclusions do not correlate exactly with the regions of the brain that degenerate 
(Vonsattel et al. 1985), although there is a good relationship between the CAG repeat 
length and the density of inclusions.
AD is a late-onset dementia with progressive loss of memory, task performance, 
speech and the ability to recognise people and objects. There is degeneration of 
neurons in the basal forebrain and hippocampus, along with altered neuronal 
connections and synaptic plasticity (Hardy and Selkoe 2002). AD aggregates come in 
mainly two forms. Extracellular aggregates known as neuritic plaques are mainly 
composed of |3A, which has its origin from the proteolytic processing of the amyloid 
precursor protein (APP). Also, there are intracellular aggregates of micro-tubule- 
associated protein tau, named neurofibrillary tangles. AD pathogenesis has been 
correlated with genetic mutations responsible for familial fonns of the disease (Ingram 
and Spillantini 2002; Goedert 2004). These rare mutations are within presenilins, 
proteins which are involved in APP cleavage, and also in APP itself. Furthermore, 
tauopathies such as FTD can be caused by mutations in the tau protein.
Amytrophic lateral sclerosis (ALS) is caused by degeneration of lower motor 
neurones in the lateral horn of the spinal cord and upper motor neurons of the cerebral 
cortex. This fatal disease results in progressive motor weakness (Cleveland and 
Rothstein 2001). Mutations in the superoxide dismutase (SOD1) gene can cause rare 
early-onset familial fonns of the disease. Disease pathology does not appear to be due 
to any alteration in SOD1 enzyme activity, although transgenic mice over expressing 
the mutated enzyme have cytoplasmic inclusions containing aggregates of the SOD1 
protein (Rakhit et al. 2002). SOD1 ubiquitinated aggregates are found in the brains of 
individuals with the mutation, although it is not usually detected in sporadic fonns of 
the disease. SOD1 does not usually form fibrillar structures in vitro. Recently, TDP- 
43, an RNA-binding and DNA-binding protein encoded by the TAR DNA-binding 
protein gene (TARDBP) has revealed that mutations in this gene might cause
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neurodegeneration through both gains and losses of function. The finding of 
pathogenic mutations in TARDBP implicates TDP-43 as an active mediator of 
neurodegeneration in ALS and other TDP-43 proteinopathies (Van Deerlin et al. 
2008).
Prion disease can either be sporadic, be caused by environmental transmission or by 
genetic mutations (Prusiner 2001). Environmentally, the disease can be passed on by 
eating prion particles derived from infected brain material, or surgically via 
unsterilized surgical instruments. Genetically, prion disease can be caused by point 
mutations in the prion gene, and therefore an altered prion protein. Protein aggregation 
is caused by the abnormally folded prion protein, and is both intracellular and 
extracellular (Ma and Lindquist 2002; Ma et al. 2002).
Aggregates usually consist of fibres containing misfolded protein with f3-sheet 
conformation, termed amyloid. The classical definition of amyloid is an extracellular, 
proteinaceous deposit, exhibiting cross-beta structure due to misfolding of unstable 
proteins. Recently this definition has come into question as some classic, amyloid 
species have been observed in distinctly intracellular locations, which may be termed 
“amyloid-like” (Sunde et al. 1997).
The proteins implicated in neurodegenerative diseases often appear to be natively 
unfolded (Uversky 2003). Amyloid fibrils are the most characteristic aggregates, 
existing as filamentous structures with a width of around 10 nm and a length of 0.1-10 
pm. The initiation of the aggregation process in a cell may be an event of “seeded 
polymerisation” (Dobson 2004). It is possible that an increase in protein concentration 
could promote aggregation. Familial PD can be caused by duplication or triplication 
of the a-synuclein locus which causes altered dosage (Singleton and Gwinn-Hardy 
2004). It is known that individuals with Down’s syndrome, who carry an extra copy of 
the APP locus on chromosome 21, often have early deposition of AJ3 plaques. A 
mutation in a protein coding sequence may result in a primary structure which is more 
prone to aggregation, or changes in the promoter sites of disease-associated genes may 
increase transcription and therefore protein concentrations.
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Table 1.1 Neurodegenerative diseases, proteins and pathology
D isorder Aetiology Pathology Disease protein
Huntington’s 
disease (HD)
Huntingtin (dominant) Intranuclear inclusions, 
cytoplasmic aggregates




Sporadic (Apiloprotein E risk 
factor)
Amyloid precursor protein (APP) 
(dominant)
Presenilin 1,2 (dominant)




Ap peptide (from APP) and 







Parkin (also DJ-1, P1NK1)
Lewy bodies, Lewy neurites 
in the substantia nigra 
Similar to sporadic 















Superoxide dismutase-1 (SOD-1) 
(dominant)









Sporadic, genetic and infectious Spongiform degeneration, 










In general, sporadic neurodegenerative diseases are associated with aging, which is 
often coupled to oxidative protein modifications. These covalent protein modifications 
may promote aggregation, for example, in the case of a-synuclein which can be 
subject to oxidative modification via dopamine adducts (Conway et al. 2001) and 
where oxidative stresses are involved in mechanisms underlying the pathogenesis of 
glial cell inclusions in MSA.
The a-synuclein from Lewy bodies (LB’s), associated with PD pathology, is 
extensively phosphorylated at Ser 129 (Okochi et al. 2000; Iwatsubo 2003). 
Investigations using cell culture suggest this phosphorylation strongly modulates 
interactions between synphilin-1 and a-synuclein, and subsequently inclusion 
fonnation. Therefore, it is possible that phosphorylation may have a role in LB 
formation. Phosphorylation is also implicated in AD as a high proportion of 
neurofibrillary tangles contain hyperphosphorylated tau protein. Also, it is suggested 
that nitrative stresses are involved in mechanisms underlying the pathogenesis of LB’s 
in PD, as well as a-synuclein pathologies in other synucleinopathies (Giasson et al. 
2000; Souza et al. 2000).
There may be other covalent protein modifications involved in protein aggregation. 
HD is characterised by the accumulation of a huntingtin protein, which contains an 
abnormal polyglutamine expansion. A pathogenic fragment of huntingtin can be 
modified either by small ubiquitin-like modifier (SUMO)-l, or by ubiquitin, on 
identical lysine residues (Steffan et al. 2004). The role of ubiquitin will be described 
in more detail later (see section 1.2).
Some neurodegenerative diseases involve proteolytic cleavage, as with A|3, the main 
component of the cerebral plaques found in the brains of patients with AD. This 
insoluble 40 to 42 amino acid peptide is fonned by the cleavage of APP, although this 
can also be cleaved normally into a non-amyloidogenic peptide. When APP is intact it 
shows little tendency to aggregate, but the small Ap peptide has a high tendency to do 
so (with AfUo being less toxic than AP42) (Esler and Wolfe 2001). As previously 
mentioned earlier, in HD, proteolytic cleavage may be involved in protein 
aggregation. Short N-terminal fragments of huntingtin containing the expanded 
polyglutamine repeats are a good deal more toxic to cells than the longer or full length
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huntingtin (de Almeida et al. 2002). These N-terminal huntingtin fragments can 
conformationally change to form polyglutamate aggregates (Poirier et al. 2002). 
Regarding PD, the role of proteolytic cleavage is less well established, in as much as it 
is known that LB’s contain both N and C terminal fragments, as well as other 
truncated fragments, although the aggregation process can only be surmised (Lee et al. 
2004).
And so, it is known that abnormal deposition of insoluble protein aggregates or 
inclusion bodies within CNS cells are commonly associated with many 
neurodegenerative diseases. Most of these protein deposits contain ubiquitinated 
proteins. These protein aggregates are sometimes believed to result from structural 
changes in the protein substrates which may in itself promote aggregation, or 
alternatively, it may prevent recognition and degradation by the ubiquitin-proteasome 
pathway (UPP). The UPP is the main non-lysosomal degradation pathway for 
intracellular proteins. Impaired proteolysis from malfunction or overload of the UPP 
might contribute to the synaptic dysfunction seen early in neurodegenerative diseases.
1,2 The Ubiquitin-Proteasome Pathway
Proteolysis by the UPP involves two main steps: ubiquitination followed by 
degradation. A de-ubiquitination step also plays an important role in this pathway as it 
removes the ubiquitin flag for recycling.
The small 76 amino acid protein ubiquitin (Ub) can form polyubiquitin chains. These 
chains are attached to target proteins for proteasomal degradation and this is achieved 
by the successive attachment of Ub monomers, by an isopeptide bond formed between 
the side chain of Lys48 in one ubiquitin and the carboxyl group of the C-terminal 
Gly76 of a neighbouring Ub. Attachment of polyubiquitin chains to lysine residues on 
a protein results in at least a 10-fold increase in its degradation rate (Beal et al. 1996).
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The polyubiquitination of proteins is a complex progression of four steps (see figure 
1.1).
1. A high-energy thioester bond is formed between Ub and an ubiquitin- 
activating enzyme (El) in a reaction that requires ATP hydrolysis.
2. A thioester bond is formed between the activated ubiquitin and ubiquitin- 
conjugating enzymes (E2).
3. The carboxyl tenninal of Ub is covalently attached to the protein substrate, by 
ubiquitin ligases (E3), which confer substrate specificity to the UPP. 
Generally, the first ubiquitin conjugated to a protein is attached to the e-amino 
group of substrate lysines via an isopeptide bond. (In some cases, ubiquitin can 
be transferred directly to the protein substrate by ubiquitin-conjugating 
enzymes (E2).)
4. Multiubiquitin chains are assembled by a family of ubiquitination factors (E4) 
that produces longer Ub-chains (Koegl et al. 1999).
While the number of El enzymes is only small, there are many E2 and E3 enzymes, 
(around 50 and 1,000 respectively, in humans) possibly indicating that this pathway 
operates through selective proteolysis. E3 proteins, e.g. parkin implicated in PD, 
recognise specific protein substrates for ubiquitination and then ligate Ub to the 
substrate.
The covalent binding of Ub to proteins flags them for degradation by the 26S 
proteasome, a multicomponent enzymatic complex with a molecular mass of 
approximately 2,000 kDa (DeMartino and Slaughter 1999) (see figure 1.2). The 26S 
proteasome includes two main units. The 20S particle, known as the 20S proteasome, 
is the catalytic core, and the 19S particle, known as PA700, is the regulatory 
component.
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Figure 1.1 The Ubiquitin-Proteasome Pathway
This pathway functions widely in intracellular protein turnover. It plays a central role in degradation of 
short-lived and regulatory proteins important in a variety of basic cellular processes. (Taken from
www.bostonbiochem.com/upp.php)
The 20S proteasome hydrolyses most of the peptide bonds in the protein to be 
degraded (Orlowski et al. 1993). The particle is composed of 28 subunits arranged in 
four heptameric-stacked rings, forming a cylindrical structure with a hollow centre 
where proteolysis occurs (see figure 1.2). The smaller 19S particle gives 
ubiquitin/ATP-dependency to proteolysis by the 26S proteasome (Orlowski et al. 
1993). It contains around 15 subunits, including ATPases, polyubiquitin-binding 
subunits and a de-ubiquitinating enzyme. The subunits in the 19S particle are 
distributed into a cap and core arrangement, with the cap required for ubiquitin/ATP- 
dependent peptide bond hydrolysis (Glickman et al. 1998). The association between 
the 20S and the 19S particles in the cell is a dynamic process requiring ATP- 
hydrolysis.
Fluorescent labelling of the two particles suggest that proteasomal proteolysis mainly 
occurs at the rough ER/nuclear envelope region of the cell (Enenkel et al. 1999). 
Functionally inefficient proteins, misfolded proteins or unassembled secretory 
proteins from the endoplasmic reticulum are degraded by the proteolytic pathway, 
which thus prevents a potentially lethal aggregation of abnormal proteins (Plemper 
and Wolf 1999). It is pointed out that although this UPP degradation does not appear 
to be essential for the viability of the cell, its importance is underlined by it being 
linked to many disease states (Plemper and Wolf 1999).
The function of inclusion bodies in neuronal cells and their role in neurodegenerative 
disease is not clear. The formation of these inclusions may be an attempt by the cell to 
sequester these ubiquitinated, abnormal proteins out of harms way, as they have not 
been successfully degraded by the UPP. And it could be surmised that these inclusions 
will eventually impede the normal functioning of the cell, and could contribute to cell 
death. It would seem logical that the size of the inclusions, and their abundance, 
would be a factor regarding their toxicity to the cell.
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Figure 1.2 The 26S proteasome
The 26S proteasome binds the ubiquitin chain, using ATP to unfold and translocate the substrate into 
the 20S core particle for degradation (taken from (Goldberg 2005)). A chain of at least four ubiquitin 
moieties is required for substrate recognition by the 26S proteosome complex. The complex consists of 
a 19S ‘cap’ and a 20S proteolytic core. The ‘cap’ cleaves the ubiquitins from the substrate, unfolds the 
protein and channels it through to the proteolytic core. Here, three peptidases actively cleave the 
polypeptide into short peptides. As well as this 26S proteosome, there are many different proteins that 
associate transiently with this unit, further increasing the complexity of the system (Glickman and
Ciechanover 2002).
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Inclusion bodies can be found in different areas within the cells, with some located in 
the cytoplasm of neurones in certain diseases such as PD and others being within the 
nucleus, such as in FTLD. It is known that molecules of a molecular weight over 
70kDa cannot diffuse freely through the cell’s nuclear envelope, including neuronal 
cells (Trushina et al. 2003). As most ubiquitinated proteins are likely to have a MW in 
excess of this amount, it is unlikely that the complexes will passively diffuse from the 
cytoplasm into the nucleus, or visa versa. This would only be possible if the nuclear 
envelope was disrupted in some way. It can be surmised that the sub-cellular 
distribution of protein aggregates is determined by aggregate size, nuclear diffusion 
limits and nuclear membrane integrity.
1.3 Parkinson’s Disease- An overview
1.3.1 Parkinson’s disease
Parkinson’s disease (PD) is defined as a disorder that mainly affects individuals of 
middle to old age. PD is the second most common neurodegenerative disorder after 
AD, with a worldwide distribution and no gender preference (Wood 1997). The 
prevalence is 0.1-0.2% overall, but this increases to 1.4% amongst 55 year olds and to 
3.4% amongst 75 year olds. The disease is characterised by severe motor symptoms 
including resting tremor, muscle rigidity and slowness of voluntary movement. A 
number of patients exhibit further symptoms of postural imbalance, gait disturbance 
and a mask-like facial expression. Others can show non-motor symptoms including, 
anxiety, depression, dementia and psychosis, in advanced stages of the disease.
Friedrich Lewy was the first to describe the main pathological feature of PD, the 
spherical intracytoplasmic inclusions. Tretiakoff named them Lewy bodies, and 
showed that they are particularly numerous in the substantia nigra pars compacta. This 
region of the brain is concentrated with dopaminergic neurones that project into the 
striatum, the major area of input from the basal ganglia. Death of the dopaminergic 
neurones of the substantia nigra (SN) leads to loss of dopamine (DA), 3,4- 
dihydroxyphenyl acetate, homovanillic acid, tyrosine hydroxylase and the dopamine
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transporter, resulting in severe DA deficiency and the clinical symptoms of PD (Fomo 
1996).
Electron microscopy in the 1960’s revealed that LB’s contained abnonnal filaments, 
although the biochemical composition of these inclusions remained unknown until 
1997, when Goedert and collegues showed that they were immunoreactive for the 
protein a-synuclein (Spillantini et al. 1997). LB’s (see figure 1.3) also contain 
neurofilaments, components of the UPP, heat-shock proteins, lipids and carbohydrates 
(Olanow et al. 2004).
a-synuclein immunoreactive inclusions are found in other neurodegenerative diseases 
and together are referred to as the “synucleinopathies”. These disorders include DLB, 
MSA, neurodegeneration with brain iron accumulation type 1 and the parkinsonism- 
dementia complex of Guam (Goedert 2001).
Clinically normal individuals are known to have LBs in their brains. As many as 8- 
12% of normal people over 60 years of age have LBs in brainstem nuclei, which is 
often termed incidental Lewy Body disease (iLBD) (Gibb and Lees 1988; Mikolaenko 
et al. 2005). When the sample group includes individuals with dementia, then the 
frequency increases to over 30% (Jellinger 2004). The areas of the brain that are 
affected are the same as in PD. It is suggested that iLBD represents preclinical PD 
rather than non-specific changes related to aging (Dickson et al. 2008).
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Figure 1.3 The Lewy body
A spherical Lewy body (LB) in a dopaminergic neuron, in the substantia nigra from an individual who 
died having sporadic PD, was shown using a fluorescent-based multiple immunostaining protocol. Red 
fluorescence (Alexa Fluor 594), green fluorescence (Alexa Fluor 488) and blue fluorescence (Hoescht 
3358) represent antibodies to ubiquitinated proteins, a-synuclein and cell nuclei (N) respectively. The 
predominance of ubiquitinated proteins was noted and that a-synuclein is largely present in the 
periphery of the Lewy body. Note also the presence of a trail and possibly transport of small aggregates 
of ubiquitinated proteins (arrow) to form the LB (taken from (McNaught and Olanow 2006).
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1.3.2 The Aetiology of Parkinson’s disease
The relative contributions of genetic versus environmental factors in the aetiology of 
PD have been keenly debated. The cause of the disease is considered to be 
multifactorial because the majority of cases are sporadic, with no obvious family 
history. The first evidence for an environmental causative agent became known in 
1983, when a group of Californian drug addicts injected themselves with heroin that 
was contaminated with l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) 
(Langston et al. 1999). The individuals exposed to MPTP showed dopaminergic 
neuronal loss similar to that observed in sporadic PD, and developed Parkinsonism, 
but with the absence of LB pathology. The discovery of this, and other toxins, 
strengthened the hypothesis that PD may have an environmental aetiology.
The hypothesis that heredity is the basis for the aetiology of PD was initially 
controversial and traditionally had little support from epidemiological data. However, 
even though agreement between monozygotic and dizygotic twins in longitudinal twin 
studies have indicated that PD has a genetic contribution, larger cross sectional twin 
studies have argued against heritability (Piccini et al. 1999; Tanner et al. 1999). And 
so, although 10-30% of PD patients report a first degree relative with the same 
disease, it is thought that the familial association should be attributed to sharing the 
same environment rather than sharing genes.
Over the years, epidemiological studies have indicated that a number of environmental 
factors may increase the risk of developing PD. These include exposure to pesticides, 
certain metals, rural living, head trauma and infection (Olanow and Tatton 1999; Lai 
et al. 2002). On the other hand, smoking (Quik 2004), caffeine and dietary 
antioxidants may hold some protective effect against neurodegenerative disease 
(Esposito et al. 2002).
However, the discovery of inherited forms of the disease shifted the emphasis back 
over to genetic factors. Studies of familial PD have documented several PD-associated 
genes. These include; a-synuclein (Polymeropoulos et al. 1997), a-synuclein locus
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duplication (Chartier-Harlin et al. 2004) and triplication (Singleton et al. 2003), parkin 
(Kitada et al. 1998), ubiquitin-C-tenninal hydrolase-Ll (UCHL-1) (Leroy et al. 1998), 
DJ-1 (Bonifati et al. 2003) and others listed in table 1.2.
The first familial form of PD was identified in a Greek family as a missense mutation 
in the a-synuclein gene (SNCA), resulting in an alanine to threonine substitution at 
point 53 (A53T) (Golbe et al. 1999). In families with an A53T substitution, the 
disease is fully penetrant at an average age of onset of 46 years, 10 years younger than 
sporadic PD (Polymeropoulos et al. 1997), and dementia appears to be more frequent 
(Spira et al. 2001). Another SNCA mutation resulting in an alanine to proline 
substitution at point 30 (A3 OP) was identified in a German family, but this time the 
disease was less penetrant with a slightly later age of onset (Kruger 2004). A more 
recently identified mutation results in a glutamate to lysine substitution at point 46 
(E46K) with dominant parkinsonism and DLB (Zarranz et al. 2004), is associated with 
an age of onset between 50 and 65 years, but with dementia presenting within around 
two years.
Recent findings suggest that the SNCA gene dosage and the corresponding protein 
levels might go some way as to determine the age of onset of PD and also disease 
progression (Eriksen et al. 2005; Mizuta et al. 2006; Mukaetova-Ladinska and 
McKeith 2006). Triplication of SNCA, which results in four normal copies of the gene, 
induces a severe form of early onset PD with rapid disease progression (Singleton et 
al. 2003). Duplication of the gene has been identified as having a similar clinical 
presentation and disease progression as sporadic PD (Chartier-Harlin et al. 2004; 
Ibanez et al. 2004). Also, polymorphisms in the SNCA promoter associated with 
higher a-synuclein expression have been found to increase the risk of developing PD 
(Holzmann et al. 2003).
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Table 1.2 Genetic causes of parkinsonism (adapted from (Farrer 2006)





PARKA 20-40 years Recessive missense and exon- 
deletion mutations
Undetermined
DJ-1 PARK7 20-40 years Recessively inherited, 









PARK5 55-58 years 
Late onset
Linkage for the lie 93 Met 
substitution




















Glu46Lys ad Ala53Thr 
substitutions
Genomic duplications and 
triplications
Diffuse Lewy body 
disease, with prominent 






PARK2 30 years on 
average
Recessive homozygous, 
compound heterozygous and 
exonic deletion / duplication / 
triplication mutations
Predominantly nigral 
neuronal loss, although 
compound 
heterozygotes with 






PARK8 Between 50 and 
70 years (range 
32-79)
Many dominant substitutions Predominantly LB’s, 
rare cases with 
neurofibrillary tangles 
and/or nigral neuronal 
loss
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Mutations in another gene implicated in PD, parkin, were first identified in Japanese 
patients with autosomal recessive Parkinson’s disease (ARPD) (Matsumine et al. 
1997; Kitada et al. 1998). Subsequently, many other parkin mutations have been 
described associated with both early and late onset PD. Parkin is a member of the E3 
ubiquitin ligase family (Shimura et al. 2001). This protein is primarily expressed in 
the central nervous system (CNS) and co-localises with a-synuclein in normal brain. 
Parkin is found in LB’s in sporadic PD (Schlossmacher et al. 2002). A loss of function 
of this protein has been proposed to cause an accumulation of a modified, 
glycosylated form of a-synuclein, termed aSp22, which is said to build up to 
pathological levels in parkin-deficient PD brains (Shimura et al. 2001). This process 
will be discussed later in Chapter 3. Pathological hallmarks of ARPD due to parkin 
mutations including loss of nigral and locus coeruleus neurones and the apparent 
absence of LB formation (Metman et al. 2001; Mizuno et al. 2001; Junn et al. 2002). 
The lack of LB’s could be consistent with the inability of the UPP to form 
ubiquitinated aggregates of a-synuclein.
It is worth mentioning mutation in another gene involved in the UPP, ubiquitin C- 
terminal hydrolase (UCHL-1). This gene was identified in a family with autosomal 
dominant PD (Leroy et al. 1998). However, this data has recently been challenged, 
based on evidence the UCHL-1 gene does not exhibit a protective effect in PD (Healy 
et al. 2006). Further investigations, of both sporadic and inherited PD cases over the 
last few years, have failed to identify any further mutations in this gene.
1.3.3 The Synuclein family
The synuclein group consists of three known proteins, a-, (3-, and y-synuclein. They 
are a family of small, soluble proteins (ranging from 123 to 140 amino acids in length) 
and have 55-62% homology in sequence, with a similar domain organisation (Lavedan 
1998). The a-, f3- and y-synuclein proteins are primarily expressed in the brain, with 
low levels in other tissues (see table 1.3). The y-synuclein protein is also found in the
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cell bodies and axons of the peripheral nervous system and retina (Buchman et al. 
1998), but its expression in breast tumours is a marker for tumour progression.
Table 1.3 Tissue expression of the human synuclein genes
Pancreas Kidney Skeletal
muscle
Liver Lung Placenta Brain Heart Breast
cancer
a + + ++ - + + ++++ ++ -
P - - + - - - ++++ - -
7 + + ++ + - - ++++ ++ ++
The relative expression, determined by Northern blot analysis of different tissues, is indicated for a 
particular gene but cannot be compared here between genes: a-synuclein, (3-synuclein (Jakes et al.
1994), y  -synuclein (Lavedan 1998) (adapted from 
http://ww w.genom e.O rg/cgi/content/full/8/9/871/Tl).
The human a-synuclein gene encodes a highly conserved 140 amino-acid protein that 
is extensively expressed throughout the brain, predominantly in the presynaptic 
terminals of neuronal cells. It is also expressed to a much lesser extent in the cells of 
non-neuronal tissues such as the heart and pancreas (see table 1.3). Conformational 
analysis of a-synuclein has revealed that it belongs to a group of unfolded proteins, 
which are characterised by a unique combination of low hydrophobicity and large net 
charge (Weinreb et al. 1996). a- and y-synuclein are slightly more compact and 
structured than (3-synuclein, which displays a random coil, but all are natively 
unfolded under physiological conditions (Uversky 2003). It has been shown that a- 
synuclein displays conformational plasticity, adopting a range of different 
conformations, depending in the surrounding enviromnent.
The a-synuclein sequence can be divided into three separate regions, or domains (see 
figure 1.4). An amino-terminal domain occupies amino acid residues 1-65, a central 
hydrophobic region at position 61-95 and then an acidic carboxy-tenninal domain at 
residues 96-140. Both the amino-terminal and the hydrophobic domain contains 6
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repeats of an 11 amino acid sequence containing variations of the consensus sequence 
KTKEGV (Nonaka et al. 2005), and a recent study shows that several of the lysine 
residues within these repeats are subject to ubiquitination. The amino-terminal domain 
of the protein binds negatively charged phospholipids and adopts an a-helical 
conformation upon binding. This conformation is similar to the lipid-binding domain 
of some apolipoproteins, suggesting that the protein may be normally be membrane 
associated (Davidson et al. 1998; Eliezer et al. 2001). Furthermore, lipid rich 
environments have been shown to promote aggregation in a-synuclein (Welch and 
Yuan 2003). The central protein domain is highly amyloidogenic which enables a- 
synuclein to undergo a conformational transformation, changing it from a random coil 
to a p-sheet structure (el-Agnaf and Irvine 2002). For a-synuclein to assemble into 
filaments, a stretch of 12 hydrophobic amino acid residues (71-82) is essential 
(Giasson et al. 2001). The acidic carboxy-terminal domain of the protein inhibits 
aggregation (Murray et al. 2003) and has been shown to reveal chaperone activity 
(Kim et al. 2002). a-synuclein has sites for glycosylation (McLean and Hyman 2002), 
nitration (Takahashi et al. 2002) and phosphorylation (Negro et al. 2002) in the 
carboxy-terminal domain.
Although (3- and y-synuclein show similar structural properties to a-synuclein, they 
vary in their ability to aggregate. On the contrary, they have been shown to actually 
inhibit the tendency of a-synuclein to aggregate (Uversky et al. 2002; Park and 
Lansbury 2003; Hashimoto et al. 2004). (3- and y-synuclein have been shown to 
accumulate in hippocampus axon terminals in PD and DLB (Galvin et al. 1999). Also, 
mutations in the p-synuclein gene (SNCB) that have resulted in amino acid 
substitutions V70M and also P123H have been identified in DLB (Ohtake et al. 2004). 
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Figure 1.4 Sequence comparison of human a-, p- and y-synucleins
Amino acid identities between at least two of the three sequences are boxed in blue. The positions of 
the a-synuclein mutations implicated in familial PD (A30P and A53T) are indicated in red. The amino- 
terminal half of the synucleins is taken up by 11 amino acid repeats with the consensus sequence 
KTKEGV, and a-synuclein assembles into filaments through these repeats. (Taken from (Goedert 
2001))
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1.3.4 Suggested functions of a-synuclein
A few of the functions suggested for a-synuclein are it being involved in synaptic 
plasticity, dopamine metabolism and signalling (Clayton and George 1999; Yu et al. 
2005; Kim et al. 2006). The role in synaptic plasticity is supported by studies showing 
that protein expression is up regulated, and the synaptic terminals rearranged, during a 
critical period of song learning in zebra finches (Clayton and George 1998). It is 
thought that in mammals synaptic vesicle function might involve a-synuclein, as 
knockout mice display faulty synaptic transmission. It is thought that this is as a result 
of vesicle depletion and impaired vesicle mobilisation (Cabin et al. 2002). a-synuclein 
has been found to bind phospholipid vesicles, containing acidic phospholipid 
molecules in in vitro studies (Davidson et al. 1998). The protein has also been shown 
to interact with, and inhibit, phospholipase D, a key enzyme of the phospholipid 
signalling pathway (Ahn et al. 2002). As mentioned earlier, a-synuclein with selective 
phosphorylation at serine 129 is evident in LB’s. This phosphorylation by G protein- 
coupled receptors, results in a reduced ability of the protein to interact with 
phospholipids and phospholipase D (Fujiwara et al. 2002).
Activated Fyn specifically phosphorylates tyrosine a-synuclein residue 125, so might 
be involved in the Fyn-mediated signalling pathway (Nakamura et al. 2001). It has 
also been suggested that a-synuclein modulated the extracellular signal-related kinase 
(ERK) signalling pathway by down regulation of ERK activity (Subramaniam et al.
2003). So therefore, it is possible that a-synuclein is a regulatory component in 
various signalling pathways in neuronal cell differentiation and plasticity.
A further role for a-synuclein involved in dopamine metabolism is supported by 
several studies. Over expression of the protein down regulates the transcription of 
several enzymes involved in the synthesis of dopamine, including tyrosine 
hydroxylase and dopa decarboxylase (Baptista et al. 2003) (figure 1.5). a-synuclein 
has also been shown to down-regulate the dopamine transporter (DAT)-mediated 
uptake of extracellular dopamine (Sidhu et al. 2004). This supports previous 
suggestions that a loss of nonnal a-synuclein activity in PD may disrupt dopamine 


















Figure 1.5 Dopamine synthesis and metabolism
DA synthesis occurs in the presynaptic terminals of dopaminergic neurones. The rate 
limiting tyrosine hydroxylase (TH) uses oxygen, iron and tetrahydrobiopterin (BH 4 ) 
cofactors to convert tyrosine to dihydroxyphenylalanine (L-DOPA) (reviewed in 
(Lotharius and Brundin 2002)). Decarboxylation of L-DOPA yields DA within the 
cytosol which is then sequestered into vesicles via the vesicle monoamine transporter 
2 (VMAT-2). Monoamine oxidase (MAO) can deaminate DA to form 3,4- 
dihydroxyphenylacetic acid and hydrogen peroxide. Catchol-O-methyltransferase 
(COMT) can also metabolise DA to 3-methoxytyramine. Interestingly, synuclein 
mutants can inhibit TH activity (reviewed in (Takeuchi and Takahashi 2007)). 
Inhibition by a-synuclein provides a possible mechanism for selective loss of DA- 
producing neurones in PD.
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1.3.5 Aggregation and a-synuclein
Under physiological conditions a-synuclein is prone to aggregation in vitro (Conway 
et al. 2000). The recombinant protein will aggregate to form insoluble amyloid-like 
fibrils that have similar anti-parallel (3-sheet structure, wound ultrastructure and 
proteolytic resistance, to those extracted from LB’s. The pathway of a-synuclein 
aggregation from monomer to fibril, is dependant on the concentration and nucleation 
of the protein (Wood et al. 1999). It is hypothesised that the natively unfolded protein 
oligomerises from its’ monomeric form, to form a seed that precedes the formation of 
|3-sheet protofibrils, eventually associating with each other to make the mature 
amyloid fibrils (figure 1.6).
Monomers
Figure 1.6 The
The hypothetical scheme depicts various proposed pathways of natively unfolded a-synuclein 
monomers converting into partially folded and/or aggregated forms. (Taken from (Paleologou et al.
2005))
The amino acid substitutions associated with familial PD, A30P, A53T and E46K, 
have been shown to increase the propensity for a-synuclein to aggregate (Conway et 
al. 2000). However, there are differences in the aggregation behaviour of the separate 
substitutions and the wild-type protein. Although the formation of soluble oligomers is 
accelerated in the A30P and A53T mutants, the fibril formation is lower in A30P and 
higher in A53T (Conway et al. 2000). The filament formation rate of E46K is similar 





formation of mature fibrils from a-synuclein monomers
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Other factors have been shown to accelerate the propensity of the protein to aggregate. 
These include low pH and high temperatures (Uversky et al. 2001), metal ions 
(Uversky et al. 2001), pesticides (Uversky et al. 2001), glycosaminoglyeans (Cohlberg 
et al. 2002), cellular polyamines (Antony et al. 2003), double stranded DNA (Cherny 
et al. 2004) and dopamine (Cappai et al. 2005). The mechanisms that lead to the 
aggregation of a-synuclein in the brain remain unknown.
Protofibrillar a-synuclein, in contrast to monomeric and fibrillar forms, can bind 
synthetic vesicles causing transient penneability (Voiles et al. 2001). If this were true 
for DA vesicles, cytosolic DA concentrations would increase. Obviously, this has 
implications for PD pathogenesis as DA induces oxidative damage both in vitro and in 
vivo. For example, MPTP used to model PD in animals causes production of free 
radicals by DA oxidation (Lotharius and O'Malley 2000). Tetrahydrobiopterin (BH 4 ), 
an obligatory TH cofactor, has also been shown to mediate dopaminergic cell death 
through formation of quinine products via dopamine-oquinone (DAQ) oxidative 
action (Choi et al. 2003).
DA contains an unstable catechol ring which can undergo spontaneous oxidation in 
the presence of molecular oxygen to form three compounds: hydrogen peroxide, 
superoxide and DAQ, which are ultimately responsible for oxidative damage. DAQ 
can form covalent adducts with a-synuclein which stabilises potentially pathogenic 
protofibrils (Conway et al. 2001). As mentioned previously, monoamine oxidase 
(MAO) can deaminate DA to form 3,4-dihydroxyphenylacetic acid and hydrogen 
peroxide (reviewed in (Lotharius and Brundin 2002)). Toxic hydrogen peroxide in the 
presence of transition metal ions such as Cu2+ and Fe3+ can form hydroxyl radicals via 
Fenton’s reaction (Choi et al. 2003):
M n+ + H20 2 ----- ► M (n+1)+ + OH + OH
Superoxide can interconvert with hydrogen peroxide (Tabner et al. 2002):
0 2 ' + e + 2H+  ► H20 2
<-----------
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Hydroxyl radicals can react and add readily to C=C bonds and abstract hydrogen 
atoms from many organic compounds to yield a variety of products which may 
themselves be toxic, or cause depletion of critical cellular proteins (Tabner et al. 
2002).
1.3.6 Diagnosis and treatment of Parkinson’s disease
PD is just one of several neurologic movement disorders that produce similar 
symptoms. The clinical examination must rule out all of the different disorders that 
can masquerade as PD. PD must be considered if the person exhibits more than one of 
the cardinal symptoms of the disease, including tremor at rest, bradykinesia, rigidity, 
and in more advanced cases, postural instability (Savitt et al. 2006). The presence of 
resting tremor supports the pathology of PD more than the other symptoms, although 
around 20% of patients fail to develop this symptom (Suchowersky et al. 2006). Non­
motor symptoms may include disrupted sleep, depression and fatigue. Because 
progression of neurologic movement disorders and their treatment varies greatly, 
proper clinical diagnosis is crucial.
The neurological examination evaluates a patient with a movement disorder, the 
doctor taking a medical history and performing a physical examination. The doctor 
asks the patient and the family members or friends about symptoms and observes the 
patient, asking him or her to walk around the room, to sit down, stand up, turn around, 
and so on, observing aspects of the patient's movement, coordination and balance. 
Although genetic testing for parkin and SNCA is available, it is only offered when 
there is a strong family history, or when symptoms present themselves at an unusually 
young age. Unfortunately, there is no diagnostic test that can confirm PD, although 
research into levels of a-synuclein in plasma and CSF is currently being investigated 
as a potential diagnostic biomarker for PD.
Electroencephalograms (EEGs) record some aspects of brain electrical activity, but 
they are not effective in spotting PD. The MRI and CAT scans of the brain produce 
detailed anatomic pictures, but unfortunately scans of the brains of people with PD
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appear normal. So, with no diagnostic tests to provide specific answers, clinicians 
must base their diagnosis of PD on judgment.
The matter is further confused in that an early PD patient may complain about 
suffering the cardinal signs of the disease, but the neurological examination may 
appear nonnal (de Lau et al. 2006). The fact that the cardinal symptoms of PD may be 
absent or shared with other movement disorders complicates matters further. An early 
study found that only 69-70% of people with autopsy-confirmed PD had at least two 
of the cardinal signs of PD, and 20-25% of people with two of the symptoms had a 
pathological diagnosis other than PD. Moreover, 13-19% of people who demonstrated 
all three of the cardinal features had a pathological diagnosis other than PD (Hughes et 
al. 1992; Hughes et al. 2001).
Dopamine replacement therapy remains the most effective medication to date for 
treating the symptoms of PD. As dopamine itself cannot cross the blood-brain barrier 
and is toxic to peripheral tissues, a dopamine precursor, levodopa (L-DOPA), is 
administered in conjunction with a dopa-decarboxylase inhibitor such as carbidopa or 
benzeraside, which slows the peripheral conversion of dopamine and enables more L- 
DOPA to reach the brain. Once in the brain, the L-DOPA is converted into DA that is 
then released physiologically. Most PD patients have a good initial response to this 
treatment, although there are limitations. The L-DOPA does not stem any further 
neuronal loss, and consequently, the symptoms of the disease continue to worsen and 
the response to treatment reduces over time. Chronic treatment is associated with 
severe side effects including dyskinesias, motor fluctuations and dementias. DA 
agonists, ropinirole or pramipexole can be used to enhance efficacy and reduce motor 
symptoms. Inhibitors of COMT can be used to prevent the breakdown of DA and 
extend its viability (Marsh and Dawson 2000; Tanner 2000).
Identification of mutations responsible for the familial forms of PD have created 
opportunities to address the pathological changes seen in the brain. One powerful 
strategy that has emerged is the overexpression of parkin. After it was shown that 
parkin was an E3 ubiquitin ligase, many studies focussed on how parkin 
polyubiquitination activity could clear aggregation prone substrates (Imai et al. 2001). 
Recently, it has been suggested that the proteosome-independent ubiquitination by a
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lysine 63-linked process could also play a major role in neuroprotection by 
intracellular stress-related pathway regulation. There is compelling evidence that two 
of the loss of function parkin mutations cause c-Jun N-terminal kinase (JNK) 
activation, which is a mediator of stress-induced apoptosis, leading towards selective 
dopaminergic cell death (Hasegawa et al. 2008). The wild type parkin protects against 
oxidative stress by inhibiting the JNK signalling pathway. It has been reported that 
parkin expression increases after stress induced by kainite and rotenone in cultured 
cells resulting in neuroprotection (Henn et al. 2007). Moreover, parkin has also been 
associated with mitochondrial morphology along with PINK1 in Drosophila, possibly 
by increasing mitochondrial fission (Poole et al. 2008). And so as PD has been 
previously associated with mitochondrial pathology, these findings open new 
mechanistic possibilities and explanations of PD pathology, and present the question 
as to whether overexpression of parkin could provide a novel strategy for 
neuroprotection in PD (Ulusoy and Kirik 2008).
1.4 Frontotemporal Lobe Degeneration -A n  overview
1.4.1 Frontotemporal Lobe Degeneration
The term Frontotemporal Lobe Degeneration (FTLD) is a general term describing a 
group of clinical syndromes associated with dementia of non-Alzheimer type and 
degeneration of the frontal and temporal lobes. It is the third most common cause of 
dementia, after AD and DLB (Neary et al. 1998), with onset between the ages of 35 
and 75 years, with equal prevalence in males and females (Mott et al. 2005). Fortyfive 
percent of patients with this disorder have at least one family member with a similar 
disorder, and 89% of these latter individuals show an inheritance pattern consistent 
with an autosomal dominant mode of transmission.
Immunohistochemical investigations in FTLD have concentrated on the identification 
of pathological aggregations of proteins such as tau and ubiquitin, within neurones 
and glial cells (Chow et al. 1999). These investigations have led to a pathological 
classification of FTLD, as follows (Cairns et al. 2007);
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1. One class are cases characterised by pathological aggregations of tau protein 
(the “tauopathies”) which include FTLD with Pick bodies, Corticobasal 
degeneration (CBD), Frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17), as well as Progressive supranuclear palsy (PSP).
2. Another group, Frontotemporal lobe degeneration with ubiquitin positive 
inclusions (FTLD-U), represents most FTLD cases, and includes cases with 
ubiquitin-positive, tau and a-synuclein negative inclusions (McKhann et al. 
2001; Josephs et al. 2004).
3. A third class covers the cases of dementia that lack distinctive histology 
(DLDH) (Shi et al. 2005) and any cases of neuronal intennediate filament 
inclusions containing neurofilament protein (Cairns et al. 2007).
4. Tau positive intraneuronal neurofibrillary tangles or Pick-like bodies, 
associated with mutations in the tau gene (MAPI).
In the study by Shi et al, (2005) the single most common cause of FTLD was FTLD- 
U, with 34% patients being affected. DLDH was the next most common with 22% 
patients being affected, followed by tau Pick-type histology with 20% and FTDP-17T 
histology with 16%. 4% (3 cases) with clinical FTD were due to cerebrovascular 
changes, not FTLD.
To summarise, it can be broadly said that FTLD is associated with either a tau-based 
pathology (tauopathy) or a ubiquitin based pathology (FTLD-U or FTD/MND when 
clinical MND is also present).
1.4.2 Aetiology of FTLD-U
The diverse pathology that exists across the FTLD-U group could imply that different 
pathological processes are at work. It could be the case that there are different proteins 
involved, or different modifications of the same protein which underlie the 
pathogenesis of each FTLD-U class. Studies on familial cases of FTDP-17 showing 
FTLD-U pathology have led to the identification of causal mutations in the
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progranulin gene, PRGN (Baker et al. 2006; Cruts et al. 2006). Progranulin is a 593 
amino acid multifunctional growth factor (Daniel et al. 2000). The protein is mainly 
expressed in epithelial, haematopoietic and some fibroblastic cell lines, and is found in 
a range of tissues throughout the body, from the epididymis, to the mammary glands, 
GI tract, and to specific parts of the brain. Compared to other tissues, progranulin 
expression in the brain is actually very low, but high expression is seen in certain 
subsets of cells, specifically cortical neurons, Purkinje cells of the cerebellum and 
granule cells of the hippocampus (Daniel et al. 2000). Granulins are peptides derived 
from progranulin, that can alter cell growth in culture (Daniel et al. 2000). The rate of 
epithelial cell proliferation is directly proportional to the PGRN gene expression (He 
and Bateman 1999). Increased progranulin has been associated with tumorigenesis.
Although progranulin, and derived peptides regulate cell growth in culture, their roles 
in vivo are not fully understood (Daniel et al. 2000). However, recent findings suggest 
that it is essential for neuronal survival (Baker et al. 2006), and this supports the 
hypothesis that neurodegeneration in FTLD results from loss of growth factor support 
(Capsoni et al. 2000), (although recently cases of FTD and MND with TDP-43 
pathology have been found, without the associated progranulin mutation (Seelaar et al. 
2007)). Very recently, it has been suggested that progranulin mediates proteolytic 
cleavage of TDP-43, generating -35 and -25 kDa species. It is possible that abnormal 
metabolism mediated by progranulin may play a pivitol role in neurodegeneration 
(Zhang et al. 2007).
Examination of cases with PRGN  mutations, all show a characteristic pathological 
picture with ubiquitin-positive neurites, neuronal cytoplasmic inclusions and neuronal 
intranuclear inclusions consistent with certain types of FTLD-U. However, the 
ubiquitinated inclusions in FTLD-U do not contain the progranulin protein. Disease is 
as a result of a loss of function in the protein, and not from the accumulation of the 
mutated protein. This is consistent with the opinion that mutations in PRGN  result in 
the production of prematurely tenninated transcripts that are immediately destroyed 
by nonsense-mediated degradation (Baker et al. 2006; Cruts et al. 2006).
Despite exhaustive immunohistochemical investigations over the past 15 years, the 
protein present in the ubiquitin-positive FTLD-U inclusions remained unknown until
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recently. The ubiquitinated target protein was identified as the TAR DNA-binding 
protein, TDP-43 (Arai et al. 2006; Neumann et al. 2006).
1.4.3 The TDP-43 protein
TDP-43 is a 41443 Da transcription factor with two functions; transcription repression 
and activation of exon skipping. It contains two RNA-recognition motifs as well as a 
glycine-rich C-terminal sequence (Buratti and Baralle 2001). The protein can 
therefore be said to have regulatory roles in multiple transcription and splicing, or 
interact with survival motor neurone protein, playing a role in the arrangement of 
nuclear bodies in eukaryotic cells (Buratti et al. 2004; Wang et al. 2004; Mercado et 
al. 2005; Arai et al. 2006; Neumann et al. 2006). So the physiological functions of 
TDP-43 may be diverse and these functions may involve binding to single stranded 
DNA, RNA, and proteins to regulate biological processes by multiple mechanisms.
TDP-43 immunohistochemistry in unaffected neurones produces the expected nuclear 
staining, but in FTLD-U, the same pathological changes previously seen with anti- 
ubiquitin immunostaining are also replicated with anti-TDP-43 antibodies (Neumann 
et al. 2006; Davidson et al. 2007).
TDP-43 pathology has been demonstrated in a number of clinical entities and this has 
led to the classification of these disorders under the term of ‘TDP-43 proteinopathies’. 
This includes cases of sporadic and familial FTLD-U, FTD/MND and sporadic MND. 
TDP-43 pathology was found in familial cases of FTLD-U, other than those 
associated with the progranulin mutations (Neumann et al. 2006). TDP-43 
immunoreactive changes are observed in the brains of 24-26% patients with AD 
(Amador-Ortiz et al. 2007; Uryu et al. 2008). Recent studies have shown TDP-43 
pathological changes to be present in Paget’s disease and FTD associated with 
mutations in VCP gene (Guinto et al. 2007; Neumann et al. 2007), in a proportion of 
patients with DLB (Nakashima-Yasuda et al. 2007), in Guam parkinsonism dementia 
complex (Hasegawa et al. 2007; Geser et al. 2008) and in some cases of CBD (Uryu 
et al. 2008). TDP-43 has not however been associated with other neurodegenerative
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diseases such as, MSA, PSP, FTDP-17, tangle-only dementia nor basophilic inclusion 
body disease (Skibinski et al. 2005; Arai et al. 2006; Cairns et al. 2007; Davidson et 
al. 2007), in tau-containing Pick bodies in FTLD (Davidson et al. 2007; Freeman et al. 
2008; Uryu et al. 2008), or in those ubiquitinated inclusions of certain other cases of 
FTLD-U called atypical FTLD-U (Mackenzie et al. 2008; Roeber et al. 2008).
In FTLD-U, examination of the distribution and morphology of the TDP-43 pathology 
confirmed previous classifications of FTLD-U (Davidson et al. 2007). However, 
although the pathogenic mechanisms of sporadic and familial cases of FTLD-U all 
involve the TDP-43 protein, they must differ in some way as they produce different 
histological phenotype and different neurodegenerative disorders.
TDP-43 pathological changes have been reported in a variety of disorders including 
low grade tumours, indicating alterations in the structure or function of this protein 
may occur in a wide range of neurodegenerative diseases and other disorders (Lee et 
al. 2008).
Mutations in TARDBP have been reported in some cases of both familial and sporadic 
forms of MND (Gitcho et al. 2008; Kabashi et al. 2008; Sreedharan et al. 2008; Van 
Deerlin et al. 2008; Yokoseki et al. 2008), although none have been found in cases of 
familial FTLD-U (Van Deerlin et al. 2008). Moreover, there has been no genetic 
association between any TARDBP polymorphisms and FTLD-U in case control 
studies (Neary et al. 1998; Nakashima-Yasuda et al. 2007). However, it is possible 
that variations within TARDBP may predispose the deposition of TDP-43 in some 
disorders, although this has not been investigated to date. Therefore the underlying 
reason as to why only some individuals with AD, DLB, CBD and so on, show TDP-43 
pathological changes, while most do not, is unclear.
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1.4.4 Aggregation and TDP-43
Investigations to give an insight into possible pathogenic mechanisms relating to 
TDP-43 have been made. Immunoblotting of urea extracts of protein from affected 
regions in cases of both sporadic and familial cases of FTLD-U have identified a 
45kDa band, plus 24 and 26kDa bands which correspond with C-terminal TDP-43 
fragments. As with tau proteins in AD and other tauopathies, the 45kDa band 
collapses to a 43kDa band after alkaline phosphatase treatment, which implies that the 
TDP-43 protein may be abnormally phosphorylated (Arai et al. 2006; Cairns et al. 
2007; Neumann et al. 2007). It also suggests that the biochemical profile of the TDP- 
43 protein in both sporadic and familial cases of FTLD-U is similar.
Electron microscopy of TDP-43 inclusions shows them to be composed of granular 
material that is not fibrillar like the proteins in other groups of diseases such as 
tauopathies and synucleinopathies. Moreover, the inclusions do not stain with amyloid 
dyes such as congo red and riboflavin S (Cairns et al. 2007).
The dysfunction or dysregulation of the progranulin protein, as seen in FTLD-U, may 
be a factor in the abnormal compartmentalisation of TDP-43. As protein 
phosphorylation is an important event in cellular signalling, it is feasible that 
hyperphosphorylation of TDP-43 may cause disruption of important signalling 
pathways or might even directly affect the trafficking of TDP-43 itself, resulting in 
neuronal dysfunction. However, the mechanistic aspects of the aggregation of 
pathologic TDP-43 in either cytoplasmic, neuritic, or nuclear inclusions, or the role in 
the pathogenesis of neurodegeneration, are still being investigated.
1.4.5 Diagnosis and treatment of FTLD
The clinical diagnostic consensus criteria for FTLD describes the syndrome as 
changes in personality, behaviour and social conduct such as disinhibition, passivity, 
inertia, over activity and stereotyped behaviour (Neary et al. 1998). The condition
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may last from 3 to 17 years before death, with an average duration of eight years after 
diagnosis.
FTLD includes three principle clinical disorders. About 70% of patients present with 
the clinical syndrome FTD, whilst the other clinical conditions, namely Semantic 
dementia (SD) and Progressive non-fluent aphasia (PNFA) have been recognised. 
Some patients may develop motor disorders such as parkinsonism during their disease 
(Foster et al. 1997). Importantly, it is recognised that there is a considerable overlap 
between FTD cases and those with Motor neurone disease (MND), and a related 
clinical disorder FTD with MND (FTD/MND) (Lomen-Hoerth et al. 2002). FTLD can 
be considered as a heterogeneous term, encompassing international criteria in an 
attempt to identify and categorise distinct clinical and pathological syndromes (Neary 
et al. 1998).
FTD usually presents between 45-65 years of age. Unlike AD, there is some 
preservation of perception, spatial orientation and memory, but the cognitive 
impairment (i.e. poor organisation and attention) that exists, may compromise these 
functions. Speech is reduced, sometime progressing to mutism (Neary et al. 1998).
SD has a mean age of onset of 58 years, with a mean length of illness of 9 years 
(Davies et al. 2005). SD is characterised by a progressive loss of conceptual 
knowledge and impaired comprehension. This results in the loss of understanding and 
the meaning of words. Speech is fluent, but is empty of content and conveys little 
meaning (Bozeat et al. 2000). Some patients may present with a predominant verbal 
deficit and this is associated with a more left sided pathology, whilst others with 
visual problems have a more right -sided atrophy (Neary et al. 1998; Snowden et al.
2004). In PNFA the patient suffers from progressive difficulties with speech 
production. There can be problems in different parts of speech production, hence 
patients can present with articulatory breakdown (hesitant speech or speech apraxia), 
agrammatism (difficulties with syntax e.g. use of the wrong tense or word order), 
anomia or phonemic breakdown (difficulties with sounds). However, it is rare for 
patients to have just one of these problems and most people will present with several 
symptoms. As the disease develops speech quantity decreases and many patients will 
become mute (Neary et al. 1998). Cognitive domains other than language are rarely
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affected early on. However, as the disease progresses other domains can be affected. 
Problems with writing, reading and speech comprehension can occur as can 
behavioural features similar to FTD, however comprehension is relatively preserved 
(Neary et al. 1998). The majority of patients with SD will have ubiquitin-positive, tau- 
negative inclusions although like all of the FTLD syndromes other pathologies have 
been described including Pick's disease and other tau positive pathology (Davies et al.
2005).
Some patients present with the clinical features of FTD but with the motor weakness 
and features of Motor neurone disease (FTD/MND). The pathological changes 
associated with MND are seen in the spinal cord (Neary et al. 1990). In other forms of 
familial FTLD, parkinsonism may be present in addition to the FTD. Genetic linkage 
studies in these cases found association with mutation in the MAPT on chromosome 
17, and therefore the hereditary disorder Frontotemporal dementia with parkinsonism 
linked to chromosome 17 (FTDP-17) was identified (Foster et al. 1997).
International criteria have been developed to assist clinical diagnosis of the disorders 
mentioned here. Despite attempts to simplify these criteria and aid diagnosis, the 
heterogeneity that exists in clinical presentation, and the overlap that exists between 
disorders, makes clinical diagnosis a challenge (Neary et al. 1998; McKhann et al. 
2001). The only way to ascertain a confident diagnosis of a distinct disease entity is on 
neuropathological examination of the brain at autopsy (Cairns et al. 2007).
At present there is no cure for FTD and no effective way to slow its progression. 
Treatment relies on managing the symptoms. Anti-psychotics that can block the 
effects of dopamine may be of value in managing aggressive, irrational and 
compulsive behaviours that can sometimes develop with FTD. Tranquilizers may be 
of help if agitation or other types of hyperactivity become problems. Speech therapy 
may be offered to people with primary progressive aphasia, who may benefit from 
therapy to help them adjust to their language difficulties and learn alternate ways to 
communicate. Antidepressants called selective serotonin reuptake inhibitors (SSRIs) 
may offer some relief from apathy and depression and help reduce food cravings, loss 
of impulse control and compulsive activity. The main effect of the disease is 
circumscribed loss of pyramidal neurones, and it is suggested that as a single
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pharmacological approach, 5-HTia receptor antagonist treatment, may be appropriate 
(Bowen et al. 2008).
As the present clinical management of FTD patients depends mainly on the 
construction of a network of carer and family support (Neary et al. 2005), perhaps one 
important area of research relating to the management issue of these disorders relates 
to the determining the underlying pathological process (FTLD-U or FTLD-Pick 
histology).
1,5 Biomarkers and neurodegenerative diseases
Generally, a biomarker is defined as a measure of a biological process that can be 
correlated with the disease process, or the response of that process to treatment. As 
neurodegenerative diseases are complex conditions that may potentially have many 
underlying causes that differ between individuals, a biomarker (or set of biomarkers) 
will most probably require several methods of measurement. Research in the scientific 
community aims to identify several types of biomarkers;
• Disease trait biomarkers predict the genetic predisposition that an individual 
will get neurodegenerative disease.
• Disease state biomarkers would distinguish individuals with a particular 
disease, for example PD, from other disorders that mimic the disease, or would 
identify individuals in the earliest stages of disease.
• Disease rate biomarkers would record disease progression, which would be 
particularly important for developing treatments that could slow or stop a 
disease.
• Translational biomarkers may predict whether or not an individual would 
respond to a specific treatment, or whether the drug itself is actually reaching 
its target and acting upon it. A biomarker of this type would be critical for drug 
development although not directly related to the disease process itself.
The development of new treatments for neurodegenerative diseases is hindered by the 
fact that, at present, there is a lack of reliable biomarkers that can accurately identify
35
individuals with a particular type of neurodegenerative disorder, measure the disease 
progression and monitor treatment effects. Intervention with protective drugs and 
therapies would be possible (once these become available) as soon as a biomarker that 
can identify people with, or at risk, for these diseases before significant neuronal loss 
has occurred.
Clinical tests lack the sensitivity and objectivity to definitively establish the presence 
of a particular disease or to track disease progression. However, the greatest obstacle 
to the identification and validation of biomarkers is the requirement of longitudinal 
studies that can ensure disease is well-characterised in a population of individuals. 
These studies involve recruiting a group of patients who exhibit the clinical 
symptoms, then observing them at regular intervals over an extended period of time. 
The extent of the symptoms, or any changes in the individuals’ status could be 
measured and correlated with the change in the biomarker.
Research to identify a biomarker that accurately measures the underlying disease 
process include markers taken from blood, urine and cerebral spinal fluid. These 
tissues/fluids can be used to measure/identify genetic, protein or other chemical 
biomarkers that may be a molecular ‘signature’ of the disease.
Previously, methods were developed in our laboratory to detect oiligomeric forms of 
a-synuclein, which led to an extensive study of blood plasma and CSF (El-Agnaf et 
al. 2003; El-Agnaf et al. 2006). There was a highly statistically significant difference 
between the concentration of these oligomers between PD samples and controls, with 
most of the PD samples giving high signals, whereas only a few control samples gave 
a high signal. Following on from these studies, techniques and methods were 
developed for the study of the a-synuclein-parkin complex, and consequently the 
newly discovered protein TDP-43, to investigate whether these proteins/protein 
complexes were useful in the development of biomarkers for neurodegenerative 
disease.
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1.6 Aims o f the thesis
The initial aim of the work carried out for this thesis was to test the hypothesis that an 
interaction between a-synuclein and parkin exists, and that the binding partner for 
parkin is in fact the 22-24kDa glycosylated form of a-synuclein (aSp22) reported 
previously (Shimura et al. 2001). The proposal was to then attempt to isolate this 
glycosylated a-synuclein species, fully characterise it, and further investigate its role 
in disease pathogenesis.
With this in mind, methods were developed for the detection and assay of the a- 
synuclein-parkin complex, and these methods were applied to extracts of human post­
mortem brain tissue, and also to samples of human blood plasma. The latter studies 
arose from previous work in our laboratory, demonstrating that a-synuclein is present 
in human CSF and blood plasma (El-Agnaf et al. 2003; El-Agnaf et al. 2006) and 
might be useful as a biomarker for PD and related disorders (El-Agnaf et al. 2006; 
Tokuda et al. 2006). The presence of parkin, or a complex between a-synuclein and 
parkin in human body fluids, in addition to a-synuclein, would not only shed light on 
this interaction but would also open up new opportunities for the development of 
biomarkers for disease.
During the course of these investigations, a new protein (TDP-43) was discovered to 
be involved in neurodegenerative disease (Arai et al. 2006; Neumann et al. 2006). For 
the second part of this thesis, the presence of this protein was investigated in human 
blood plasma, and the levels of this protein measured in a large number of blood 
plasma samples from patients with various neurodegenerative diseases. The aim was 




2 Materials and Methods
2.1 Solutions, buffers and antibodies
All reagents were of analytical grade and obtained from Sigma-Aldrich or Merck 
unless otherwise stated. Solutions are detailed in Table 2.1, in alphabetical order, and 
antibodies are listed in Tables 2.2 and 2.3.
Table 2.1 Summary of solutions and buffers 
Solution Details
Dithiothreitol (DTT) 1 M in dH20 , stored at -20°C
SDS-PAGE sample 3x stock solution: 0.125 M Tris-HCl pH 6.8, 2% (w/v)
loading buffer SDS, 10% (v/v) glycerol, 0.01% (w/v) bromophenol blue.
Before use, 100 mM DTT was added.
SDS-PAGE running 
buffer
10 x stock solution: 30.3 g Tris base, 144 g glycine, 50 ml 
20% (w/v) SDS, dH2Q to 1 litre.
1 x working solution, pH ~ 8.6:25 mM Tris base, 192 mM 
glycine, 0.05% (w/v) SDS.
De-staining solution 0.25% (v/v) ethanol, 10% glacial acetic acid in dH2Q.
PBS 1 x PBS: 137 mM NaCl, 7 mM KC1, 3 mM NaHP04, 1.4 
mM KH2P 0 4
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Coomassie blue staining 0.25% (w/v) Coomassie blue R50, 40% (v/v) ethanol, 10% 
solution (v/v) acetic acid in dH2C).
Blocking solutions for 5% (w/v) Marvel dried milk in PBS-T
immunoblotting
Anion exchange buffers A- 50 mM Tris HC1, pH7.5
B- 50 mM Tris HC1, 2 M NaCl, pH7.5, filtered
Anion exchange buffers A- 50 mM Tris HC1, 1% NP-40, pH8
with non-ionic detergent B- 50 mM Tris HC1, 2 M NaCl, 1% NP-40, pH8
Running buffer for 50 mM Tris HC1, 0.15 M NaCl, 4 M Guanidine
Superose 6 column hydrochloride, pH7, filtered
(dissociative conditions)
Running buffer for 
Superose 6 column
50 mM Tris HC1, 0.15 M NaCl, pH7, filtered
Running buffer for 0.15 M Na Cl
Superdex 200 column 50 mM Tris HC1, pH7, filtered
Blocking solution for 2.5% gelatine in PBS-T, made fresh
ELISA
0.5 M Sodium 
phosphate buffer
Add 2.65 ml of 0.5 M NaH2P 0 4.H20  to 47.35 ml of 0.5 M 
Na2H P04.H20
20 mM DMP buffer Dissolve 5 mg of dimethyl pimelamidate in 1 ml of 0.2 M 
triethanolamine
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Table 2.2 Summary of primary antibodies
Primary Antibody Epitopes
Anti-a,P,y-synuclein (FL-140) rabbit polyclonal Amino acids 1-140 (full length of 
(200 pg/ml), Santa Cruz Biotechnology, CA. human a-syn)
Anti-a-synuclein (211) mouse monoclonal (200 Amino acids 121-125 of human a- 
pg/ml), Santa Cruz Biotechnology, CA. syn
Anti-human parkin (N-18) goat polyclonal (200 Amino terminus of human parkin 
pg/ml), Santa Cruz, CA.
Anti-human parkin (PARK 11-S) rabbit Carboxy terminus of human parkin 
polyclonal (100 pg/100 pi), A Diagnostic 
International, CA.
Anti TDP-43 rabbit polyclonal antibody Full length recombinant human 
(10782-2-AP) (30pg/150pl), Proteintech Europe TDP-43 
Ltd., UK
Anti-TDP-43 mouse monoclonal antibody Full length recombinant human
(H00023435-M01, clone 2E2-D3), Abnova TDP-43 with GST tag 
Corporation, Taiwan
Table 2.3 Summary of secondary antibodies
Rabbit IgG (purified immunoglobulin), Sigma (Cat. No. A-0418)
Mouse IgG (purified immunoglobulin), Sigma (Cat. No. A-2478)
Peroxidase- conjugated goat anti-rabbit (HRP), DAKO
Rabbit IgG (purified immunoglobulin), Sigma (Cat. No. A-0418)
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Peroxidase-conjugated rabbit anti-goat (HRP), (DAKO) 
Peroxidase-conjugated goat anti-mouse (HRP), DAKO
2.2 Human plasma samples for a-synuclein/parkin study
The controlled experiment compares the results obtained from the experimental blood 
plasma samples from individuals with a neurodegenerative disease against a control 
sample group, which is practically identical to the experimental sample except for the 
one aspect whose effect is being tested. Control blood samples were obtained from 
the Haematology Department at Blackpool Victoria Hospital with ethical approval. 
Around 3 ml of blood was collected in tubes containing sodium citrate, and the plasma 
was separated by centrifuging the blood at 3,000 rpm at 4°C for 20 min. The plasma 
was transferred to plastic tubes containing protease inhibitors including AEBSF, 
aprotinin, E-64, EDTA and leupeptin (Calbiochem-Novabiochem Corporation, San 
Diego, CA), and stored at -80°C. Appropriate care was taken as to not contaminate the 
plasma samples with cells or components of the pellet obtained from the 
centrifugation. The samples were thawed at room temperature directly before analysis. 
Repeated freeze/thaw cycles were avoided. Blood samples were obtained from 
patients that had been clinically diagnosed with a neurodegenerative disease by a 
Consultant Neurologist within the out-patients clinic at the Cerebral Function Unit, 
Greater Manchester Neurosciences Centre at Hope Hospital, Salford, UK. Patients had 
undergone historical interview in the presence of a family caregiver and 
comprehensive cognitive assessment to obtain information regarding the nature and 
progression of functional and cognitive decline. Patients fulfilled the National Institute 
of Neurological and Communicative Disorders and Stroke -  Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) criteria for probable AD 
(McKhann et al. 1984), and International criteria for FTD (Neary et al. 1998). Again, 
all blood samples were collected with the approval of the local ethics research 
committee.
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2.3 Human plasma samples for TDP-43 study
For this study patients were recruited as above, although control subjects comprised of 
either spouses of patients attending the CFU clinic, Greater Manchester Neurosciences 
Centre (n=T3), or a sample of healthy volunteers (n=72) drawn randomly from a 
cohort of 767 mentally normal people aged over 50 years, resident within the same 
Greater Manchester region from which the patients suffering from neurodegenerative 
diseases were recruited (Payton et al. 2003). These latter control subjects belonged to 
a longitudinal ageing study group who had been screened psychologically for the 
absence of any cognitive impairment consistent with a dementia. All blood samples 
had been collected with the approval of the local ethics research committee.
2.4 Human brain lysate
Post-mortem brain samples were supplied by Professor David Mann, Greater 
Manchester Neurosciences Centre, Hope Hospital, Salford, U.K. Ethical approval was 
obtained for all samples. A frozen post-mortem sample (3 g) of frontal cortex was 
homogenised in 3 ml CellLytic buffer, (Sigma-Aldrich Company Ltd., Dorset, U.K., 
Product number: C3228) consisting of a mild detergent, bicine, 150 mM NaCl and 
containing protease inhibitors (as before), and centrifuged at 3,000 x g for 30 min. The 
supernatant was collected and stored at -80°C prior to analysis.
2.5 Methods
2.5.1 Recombinant a-synuclein
Recombinant a-synuclein was prepared from E. coli using a previously described 
protocol (King 2005). a-synuclein pJEK2 was used to transform FB850, a rec A" 
derivative of BL21 (DES) pLysS. FB850 carrying this plasmid was grown in an 800 
ml batch culture. At OD6oo of 0.4-0.5 (T=0), protein expression was induced through
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addition of isopropyl-|3-D-thiogalactopyranoside (IPTG). A protein with a molecular 
weight of approximately 17 kDa started to accumulate in the cells 30 min after 
induction and reached maximum levels after 150 min. Immunoblot analysis identified 
this protein as a-synuclein using mouse monoclonal antibody (211). After a 3 h 
induction, the suspension was centrifuged, and the cells resuspended in buffer. The 
cells were lysed by sonication, then cell debris and insoluble material was removed by 
centrifugation at 4°C for 1 h at 30,000 rpm. a-synuclein was extracted from the 
supernatant by ammonium sulphate precipitation, then purified using a series of 
chromatography columns; phenyl sepharose, heparin, hydroxyapatite and mono Q. 
After purification, 5pg of protein ran as a single band when observed on a Coomassie 
blue-stained SDS gel, corresponding to monomeric a-synuclein.
2.5.2 Bradford Assay
Protein standards were prepared from a stock solution of bovine serum albumin (BSA) 
(Sigma-Aldrich, UK) of concentration 5 mg/ml. The stock solution was then used to 
prepare a range of concentrations by serial dilution from 5 mg/ml down to 0.05 mg/ml 
in Phosphate buffered saline (PBS) (0.01 M phosphate buffer, 0.0027 M potassium 
chloride and 0.137 M sodium chloride, pH 7.4). 0.5 ml of distilled water was added to 
0.5 ml of Bradford reagent (8.5% phosphoric acid, 5% ethanol, 0.001% Coomassie 
Blue G-250) in an Eppendorf tube and 5 pi of the known protein sample was added 
and mixed well. The liquid was then transferred to a plastic cuvette and the 
absorbance was measured at 595 nm. A control was prepared by adding 5 pi of 
distilled water to the 1 ml solution of water and Bradford reagent. Each concentration 
was prepared in triplicate, an average calculated, and the results used to generate a 
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Figure 2.1 Bradford assay to estimate protein content
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Figure 2.2 Bradford assay effective range between 0 . 1 - 2  mg/ml BSA
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2.5.3 Determining total protein concentration of plasma samples for a-
synuclein/parkin study
Each individual plasma sample was diluted by adding 2 pi plasma sample to 400 pi of 
distilled water. 5 pi of the previously diluted sample was then added to 0.5 ml 
Bradford reagent and 0.5 ml of distilled water. The solution was mixed, transferred to 
a cuvette, and absorbance measured at 595 nm. Each plasma sample was measured in 
triplicate and the previously generated standard curve equation (x = (y - 
0.0605)/0.1693) was used to estimate the total protein concentration of each sample. 
The plasma samples were then standardised to an equal protein concentration (60 
mg/ml), making the volume up to 600 pi using filtered PBS (table 2.4).
Table 2.4 Standardisation of plasma protein concentrations
Plasm a Average 1:200 Protein Actual protein Volume plasm a Volume PBS
sam ple A595nm concentration (mg/ml) concentration (mg/ml) required  (pi) requ ired  (pi)
AD(225) 0.119 0.35 69.10 521 79
AD(228) 0.115 0.32 64.38 559 41
AD(230) 0.118 0.34 67.93 530 70
AD(232) 0.123 0.36 73.83 488 112
AD(233) 0.115 0.32 64.38 559 41
AD(234) 0.122 0.36 72.65 496 104
AD(99) 0.123 0.36 73.83 488 112
CON(236) 0.116 0.33 65.56 549 51
CON(237) 0.118 0.34 67.93 530 70
CON(238) 0.121 0.36 71.47 484 116
CON(239) 0.125 0.38 76.19 473 127
CON(240) 0.119 0.34 67.93 530 30
CON(241) 0.124 0.38 75.01 480 120
CON(242) 0.120 0.35 70.29 512 88
CON(243) 0.116 0.33 65.56 549 51
CON(244) 0.113 0.31 62.02 580 20
DLB(226) 0.112 0.31 60.84 600 0
DLB(227) 0.125 0.38 76.19 472 128
DLB(81) 0.113 0.31 62.02 581 19
FTD(100) 0.120 0.35 70.29 512 88
FTD(224) 0.125 0.38 76.19 472 128
FTD(72) 0.111 0.30 59.70 600 0
PD (119) 0.115 0.32 64.38 559 41
PD(13) 0.119 0.34 67.93 530 70
PD(14) 0.128 0.40 79.74 452 148
PD(163) 0.125 0.38 76.19 472 128
PD(166) 0.118 0.34 67.93 530 70
PD(26) 0.112 0.31 60.84 600 0
PD(64) 0.129 0.40 79.74 452 148
SD(142) 0.114 0.32 63.20 570 30
SD(231) 0.117 0.33 66.74 540 60
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2.5.4 Immunoassay for measuring total a-synuclein
This assay was used to measure the total a-synuclein in plasma samples, as previously 
described (Salem 2004). Salem performed experiments initially to optimise the 
conditions required, and the specificity of the antibodies were checked. These 
conditions were verified to ensure that the quoted descriptions were correct.
An ELISA plate was coated with 100 jul/well of anti-a-synuclein (211) i.e. 0.1 pg per 
well, diluted in 200 mM NaHCC^ pH 9.6, and incubated at 4°C overnight (i.e. 0.1 pg 
of antibody per well). The wells were then washed 4 times with PBS 0.05% Tween- 
20, and incubated for 2 h at 37°C with 200 pl/well of freshly prepared blocking buffer. 
The plate was washed again 4 times with PBS-T. 100 pi of the plasma samples were 
added to each well, (each sample was diluted 1:1 with PBS), and the assays were 
performed in triplicate to calculate a standard error. Following this, the plate was 
incubated at 37°C for 2 h. After a repeat washing with PBS-T, 100 pl/well of the 
detection antibody, anti-a/p/y-synuclein (FL-140) , dilution 1:1000 in blocking buffer 
was added (i.e. 0.02 pg per well of antibody), and the plate incubated at 37°C for 2 h.. 
After another wash with PBS-T, the plate was incubated with 100 pl/well of 
secondary antibody (goat anti-rabbit HRP, dilution 1:10 000 in blocking buffer at 
37°C for 2 h. The plate was then washed again with PBS-T before adding 100 pl/well 
Sure Blue TMB Microwell Peroxidase Substrate (KPL, USA) and leaving the colour 
to develop for 30 min at room temperature. Finally 100 pl/well of stop solution (0.3 M 
H2SO4) was added and absorbance at 450 nm determined.
2.5.5 Preparation of biotinylated antibody
200g Sulfo-NHS-LC-Biotin (Pierce) was reacted with the antibody to be biotinylated 
(1 ml at 200 pg/ml) in PBS and then placed on ice for 2 h. The mixture was desalted 
on Bio-Spin-6 columns to remove excess uncoupled biotin. The biotinylated 
antibodies were stored at 4°C until use.
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2.5.6 Immunoassay for measuring oligomeric a-synuclein
This assay was used to measure the total oligomeric a-synuclein, as previously 
described (Salem 2004). This author performed experiments initially to optimise the 
conditions required, and the specificity of the antibodies were checked. These 
conditions were verified to ensure that the quoted descriptions were correct.
An ELISA plate was coated by overnight incubation with 1 pg/ml of non-biotinylated 
anti-a-synuclein (211), diluted in 200 mM NaHCCb, pH 9.6, containing 0.02% (w/v) 
sodium azide, at 4°C overnight. The wells were then washed 4 times with PBS 0.05% 
Tween-20, and incubated for 2 h at 37°C with 200 pl/well of freshly prepared 
blocking buffer. The plate was washed again 4 times with PBS-T, and 100 pi of the 
sample was added to each well (the assays were performed in triplicate to calculate a 
standard error). Following this, the plate was incubated at 37°C for 2 h. After a repeat 
washing with PBS-T, 100 pl/well of biotinylated anti-a-synuclein (211) diluted to 1 
pg/ml in blocking buffer was added and the plate incubated at 37°C for 2 h. The plate 
was washed 4 times with PBS-T and incubated with 100 pl/well of ExtrAvidin- 
alkaline phosphatase diluted to 3:5000 in blocking buffer and incubated for 1 h at 
37°C. After another 4 washes with PBS-T, the enzyme substrate para- 
nitrophenylphosphate (pNPP) was added (100 pl/well) and the colour left to develop 
for 30 min at room temperature. Finally 100 pl/well of stop solution (3 M NaOH) was 
added and absorbance at 405 nm determined.
2.5.7 Immunoassay for measuring total parkin
The ELISA plate was coated with 100 pl/well of the capture antibody, anti-parkin (N- 
18) diluted in 200mM NaHCCb, pH 9.6, at a ratio of 1:1000 (0.02 pg per well of 
antibody). Detection was via 100 pl/well of the anti-parkin antibody (PARK 11-S), 
dilution 1:10 000 in blocking buffer (i.e.O.Olpg of antibody per well). Following this, 
the plate was incubated with 100 pl/well of secondary antibody, goat anti-rabbit HRP, 
dilution 1:10 000 in blocking buffer. All other parameters remained the same as the 
previously described a-synuclein assay (section 2.1.4).
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2.5.8 Immunoassay protocol for measuring the a-synuclein/parkin complex
Capturing a-synuclein and detecting parkin
This immunoassay protocol was based on the method described in section 2.1.4. An 
ELISA plate was coated with 100 pl/well of anti-a-synuclein (211) as before and 
detection was via 100 pl/well of the anti-parkin antibody (PARK 11-S), dilution 
1:10,000 in blocking buffer (i.e. 0.01 pg of antibody per well). Following this, the 
plate was incubated with 100 pl/well of secondary antibody, goat anti-rabbit HRP, 
dilution 1:10,000 in blocking buffer. All other parameters remained the same.
Capturing parkin and detecting a-synuclein
This immunoassay protocol was based on the method described in section 2.1.4. An 
ELISA plate was coated with 100 pl/well of the capture antibody, anti-parkin (N-18) 
and detection was via 100 pl/well of the anti-a-synuclein antibody (211). Following 
this, the plate was incubated with 100 pl/well of secondary antibody, goat anti-rabbit 
HRP, dilution 1:10,000 in blocking buffer. All other parameters remained the same.
2.5.9 Crosslinking of antibody to Dynabeads
Dynabeads covalently coupled with recombinant protein A, were vortexed for 1 -2 min 
before 100 pi was transferred to a plastic Eppendorf tube. The tube was then placed in 
the Dynal MPC (Magnetic Particle Concentrator) for 1 min before the liquid was 
removed. The Dynabeads were then washed 3 times with 0.1 M sodium phosphate 
buffer pH 8.2, using the MPC holder each time to separate the beads from the 
solution. 100 pi of 0.5 M sodium phosphate buffer pH 8.2, was mixed with 400 pi of 
antibody. The antibody solution was then added to the tube containing the Dynabeads 
and incubated for 30 min at room temperature, mixing by rotation. After this period of 
time, the Dynabeads were washed 3 times with 0.5 ml sodium phosphate buffer pH
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8.2, and then again washed twice with 1 ml of 0.2 M triethanolamine pH 8.2. 1 ml of 
20 mM DMP buffer was added to the tube containing the Dynabeads and incubated 
for 30 min, mixing by rotation at room temperature. The reaction was stopped by 
placing the tube in the MPC holder, removing the DMP buffer, and then adding 1 ml 
of 50 mM Tris buffer pH 7.5. The tube was then incubated for 30 min by rotation at 
room temperature. Finally the beads were washed 3 times in PBS then stored at 4°C in 
PBS containing 0.02% NaN3.
2.5.10 Immunoprecipitation
Dynabeads are previously crosslinked to antibody, as previously described. 400 pi of 
plasma was added to the beads and incubated overnight at 4°C overnight. The beads 
were then washed 3 times with 0.1 M phosphate buffer pH 8.2. Captured proteins 
were eluted from the beads by boiling for 10 min in NUPAGE LDS sample (see figure 
2.3). As a control, an equal amount of beads were coated with non-specific IgG and 
incubated with the same samples.
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Anti-parkin antibody
The magnetic Dynabeads are 
crosslinked to anti-parkin antibody.
The beads are incubated with the  
plasma sample. The complex will bind 
to the antibody
The Dynabeads and a-syn/parkin  
complex are separated from the  
sample (using a magnet).
The proteins are released from the Dynabeads by boiling in SDS sample buffer. 
Identification of the proteins present is performed by SDS PAGE, followed by 
immunoblotting (IB).





2.5.11 Sodium dodecyl sulphate -  polyacrylamide gel electrophoresis (SDS -  
PAGE)
One dimensional gel electophoresis under denaturing conditions separates proteins on 
the basis of molecular size as they migrate through a polyacrylamide gel matrix 
towards the anode. SDS -  polyacrylamide gels were cast as a resolving gel topped 
with a stacking gel. They were run under a constant voltage in a Mini-PROTEAN®3 
electrophoresis apparatus (Biorad).
Recipes to make 3 ml of stacking gel and 10 ml of resolving gel (the volumes required 
to prepare 2 mini gels) are shown in Table 2.5.
Table 2.5 Recipe for polyacrylamide gels
Stock solution Stacking gel (ml) 12.5 % Resolving gel (ml)
30% acrylamide / 0.8% bisacrylamide 0.51 4.17
0.5 M Tris-HCl pH 6 .8 0.75
1.5 M Tris-HCl pH 8 .8 2.5
dH20 1 .6 8 3.13
10 % (w/v) SDS 0.03 0 .1
1 0  % (w/v) ammonium persulphate 0.03 0 .1
TEMED 0.003 0 .0 1
Samples to be analysed by SDS-PAGE were solubilised by diluting with SDS sample 
buffer and then heated to 98°C for 3 min. The gels then underwent electrophoresis in 
SDS-PAGE running buffer at a constant 150 V. Protein samples to be analysed by the 
NUPAGE pre-cast gel system (Invitrogen) were solubilised by diluting with 4x LDS 
sample loading buffer (Invitrogen) and then heated to 98°C for 3 min. NuPAGE 4- 
12% gradient gels (Invitrigen) were electrophoresed in lxMES, or lxMOPS buffer 
(Invitrogen) at 200V. Both SDS-PAGE and NuPAGE gels were run until the tracking 
dye reached the bottom of the gel. Proteins in the gel were visualised either by 
Coomassie blue staining or immunoblotting.
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2.5.12 Coomassie Blue Staining
Polyacrylamide gels were covered with Coomassie staining solution and gently 
agitated for at least 4 h. The detection of protein bands in the gels is dependant on the 
non-specific binding of the dye to the protein. The staining solution was then replaced 
by a destaining solution, which was continued until the gel itself achieves a clear 
background, with the proteins visible as blue bands. Gels were stored in 7% (v/v) 
acetic acid.
2.5.13 Immunoblotting
Immunoblotting (Western blotting) was used to identify specific proteins recognised 
by either monoclonal or polyclonal antibodies. Immunoblots were carried out using 
the blotting module. Nitrocellulose membrane, (0.45pm, Invitrogen) was prepared by 
briefly soaking it in the transfer buffer. The filter paper is soaked for 10 min in the 
same buffer. The transfer stacks were assembled and transfer of proteins achieved by 
applying a constant voltage of 30 V for 1 h.
Membranes were blocked with 5% Marvel dried skimmed milk, dissolved in PBS-T 
for 1 h on a rocking platform. The blocking buffer was then poured off and replaced 
with the primary antibody, diluted with PBS-T. The membranes were probed with the 
following antibodies:- anti-a-synuclein (211) mouse monoclonal antibody, 1 : 1000; 
anti-a-synuclein (FL-140) rabbit polyclonal antibody, 1 : 1000; anti-parkin (N-18) 
goat polyclonal antibody, 1:1000; anti-TDP-43 rabbit polyclonal antibody, 1:1000; 
or, anti-TDP-43 mouse monoclonal antibody, 1:1000. The membrane was incubated 
for 1 h at room temperature, or left at 4°C overnight, on a rocking platfonn. The 
primary antibody was then removed and the membrane rinsed for 2 X 5 min then 1 X 
15 min in PBS-T. The secondary antibody, horseradish peroxidase (HRP) conjugated 
to either goat anti-rabbit, rabbit anti-goat or goat anti-mouse as appropriate, was 
diluted in PBS-T to the correct ratio and applied to the membrane for 1 h at room 
temperature, on a rocking platform. Then the secondary antibody solution was poured 
off and the membrane washed as before in PBS-T. Finally, Super Signal West-Pico
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chemoiluminescent substrate (Piearce) was applied for 5 min, and the membrane then 
exposed to film in the darkroom.
2.5.14 Dialysis of samples
Samples were dialysed in Snakeskin pleated dialysis tubing MWCO 3500 (Piearce) 
against 3 X 2 1 of the appropriate buffer.
2.5.15 Size exclusion chromatography
Superose 6 was packed into a 44cm long column with an internal diameter of 1 cm. 
Samples (0.5 ml) were loaded onto the column connected to a fast protein liquid 
chromatography (FPLC) system (Atka Purifier, GE Healthcare) and eluted with 
running buffer (0.15 M NaCl, 50mM Tris HC1) at a flow rate of 0.5 ml/min. The 
column was equilibrated with 20 of a column of buffer and eluted with 1.5 columns 
of buffer. Absorbance of the eluate was monitored on line at 280 nm. Fractions of 1 
ml were collected.
2.5.16 Anion, and cation, exchange chromatography
The Q sepharose 1 ml Fast Flow HiTrap XL strong anion column (GE Healthcare) (or 
SP sepharose strong cation column) was loaded with 25 pi of human plasma 
(approximately 2 mg total protein). The column was connected to an FPLC system 
(Atka purifier, GE Healthcare) and equilibrated with the binding buffer (50mM Tris 
HC1, pH7.4) at 0.5 ml/min for five mins before the sample was injected. Bound 
proteins were eluted by a salt gradient of 0-1 M NaCl over 20 min. 0.5 ml fractions 
were collected and the fractions containing protein were identified from the UV 
chromatogram.
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CHAPTER THREE -  RESULTS
3 Optimisation of an ELISA method for detection of parkin 
and for any a-synuclein / parkin complex
3,1 Introduction
Parkinson’s disease (PD) is characterised pathologically by selective loss of 
dopaminergic neurons from the substantia nigra (SN), and also with the presence of 
aggregated intraneuronal protein deposits called Lewy bodies (LB’s), and neuronal 
processes called Lewy neurites (LN’s) (Dauer and Przedborski 2003). LB’s and LN’s 
contain several proteins, including a-synuclein (Spillantini et al. 1998) and parkin 
(Schlossmacher et al. 2002). a-Synuclein has also been linked to other 
neurodegenerative diseases such as multiple system atrophy (MSA) and DLB, 
disorders collectively known as a-synucleinopathies (Goedert 2001). The molecular 
pathogenesis of PD remains elusive, although several genes are thought to play a part 
in some cases. Along with mutations in the a-synuclein gene, mutations in the parkin 
and UCHL-1 genes have also been implicated in familial forms of the disease (Kitada 
et al. 1998). Autosomal dominant PD arises from mutations in the a-synuclein gene 
(Polymeropoulos et al. 1997), and an a-synuclein gene triplication has been 
discovered in two families (Singleton et al. 2003) that results in both a doubling of a- 
synuclein concentration in the blood and clinical signs of Lewy body disease (Miller 
et al. 2004). Mutations in parkin cause an autosomal recessive juvenile form of PD 
(ARJP) (Kitada et al. 1998) but LB’s are not usually present. ARJP patients suffer 
midbrain dopaminergic neurone loss and develop typical Parkinsonian symptoms.
As previously discussed, intracellular protein degradation within eukaryotic cells can 
be signalled by the covalent linkage of ubiquitin to proteins (Glickman and 
Ciechanover 2002). An ubiquitin-activating enzyme (El) initially activates the 
ubiquitin molecule which is transferred to a ubiquitin-conjugating protein (E2) and 
ubiquitin-protein isopeptide ligase (E3) enzymes (Tanaka et al. 2001). Substrates with
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four or more conjugated ubiquitin molecules are targeted for degradation by the 26S 
proteasome. Studies have revealed that parkin has E3 ubiquitin-protein ligase activity 
(Shimura et al. 2001). It is suggested that loss of parkin function may lead to the 
accumulation of abnormal parkin substrates, which could promote neurotoxicity and 
neuronal cell death. Several protein substrates have been identified, through protein- 
protein interaction studies, for their ubiquitin-ligase activity. These include CDCrel-1, 
a protein involved in cytokinesis that may influence synaptic vesicle function (Kubo et 
al. 2001), synphilin-1, an a-synuclein interacting protein (Chung et al. 2001) and a 22- 
kD O-glycosylated iso form of a-synuclein, tenned aSp22 (Shimura et al. 2001). There 
are many uncertainties regarding the biochemical relationship between parkin and a- 
synuclein and their relevance to PD. It may be of consequence that both proteins 
interact with vesicles (Lee et al. 2001) and that a-synuclein can bind and negatively 
regulate the activity of human dopamine transporter (hDAT) (Lee et al. 2001).
As mentioned previously, it has been proposed that a-synuclein and parkin interact 
functionally, with parkin ubiquitinating a-synuclein normally and with this process 
being altered in ARJP (Shimura et al. 2001). A protein complex was identified in 
human brain that included parkin as an E3 ubiquitin-ligase, UbcH7 as its E2 ubiquitin 
conjugating enzyme, and a novel 22 kDa O-glycosylated form of a-synuclein (aSp22) 
as its substrate. In contrast to wild type parkin, the mutant parkin that is associated 
with ARJP failed to bind aSp22. aSp22 was modified by nonnal but not mutant 
parkin, in an in vitro ubiquitination assay, into a polyubiquitinated, higher molecular 
weight species. The authors surmised that this would lead to the accumulation of non- 
ubiquitinated aSp22 in parkin-deficient ARJP disease brains.
As a-synuclein is present in extracellular biological fluids, including human plasma 
(El-Agnaf et al. 2003), this thesis investigates whether the a-synuclein/parkin 
interaction could also be detected in human blood plasma using antibody-sandwich 
ELISA assays. This work was undertaken with the view that any interaction between 
the two proteins would be of great interest in understanding the molecular pathology 
of PD. If it is only the glycosylated form of a-synuclein that interacts with parkin, then 
what could be the significance of this? Also, it would be useful to investigate the level 
of the a-synuclein/parkin complex as a potential biomarker for PD and ARJP. In 
addition, other diseases were studied that sometimes mimic PD, such as DLB and
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FTD, to explore whether there might be differences between the levels of any a- 
synuclein/parkin interaction in the synucleinopathies and the non-synucleinopathies.
An ELISA that detects soluble forms of a-synuclein has been developed in this 
laboratory (Salem 2004). Initially, Salem (2004) identified which antibodies were 
useful in detecting the protein in biological samples, and then the concentrations of the 
antibodies were optimised to give the most sensitive signal with the lowest 
background. Different concentrations of both the capture antibody and the detection 
antibody were applied to known concentrations of the recombinant protein, ranging 
from 0.0001 pg/ml to 10 pg/ml. The best combination of antibodies was found to be 
anti-a-synuclein antibody (211) to capture the protein, and anti-a-synuclein (FL-140) 
to detect it. The results established the most effective concentration of the anti-a- 
synuclein capture antibody (211) was 1:200, and the anti-a-synuclein detection 
antibody (FL-140) concentration at 1:1000. Investigations confirmed that these 
concentrations were also found to give the best “signal to noise” ratio in the current 
study.
3.2 ELISA a-synuclein detection levels in PBS, and BSA
To determine whether the other proteins in biological samples, for example blood 
albumins, effect the sensitivity of the ELISA signal/absorbance, known concentrations 
of the recombinant a-synuclein protein ranging from 100 pg/ml down to 0.001 ng/ml 
were dissolved in PBS and assayed for a-synuclein as previously described (section 
2.1.4). Each concentration was prepared in triplicate to calculate a standard error. 
Subsequently, the assay was repeated using a-synuclein dissolved in PBS containing 1 
mg/ml bovine serum albumin (BSA). The two sets of data can be compared to see if 
the high concentrations of other proteins affect the sensitivity of the assay.
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3.5
□  D is so lv e d  in P B S  on ly  
H  D isso lv e d  in P B S /B S A (1  m g/m l)
100 10 1 0.1 0.01 0.001 0.0001 0.00001 0.000001 PBS/BSA
Control
Alpha-synuclein concentration (pg/ml)
Figure 3.1 ELISA to detect recombinant a-synuclein when dissolved in PBS
only
The ELISA can detect protein levels as low as 0.001 ng/ml when the recombinant a- 
synuclein is dissolved in PBS alone (figure 3.1). However, the sensitivity of the assay 
is greatly reduced when the recombinant protein is mixed with BSA. The detection 
level is now reduced to 0.1 pg/ml, approximately 105 less sensitive. It is possible that 
the detection antibody experiences a “masking” effect due to the presence of the BSA 
in the solution. With this in mind, it was decided that all the plasma samples should be 
assayed for protein content and the concentration adjusted to a standard, to ensure an 
equal inhibitory effect for all samples analysed (see Section 2.1.3).
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3.3 ELISA to determine the optimal concentrations o f antibodies
3.3.1 Identifying the most suitable antibodies to detect the a-synuclein/parkin 
complex
An ELISA to detect an interaction between a-synuclein and parkin (an a-synuclein- 
parkin complex) was developed. Initially, suitable antibodies for detecting a-synuclein 
from plasma were identified, along with a suitable antibody for parkin detection. 
Different combinations of antibodies which are specific for a-synuclein were used for 
capture, and detection was via anti-parkin antibodies (figure 3.2). Subsequently, the 
optimal conditions for a modified assay were investigated, this time capturing any 
parkin present with an anti-parkin antibody, and detecting a-synuclein with an anti-a- 
synuclein antibody (figure 3.3). The antibody concentrations used were the 
manufacturers’ recommended starting dilution for ELISA analysis. Anti-a-synuclein 
(211) was diluted to 1:100, anti-a-synuclein (FL-140) diluted to 1:200, and anti-parkin 
(N-18) was diluted to 1:100, with anti-parkin (PARK-1 IS) to 1:10 000. Two blood 
plasma samples (1:1, plasma : PBS) were used in this investigation. One gave a high 
ELISA absorbance for the previous a-synuclein assay, and the other a low reading. As 
there is a reported link between a-synuclein and parkin, it was hypothesised that if a 
plasma sample with a relatively high a-synuclein level may also have a higher level of 
the associating parkin protein. The combinations of both capture and detection 
antibodies are shown in figures 3.2 and 3.3. The PBS, which was used as a negative 
control, gave background absorbance that was deducted from the absorbance values 
from the plasma samples, before they were plotted. Recombinant a-synuclein, 4pg/ml, 
was ultilised as a further control. This protein gave absorbance signals comparable to 
the background absorbance from the PBS controls. This suggests that the anti-parkin 
detection antibody does not interact with the a-synuclein.
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□  [a-syn]>1.9 pg/ml 
B [a -s y n ] 0.07 pg/ml
211 captured, N-18 211 captured, FL-140 captured, N-18 FL-140 captured,
detected PARK11-S detected detected PARK11-S detected
Figure 3.2 Optimisation of antibodies for ELISA, a-synuclein capture, 
parkin detection, for two different plasma samples (high and low levels of a-
synuclein)
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□  [a-syn]> 1 .9 pg/m l 










PA R K 11-S cap tu red , N-18 ca p tu red , FL-140 PA R K 11-S cap tu red , N-18 c a p tu red , 211 
FL-140 d e te c te d  d e te c te d  211 d e te c te d  d e te c te d
Figure 3.3 Optimisation of antibodies for ELISA, a-synuclein capture, 
parkin detection, for two different plasma samples (high and low levels of a-
synuclein)
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The results revealed that the best combination of antibodies for the a-synuclein 
capture, parkin detection assay, was the 211 and N-18, respectively (figure 3.2). For 
the parkin capture, a-synuclein detection ELISA the most effective antibodies were 
the N-18 and FL-140, respectively (figure 3.3).
3.3.2 Identifying the most suitable antibodies to detect parkin
An ELISA to detect parkin in biological samples was developed. Initially, two 
commercially available antibodies for parkin were identified, which had different 
epitopes. The antibody concentrations used were the manufacturer’s recommended 
starting dilution for ELISA analysis. The different combinations of these two different 
parkin antibodies were used for capture or detection (figure 3.4). The same blood 
plasma samples used in the previous ELISA (in section 3.3.1) were assayed with these 
anti-parkin antibodies, as explained in the previous section. Again, PBS values were 
deducted from measured absorbance values. Recombinant a-synuclein 4pg/ml was 
utilised as a further control. This protein gave absorbance values comparable with the 
PBS control, suggesting the parkin antibodies did not interact with the recombinant a- 
synuclein. This implies the specific use of the two antibodies in this ELISA will detect 
any a-synuclein/parkin complex.
6 0
N-18 captured, PARK 11-S detected PARK 11-S captured, N-18 detected
Figure 3.4 Optimisation of antibodies for ELISA to detect parkin, for two 
different plasma samples (high and low levels of a-synuclein)
The results revealed that the best combination o f  antibodies for the parkin capture, 
parkin detection assay, was the N-18 for capture followed by detection with the PARK 
11-S (figure 3.4). The negative control plasm a sample and the “blank” PBS gave a 
m easured absorbance value o f  less than 0.1.
This ELISA would benefit from a standard curve constructed through the assay o f 
known concentrations o f the parkin protein. Parkin was not comm ercially available 
and so attempts were made to recom binantly express the protein using E. coli. 
Unfortunately, after several months and m any attempts, these efforts were 
unsuccessful. Therefore, it was not possible to validate this assay using a positive 
control.
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3.3.3 Optimising antibody concentrations
Experiments were undertaken to determine the difference in ELISA detection/signal 
levels, when the capture antibody and the detection antibody are at different 
concentrations. The concentrations investigated were taken from the manufacturers’ 
recommended dilution ranges for ELISA’s. They were 1:100, 1:200, 1:1000, 1:10 000 
and 1:20 000. A plasma sample known to give a high signal for a-synuclein was 
captured and detected with different antibodies. The optimal concentrations for each 
antibody giving the best measured absorbance values, in each ELISA, are summarised 
in table 3.1.
Table 3.1 Optimal ELISA antibody concentrations for each of the developed ELISA’s
ELISA Antibody Concentration (Dilution)
Detection of the 
a-synuclein/parkin 
complex
Anti-a-synuclein (211) 0.1 pg/100 pi (1:200)
Anti-parkin (N-18) 0.1 pg/100 pi (1:1000)
Detection of the 
parkin/ a-synu clein 
complex
Anti-parkin (N-18) 0.1 p g /lO p  1(1:1000)
Anti-a-synuclein (211) 0.02 pg/100 pi (1:1000)
Detection of parkin
Anti-parkin (N-18) 0.02 pg/100 pi (1:1000)
Anti-parkin (PARK 11-S) 0.01 pg/100 pi (1:20000)
3.3.4 Standard curve for measuring total a-synuclein
The ELISA method to measure total a-synuclein, i.e. all forms of a-synuclein 
including monomeric, oligomeric and complexed forms, (section 2.1.4) was used to 
measure absorbance values at different concentrations of recombinant a-synuclein 
dissolved in PBS, ranging between 0.001 pg/ml and 2 pg/ml. The recombinant a- 
synuclein was captured with anti-a-synuclein (211) and detected with anti-a-synuclein 
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Figure 3.5 Standard curve for ELISA measuring all forms of a-synuclein,
between 0-4.0 jag/ml
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Figure 3.6 Standard curve for ELISA measuring all forms of a-synuclein,
between 0-1.4 |ag/ml
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The ELISA is linear between the a-synuclein concentration ranges of 0.01 -  1.4 
pg/ml. At very low concentrations the assay is not accurate, and at values above 1.4 
pg/ml the ELISA plateaus off as the assay starts to saturate (see figure 3.5). This 
standard curve enables an estimation of the a-synuclein concentration in each blood 
plasma sample to be calculated (figure 3.6).
It should be noted however, that these values may be an under estimation of a- 
synuclein concentration, as the recombinant a-synuclein is dissolved in PBS alone, i.e. 
not in the presence of other proteins. As discussed previously (section 3.2), other 
plasma proteins may have an inhibitory effect on the assay. A more biologically 
representative standard curve would be gained if the recombinant a-synuclein was 
assayed dissolved in a plasma sample that had previously been determined as lacking 
in a-synuclein. This was not carried out as larger volumes of plasma samples were not 
available.
These preliminary results provide, for the first time, some evidence that a complex of 
some description may exist between a-synuclein and parkin, and it might be present in 
human blood plasma. Moreover, the parkin ELISA suggests that parkin is present in 
blood plasma, and this finding has not been documented before either. However, these 
initial findings need further validation and to this extent, a more detailed investigation 
follows.
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CHAPTER FOUR - RESULTS
4 Detection of parkin and a-synuclein/parkin complex in 
human plasma by ELISA
4.1 Introduction
Because a-synuclein is present in extracellular biological fluids, including human 
plasma (El-Agnaf et al. 2003), in this study investigations were carried out to explore 
whether the a-synuclein/parkin interaction could also be detected in human blood 
plasma, using the previously developed antibody-sandwich ELISA assays. If detection 
of the complex was possible, attempts could be made as to further characterise the 
protein interaction, and confirm that the complex does indeed include a glycosylated 
form of a-synuclein, as previously reported (Shimura et al. 2001). If so, blood plasma 
could be utilised as a source to purify and characterise the glycosylated a-synuclein 
species. In addition to this, investigations into the relative levels of this complex, 
between individuals with neurodegenerative disease and control subjects, may 
potentially be of use as a biomarker for PD and ARJP. And so with this in mind, other 
diseases were studied as well, that can clinically mimic PD, such as DLB, AD and 
FTD, in order to explore any differences between the levels of any putative a- 
synuclein/parkin interaction in the synucleinopathies and the non-synucleinopathies.
An ELISA that detects soluble fonns of parkin and the a-synuclein/parkin complex 
has been developed. Initially, antibodies that were useful in detecting the proteins in 
biological samples were identified, and then the concentrations of the antibodies were 
optimised to give the most sensitive signal with the lowest background. Different 
concentrations of both the capture antibody and the detection antibody were applied to 
human plasma samples. The best combination of antibodies was found to be anti-a- 
synuclein antibody (211) to capture the protein complex, and anti-parkin (N-18) to 
detect it. These results established that the most effective concentration of the anti-a- 
synuclein capture antibody (211) was 1:200, and the anti-parkin detection antibody
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(N-18) concentration at 1:1000. Investigations confirmed that these concentrations 
were also found to give the best measured absorbance values in the current study.
4.2 Measuring total a-synuclein in plasma from patients with 
synucleinopathies and control samples
The total concentration of a-synuclein protein from 31 plasma samples was 
determined by ELISA. Nineteen of the samples were from patients with a 
neurodegenerative synucleinopathy (46% male, 54% female, age range 53-85 years, 
mean age 63.5), and 3 were of patients from a similar age range with frontal temporal 
dementia (FTD), a non-synucleinopathy (table 2.4). The blood plasma a-synuclein 
concentration can be estimated by assaying the samples with the a-synuclein ELISA 
(figure 4.1), and different disease groups can be compared to levels in control plasma 
samples from patients with no pathological disorder. The a-synuclein standard curve 
(figure 3.6) was then used to calculate the a-synuclein concentration in individual 
samples (figure 4.2).
It should be noted that the data for figure 3.6, the a-synuclein standard curve to 
estimate protein concentration, was acquired at the same time as the data for figure 
4.1, the detection of a-synuclein in plasma samples. The experiments were carried out 
at the same time in order to ensure consistency and comparability.
Also of note is that the plasma absorbance readings above 2.0 are above the calibrated 
range and were saturated. In order to achieve a more reliable estimation of a-synuclein 
concentration, those plasma samples in question would have had to be diluted down 




Figure 4.1 Detection of a-synuclein in human plasma samples
Measured ELISA absorbance values from plasma samples (diluted 1:1 in PBS). The assay is done in 
triplicate in order to calculate a standard error. The a-synuclein standard curve is used to estimate the
protein concentration (figure 3.6).
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Figure 4.2 Concentration of a-synuclein in human plasma samples
(* indicates values which may be saturated and therefore potentially under-represents the a-synuclein 
concentration). As the plasma samples are diluted 1:1 in PBS, the actual a-synuclein concentration 
should be doubled for the true estimation of plasma concentration.
67
Figure 4.3 displays the same data as figure 4.2, but as a box-whisker plot. This 
categorises the a-synuclein concentrations into separate disease groups. Here, it can be 
seen that there is a variation between data points within each disease group. PD 
samples have either high (absorbance greater than 2) or low a-synuclein 
concentrations and AD samples also have a range of values from high to low. DLB 
individuals however, appear to have very low a-synuclein concentrations, but 
interestingly the SD cases have relatively high concentrations. The non- 
synucleinopathy FTD all have low concentrations along with the control samples. 
Preliminary results may indicate that a high plasma a-synuclein concentration is 


















PD(8) AD(6) DLB(3) SD(3) FTD(3) Control (9)
Disease group (n)
Figure 4.3 Box-whisker plots for the plasma ELISA results
The length of the box represents the interquartile range (25-75%) of the sample, the line drawn across 
the box the median and outliers being denoted by dots.
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It might be expected that PD patients for example, have a higher than average level of 
a-synuclein in the blood, but on the other hand, if the protein is sequestered into Lewy 
bodies they might have a lower than average concentration. Either way, one may 
expect to see a difference in a-synuclein levels in synucleinopathies and control cases, 
even with this small group of samples. Figures 4.3 reveals the SD plasma samples 
have the highest mean a-synuclein concentration, and the non-synucleinopathy FTD 
group the lowest concentration.
Table 4.1 reveals the mean a-synuclein concentration within different disease groups 
and the standard deviation.
Table 4.1 Average plasma a-synuclein concentrations for different disease groups





PD 8 0.60 0.78
AD 6 0.55 0.44
DLB 3 0.09 0.12
SD 3 1.39 0.73
FTD 3 0.10 0.09
Control 9 0.36 0.47
The validity of any statistical analysis would have been undermined by the small 
sample sizes, and was therefore not carried out. Initially, as the study was focussing 
on the characterisation of the a-synuclein/parkin complex in plasma, further 
investigations to validate these results (i.e. to extend them to larger numbers of 
samples) were postponed for potential work in the future.
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4.3 Parkin interacts with a-synuclein in human plasma
To determ ine whether a parkin/a-synuclein complex could be detected in human 
blood plasma, antibody-sandwich ELISA assays were developed (Chapter 3). The 
plasm a samples (that were previously assayed in the a-synuclein ELISA) were 
assayed again, this time to detect any parkin that was complexed with the a-synuclein 
protein. Anti-parkin antibody N-18 (1:1000 dilution) coated the wells as the parkin 
capture antibody, and detection was via the anti-a-synuclein antibody FL-140 
(1:1000), followed by goat anti-rabbit HRP (1:10,000). There was no apparent 
correlation between the levels o f the protein complex in the different disease groups, 
w ith 1 out o f  7 PD samples giving a very high signal (A 450 nm > 1.0), 6  out o f  19 
AD samples giving a similarly high reading, 1 out o f  5 dementia with DLB, 1 out o f  7 
FTD samples and 1 out o f 6  control samples giving the same high absorbance (figure 
4.4). The medians o f  the groups are all similar (figure 4.5). However, analysis o f  more 
samples m ay reveal genuine differences between disease groups.
AD
oJl
PD DLB —* FTD Control
Figure 4.4 The levels of association between parkin and a-synuclein in
human plasma




AD(19) PD( 7) DLB(5) FTD(7) Control(6) 
Disease group (n)
Figure 4.5 Box-whisker plots for the same plasma samples - parkin capture, 
a-synuclein detection ELISA results.
The length of the box represents the interquartile range of the sample, the line drawn across the box the
median and outliers being denoted by dots.
There appears to be a large variation in the absorbance levels, which represent the 
relative amounts o f  a complex, or interaction, between a-synuclein and parkin. There 
is no apparent correlation between the A 4 5 0  levels shared by members o f  the same 
disease group, i.e. the values are spread over a large absorbance range in each 
category, including the control group.
The same plasm a samples were screened again, this time capturing the complex with 
anti-a-synuclein monoclonal antibody (2 1 1 ) ( 1 :2 0 0 ) and detecting with anti-parkin 
antibody N-18 (1:1000). For each plasm a sample, the average absorbance at 450mn 
for the a-synuclein capture, parkin detection ELISA was plotted against the A 4 5 0  for 
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Figure 4.6 Confirmation of the association of parkin and a-synuclein in 
human plasma
As expected, the two sets of data showed some agreement, with R2 value of 0.65 
(figure 4.6) showing that there is an association between the data from the two assays. 
It is to be expected that when the sandwich ELISA captured a-synuclein, then 
followed by detection of parkin, then that data would be mirrored when undertaking 
the assay the other way round, i.e. capturing the parkin protein and detecting any a- 
synuclein, if the assay was detecting a complex between a-synuclein and parkin.
The data were analysed using SPSS v 14.0 and Spearman’s Rank employed to test 
whether the ranks of the two sets of measurements are linearly associated. As 
expected, the two variables show a highly significant correlation (p<0.001). There is a 
strong association between the two sets of data.
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4.3.2 Comparison of the plasma levels of parkin with the levels of the parkin/a- 
synuclein complex
The same plasma samples were screened in a further assay, this time to detect the 
levels of parkin. This ELISA detects parkin levels by capturing the protein with anti­
parkin N-18 (1:1000), and detecting it with anti-parkin PARK 11-S (1:20 000). Again, 
the average absorbance at 450nm for each plasma sample in the ELISA to measure 
total parkin (y axis) versus the average absorbance values measured in the ELISA to 










A 450 nm parkin capture / a-synuclein detection
Figure 4.8 Parkin levels in plasma compared to the parkin/a-synuclein
complex levels
The two sets of data are plotted to reveal an overall direct correlation between the two 
sets of data. Once again data were analysed using SPSS v 14.0 and Spearman’s Rank 
employed to test whether the ranks of the two sets of measurements are linearly
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associated. SPSS shows that the probability significance (2-tailed) of getting such test 
statistics is <0.001. There is a strong association between the amount of parkin and the 
concentration of a-synuclein/parkin complex. When the levels of parkin are high in a 
particular sample, the levels of the complex are also high. The R2 value for this data 
comparison is 0.81, whereas previously when comparing the levels of the complex to 
levels of a-synuclein, the R2 value is only 0.54. This suggests the degree of 
association between these two groups of data is more significant then the previous 
comparison (the a-synuclein versus a-synuclein/parkin complex). It may be the case 
that the level of parkin most directly influences the amount of complex present in the 
plasma.
4.4 Discussion
The a-synuclein protein was linked to Parkinson’s disease with the discovery of 
mutations (Polymeropoulos et al. 1997), duplication (Chartier-Harlin et al. 2004) and 
triplication (Singleton et al. 2003) of the SNCA gene, encoding the a-synuclein 
protein, in familial cases of PD and DLB. Lewy bodies which are the main 
pathological feature of PD and DLB brains are formed by the conversion of soluble 
monomers of the a-synuclein protein into insoluble aggregates (Spillantini et al. 
1998). Studies on mouse models that either overexpress SNCA or lack the SNCA gene 
(SNCA knock-out mice) suggest a central role for a-synuclein in PD. It has also been 
suggested that parkin molecules are a factor when considering the formation of Lewy 
bodies (Shimura et al. 2001).
In this study, ELISA methods were used to measure the amounts of a-synuclein, 
parkin, and some form of complex between these two proteins, in plasma from control 
cases and from individuals with a neurodegenerative disease.
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4.4.1 Possible methods of secretion of a-synuclein
Because a-synuclein lacks a target sequence for the ER, it has been thought to exist as 
an intracellular protein (Jakes et al. 1994). However, the results presented here support 
more recent thinking that the protein may also exist as an extracellular form in plasma 
(El-Agnaf et al. 2003).
The mechanisms whereby proteins are sorted to the major organelles and 
compartments of cells are well understood. The initial ‘sorting’ occurs during the first 
growth of polypeptide chains on cytosolic ribosomes. Some proteins contain a specific 
signal targeting sequence, the endoplasic reticulum (ER) signal sequence that directs 
the ribosomes synthesising them to the ER. This sequence is usually found on the N- 
terminus and contains a run of hydrophobic amino acids. Protein synthesis is 
completed on ribosomes attached to the ER membrane. The completed polypeptide 
chains are then moved to the Golgi complex and are subsequently secreted to various 
destinations. Synthesis of proteins that lack the ER targeting sequence is completed on 
free ribosomes and the proteins released into the cytosol, where some of them are 
directed to other organelles, e.g. the mitochondria, peroxisomes or the nucleus, 
depending on the other specific signal sequences they may contain.
Although the precise mechanism by which a-synuclein is released extracellularly is 
not known, it may be significant that the C-terminal tail of the protein contains two di- 
acidic motifs in the form of Asp-X-Glu. This motif is known to be an ER to Golgi 
directing signal (Nishimura et al. 1999) and it interacts with the ER coat protein II 
complex (COPII) (Barlowe 2002). COPII consists of three proteins (Sari, Sec23- 
Sec24 and Secl3-Sec31 complex) that are sequentially recruited to the ER membrane 
surface. Sari is a small 21 kDa protein GTPase, whereas Sec23-Sec24 and Seel 3- 
Sec31 are large protein complexes. COPII forms transport vesicles to carry newly 
synthesised proteins from the ER to the Golgi and collect the appropriate cargo 
proteins into these vesicles (Barlowe 2002; Barlowe 2003). Although a-synuclein 
does not have an ER directing signal, and so is thought to be cytosolic in its 
distribution, it is enriched in synaptosomal fractions of mouse and human brain, and 
similarities between the N-terminus of a-synuclein and the lipid-binding domains of 
some apolipoproteins suggest a role for a-synuclein interacting with lipid membranes
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(Davidson et al. 1998). This data is supported by other findings that a-synuclein has a 
motif at the N- and the C-terminal that is homologous to the fatty acid binding protein 
(FABP) signature motif (Sharon et al. 2001). Other studies have suggested that the N- 
terminal region of the protein may reversibly interact with membranes via 7 repeated 
motifs of 11 amino acids each that are shared with the class A2 helices of 
apolipoproteins (Clayton and George 1999). a-synuclein appears to associate with 
membranes, not only via this N-terminal domain, but also via its C-terminal domain, 
in which no such lipophilic sequence exists (McLean et al. 2000). Additionally, the 
amphipathic a-helical, lipid-binding domain of a-synuclein has been reported to 
strongly bind to membranes (Sharon et al. 2001; Voiles and Lansbury 2002) and even 
make them permeable. It could be suggested that these membrane binding properties 
might allow a-synuclein to associate with the ER membrane. There, the di-acidic 
motifs on the protein could interact with the COPII complex, transporting proteins 
from the ER to the Golgi, and then via the default pathway of secretion from the cell.
Work on vimentin, a large 53kDa intermediate filament protein, has provided 
evidence that large proteins without ER leader sequence, can be secreted from cells. 
Studies have shown that , despite lacking an ER sequence, in some circumstances 
vimenitin can cross into the ER and be secreted from the cell through the ER-Golgi 
pathway (Mor-Vaknin et al. 2003). It may be of significance that, like a-synuclein, 
vimentin also has a di-acidic Asp-X-Glu motif on its C-terminus.
Synucleins (a- and y-synuclein) are expressed in blood platelets. Investigations into 
the synucleins contained in platelets from PD and normal control individuals showed 
that neither of these proteins were secreted upon thrombin activation (Li et al. 2002), 
and therefore it was deemed unlikely that the a-synuclein in human plasma originated 
from platelets. There was no significant difference between the levels of platelet 
synucleins in PD and normal samples. Using AD as an analogy, it has been reported 
that in a transgenic mouse model of AD, after peripheral administration of a 
monoclonal antibody to Ap, a rapid increase in plasma Ap was observed, and the 
magnitude of this increase was highly correlated with the amyloid concentration in the 
hippocampus and cortex (DeMattos et al. 2002). As this data suggests that Ap can 
efflux from the brain to the plasma, it is possible that an equivalent mechanism could 
do the same for other neuronal proteins, including a-synuclein. Glial cytoplasmic
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inclusions in oligodendrocytes, in MSA brains, contain a-synuclein fibrils (Gai et al. 
1998; Spillantini et al. 1998), although the protein is not expressed in these cells 
(Solano et al. 2000). This could suggest that these a-synuclein deposits found in the 
brains of patients with MSA may also originate from neuronal secretion.
It has also been demonstrated that, as a part of the normal life cycle of the protein, 
some of the intracellular a-synuclein is released from neuronal cells to the culture 
medium, via vesicular entry and exocytosis (Lee et al. 2005). It is speculated that this 
might represent a novel mechanism by which cells expel damaged or misfolded a- 
synuclein. Furthermore, the study (Lee et al. 2005) shows that a-synuclein is highly 
prone to aggregation within the vesicles. The aggregates are secreted from cells, and 
mitochondrial and proteasomal dysfunctions (conditions that are associated with 
intracellular aggregation and PD pathogenesis; (Ciechanover 2001)) cause elevated 
secretion of a-synuclein aggregates. This release of a-synuclein may explain the 
presence of the protein in human blood and also CSF (El-Agnaf et al. 2003). 
Moreover, it has been established that over 30% of newly synthesised cellular 
proteins are discarded without being properly folded, even though they are normally 
synthesised without mutations in their genes or errors in translation (Schubert et al. 
2000).
Taking all this evidence into account, it could be speculated that full length a- 
synuclein is released by neurons as part of normal cellular processing, rather than as a 
result of neuronal degeneration. The protein could be secreted into the surrounding 
media in the brain, and this could circulate to the CSF and on to the blood.
Investigations into the existence of an unbroken neuronal chain, from the enteric to the 
central nervous system, lends support to the hypothesis that a putative environmental 
pathogen capable of passing the gastric epithelial lining may induce alpha-synuclein 
misfolding and aggregation in specific cell types of the submucosal plexus (Braak et 
al. 2006). This could reach the brain via a consecutive series of projection neurons. If 
this were the case, then it is feasible that plasma a-synuclein may originate from the 
neurones of the enteric system and not within the brain itself.
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One of the more interesting possibilities to arise from this is the potential use of a- 
synuclein, or other proteins implicated in neurodegenerative disorders, in biological 
fluids as a biomarker for PD or related diseases.
4.4.2 Detection of total a-synuclein in human blood plasma
Using different anti-a-synuclein antibodies for capture and detection, one type of 
ELISA can detect all forms of a-synuclein. This assay was used to measure the total 
amount of a-synuclein in plasma samples from patients with FTD, DLB, PD, AD and 
control cases. Present results show that there was a wide variation within the disease 
groups and the control group, with no obvious links to specific disease. The 
comparatively high levels of a-synuclein in plasma are not confined to patients with 
PD or other synucleinopathies. If the presence of a-synuclein in blood plasma was to 
be used as a diagnostic marker for PD, the levels would have to be significantly 
different from those diseases that were not associated with a-synuclein, i.e. the non- 
synucleinopathies.
The exact function of a-synuclein remains unclear, although it has been linked to 
many cellular processes, including the possibility that it may be a signalling molecule. 
Other possible functions are lipid binding and synaptic plasticity, i.e. the moulding 
and re-moulding of the synapse to accommodate synaptic transmission. Involvement 
with vesicle formation and dopamine transport has also been suggested. Consequently, 
because the precise function of a-synuclein remains unknown, its role in plasma can 
only be speculated. As the protein is only 14.4kDa in size, one would expect it to be 
readily excreted by the kidneys. In order to become large enough to avoid excretion, a 
-synuclein might need to be complexed with either itself or other proteins.
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4.4.3 Detection of an a-synuclein/parkin interaction
An ELISA capturing parkin and detecting a-synuclein was developed to assay human 
plasma for the presence of any protein complex that contains the two proteins. This 
assay suggested that parkin was present in plasma complexed with a-synuclein. To 
corroborate these results, another ELISA was developed that captured a-synuclein and 
detected parkin. The absorbance values recorded from this assay correlated with the 
absorbance levels from the first ELISA (figure 4.7). One would predict that the 
relative absorbance levels measured for an individual plasma sample would be similar, 
e.g. if  the a-synuclein capture, parkin detection absorbance was very low, the parkin 
capture, a-synuclein detection readings would also be low. There is not a 100% 
correlation when comparing the two sets of results, possibly due to the nature of the 
assays. It is recognised that as ELISA experiments are so sensitive, very slight 
variations in parameters such as incubation times and temperature may have effects on 
the results obtained. It is also possible, regarding these two experiments, that epitopes 
on the proteins within the complex were partially shielded, resulting in a difference in 
the measured absorbance at 450nm.
a-synuclein is reported to be a substrate for parkin (Shimura et al. 2001) and a novel, 
glycosylated form of a-synuclein, aSp22, has been found complexed with parkin. It 
has been suggested that parkin, an E3 ubiquitin ligase, is a factor in the formation of 
Lewy bodies (Shimura et al. 2001). Lewy bodies are the characteristic inclusions that 
form the basis of the post-mortem diagnosis for PD patients. However, Lewy bodies 
are usually absent in parkin-deficient ARJP brains (van de Warrenburg et al. 2001). It 
is not known whether Lewy bodies are pathological, or protective in nature. It is 
possible that their influence changes as the disease progresses. For example, in the 
early stages of PD, excess a-synuclein may be “mopped up” by parkin into Lewy 
bodies as a protective mechanism, only for these inclusions to interfere with normal 
cellular processes in the later stages of disease, leading to neuronal death. The a- 
synuclein identified in Lewy bodies is poly-ubiquitinated (Trojanowski et al. 1998). 
One popular hypothetical model suggests that the loss of parkin in the brains of ARJP 
patients, and therefore the loss of E3 ubiquitin ligase activity, could initiate an 
accumulation of parkin substrates, including non-ubiquitinated aSp22. This build up 
may generate accelerated neuronal loss and a younger age of onset of disease (Kitada
et al. 1998). However, if this is the case, why has aSp22 not been identified in Lewy 
bodies or elsewhere in the brain? On the contrary in PD, parkin is thought to 
ubiquitinate this modified a-synuclein and target it for degradation by the proteasome. 
This would continue up until a time when the process is not efficient enough to 
prevent a build up of substrate, and results in a later onset of the disease. However, 
very little is known about this O-glycosylated form of a-synuclein, and even its 
existence has not been confirmed by other groups (Giasson and Lee 2001). The results 
o f the present study support the theory that a-synuclein is bound by parkin and may be 
a substrate. However, there is ambiguity as to which form of a-synuclein is complexed 
to the parkin.
The present study reports that the a-synuclein/parkin complex is detected in blood 
plasma, a-synuclein, as mentioned previously, is believed to be secreted from the cell 
through exocytosed vesicles. Also, like a-synuclein, parkin has been found to be 
associated with cellular vesicles (Kubo et al. 2001). Therefore, it seems feasible that 
parkin could be secreted from the cell already complexed to a-synuclein. Once it is 
secreted from the neuronal cells, the complex may cross the blood-brain barrier, where 
it would enter the plasma.
Why the parkin is complexed to a-synuclein in the first place is open to speculation. 
Parkin possibly targets misfolded/mutated/excess a-synuclein for ubiquitination and 
consequently proteosomal degradation. It may be possible that as well as degradation, 
the proteins are sequestered into cytoplasmic inclusions, as both a-synuclein and 
parkin are present in Lewy bodies. Maybe the vesicular exocytosis is another 
mechanism by which the proteins are regulated within the cell. As mentioned 
previously, parkin may be responsible for the formation of Lewy bodies, as these are 
lacking in ARJP patients (who lack the functional parkin protein). Perhaps the non- 
ubiquitinated a-synuclein accumulates, thus attributing to cell death. It is also possible 
that one of the other physiological targets of parkin may contribute to the pathogenesis 
of PD.
One type of ELISA can detect monomeric and complexed forms of parkin, using 
different parkin antibodies for capture and detection. This assay was used to measure 
the comparative levels of parkin in plasma samples from patients with FTD, DLB, PD,
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AD and control cases (figure 4.6). The assay suggested that parkin was indeed present 
in the plasma samples. The absorbance values recorded from this assay can be seen to 
correlate with the absorbance levels from the ELISA that detects the a- 
synuclein/parkin complex (figure 4.8). When the level of parkin is high in a particular 
sample, generally the levels of the complex are also elevated. The results suggest that 
the level of parkin is the factor that determines the level of complex.
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CHAPTER FIVE -  RESULTS
5 Detection of a-synuclein and parkin in human brain and 
plasma by immunoprecipitation and immunoblotting
5.1 Introduction
Previously, an ELISA has been developed that suggests that parkin interacts with a- 
synuclein in human plasma. Initially the sandwich ELISA captured the parkin (anti­
parkin antibody N-18, 1:1000 dilution) and detection was via an anti-a-synuclein 
antibody (FL-140, 1:1000). The same plasma samples were screened again, this time 
capturing the complex with anti-a-synuclein antibody and detecting with anti-parkin 
antibody. The two sets of data showed agreement, therefore suggesting these results 
are valid.
However, it is not known whether the a-synuclein in the a-synuclein/parkin complex 
is the normal 14.4kDa protein, or the modified (glycosylated) a-Sp22.
5.2 Immunoprecipitation o f the a-synuclein/parkin complex in human 
plasma
Data is required to further establish and confirm the presence of a protein complex 
between the two molecules, and also, to investigate the question of whether the a- 
synuclein in the a-synuclein/parkin complex is the normal 14.4 kDa protein, or the 
modified (glycosylated) a-Sp22. Immunoprecipitation was utilised as a method to 
capture the proteins, and help towards characterising the complex further. A plasma 
sample with a high measured absorbance value of over 2.5 at 450nm for the 
synuclein/parkin complex ELSA, and a control sample with low reading of near zero, 
were incubated for immunoprecipitation (IP) using magnetic Dynabeads coupled to
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anti-parkin antibody (N-18), and also control beads coupled to rabbit IgG. The bound 
proteins were eluted from the beads, separated on SDS gels before transfer to 
nitrocellulose for analysis by immunoblotting. The blots were probed with anti-parkin 
(PARK 11-S), and also with anti-a-synuclein antibodies (FL-140 and 211).
Im m unoblots with anti-parkin (PARK 11-S) revealed the 53kDa parkin protein as 
expected (figure 5.1). This would suggest that the parkin im m unoprecipitation had 
been successful. The immunoblots on the low reading plasm a sample gave no 
bands/data. The control beads coated with the IgG showed no non-specific binding.
_^_  53kDa
parkin
a b e d
Figure 5.1 Plasma that gave a high a-synuclein/parkin ELISA absorbance 
value of over 2.5 was immunoprecipitated with anti-parkin antibody (N-18)
The precipitate was analysed by immunoblotting with anti-parkin antibody (PARK 11-S). The 53kDa 
parkin protein was specifically captured by the anti-parkin antibody that was crosslinked to the 
Dynabeads. 12.5% SDS-PAGE. Lane a, Multimark molecular weight markers (Invitrogen); lane b, 
control beads coated with rabbit IgG and incubated with plasma that gave a high ELISA absorbance 
reading when assayed for the complex; lane c, beads coated with N-18 and incubated with plasma with 
a low complex onxentration; and lane d, beads coated with anti-parkin antibody N-18 and incubated
with a high complex concentration plasma.
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Immunoblots with both primary anti-a-synuclein antibodies FL-140 and 211, to detect 
any a-synuclein present, both revealed the reported binding partner of parkin, a- 
synuclein (figure 5.2). This confirms that a-synuclein does co-precipitate with parkin. 
However, the a-synuclein is not the reported 22-24 kDa form aSp22, but an 
approximately 17 kDa form that co-migrates with the recombinant a-synuclein, and so 





a b c d e f
Figure 5.2 The same immunoprecipitate was also analysed by 
immunoblotting with anti-a-synuclein antibodies FL-140 (figure 5.2 a-c) and 211
(figure 5.2 c-d)
Results show that both antibodies reveal a band corresponding to a-synuclein, suggesting that this 
protein co-precipitates with parkin. However, as the protein co-migrates with the recombinant a- 
synuclein, it may be deduced that this synuclein is not the reported 22-24 kDa form aSp22, but the non- 
glycosylated protein. 12.5% SDS-PAGE. Lanes a and d, control beads coated with IgG and incubated 
with a plasma sample that gave a high absorbence reading when assayed for the complex by ELISA; 
lanes b and e, beads coated with anti-a-synuclein antibody and incubated with the same high complex 
concentration plasma sample and lanes c and f, recombinant a-synuclein.
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A second immunoprecipitation experiment was then performed. Again, the same 
plasma sample with a high absorbance of over 2.5 at 450nm for the synuclein/parkin 
complex ELISA, and the control sample with a low reading of near zero, were 
incubated for immunoprecipitation using magnetic Dynabeads, this time coupled to 
monoclonal anti-a-synuclein antibody (211), along with control beads coupled to 
rabbit IgG. The bound proteins were eluted from the beads, and then separated on 
SDS gels before transfer to nitrocellulose for analysis by immunoblotting. The blots 
were probed with anti-a-synuclein antibody (FL-140), which revealed the 17kDa fonn 
of a-synuclein protein (figure 5.3). This would suggest that the a-synuclein 
immunoprecipitation had been successful. The immunoblots on the low reading 
plasma sample gave no bands/data (figure 5.3). The control beads coated with the IgG 




Figure 5.3 A plasma sample that gave a relatively high ELISA absorbance at 
450 nm of 2.5, was immunoprecipitated with anti-a-synuclein antibody (211)
The precipitate was analysed by immunoblotting with anti-a-synuclein antibody (FL-140). The 
14.4kDa a-synuclein protein was specifically captured by the anti-a-synuclein antibody that was 
crosslinked to the Dynabeads. 12.5% SDS-PAGE. Lane a, Magicmark (Invitrogen); lane b, beads 
coated with anti-a-synuclein antibody (211) and incubated with plasma that gave a high absorbence 
when assayed for the complex; lane c, recombinant a-synuclein, lane d, beads incubated with a low
complex concentration plasma sample.
8 6
Immunoblots with primary anti-parkin antibody N-18, to detect any parkin present in 
the precipitate, revealed the reported binding partner of a-synuclein, the 53 kDa 
parkin (figure 5.4). This confirms that parkin does co-precipitate with a-synuclein. 
Experiments on the low reading plasma gave no data. The control beads coated with 






Figure 5.4 The same precipitate analysed by immunoblotting with parkin 
antibody PARK-11S
Results show that the antibody reveals a band corresponding to parkin, suggesting that this protein co­
precipitates with a-synuclein. 12.5% SDS-PAGE. Lane a, Magicmark (Invitrogen); lane b, beads coated 
with anti-a-synuclein antibody (211) and incubated with a plasma sample that gave a high reading by 
ELISA when assayed for the protein complex; lane c, beads incubated with a plasma sample that
contained a low complex concentration.
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5.3 Immunoprecipitation of the a-synuclein/parkin complex in human 
brain
If parkin has been found to bind non-glycosylated a-synuclein in human plasma from 
patients with neurodegenerative diseases and also normal control subjects, the 
question arises as to whether the a-synuclein in the brain is also bound to parkin, and 
if  so, is it the normal 14.4 kDa form or the modified, heavier form.
Identical immunoprecipitation experiments were carried out on human brain 
homogenates from a patient with a neurodegenerative, synucleinopathy (DLB) that 
gave high absorbance readings when assayed using the previous ELISA techniques, 
and also with a low reading/absorbance, normal control brain sample.
As before, Dynabeads were crosslinked to either anti-parkin (N-18) antibody or anti- 
a-synuclein (211) antibody, and then incubated with the brain extract. This was again 
followed with detection by immunoblotting with either anti-parkin antibody (N-18) or 
anti-synuclein antibody (FL-140).
a) b)
Figure 5.5 a-synuclein immunoprecipitation experiments carried out on
human brain tissue
Brain tissue from a patient with DLB that gave a high absorbance measurement when assayed for the a- 
synuclein/parkin complex, and a normal, low reading control brain. Dynabeads were crosslinked to 
anti-synuclein (211) antibody, then incubated with the human brain homogenates. This was followed 
with detection by immunoblotting, either with anti-synuclein (FL-140) (figure a) or anti-parkin (N-18) 
antibody (figure b). 12.5% SDS-PAGE. Lane a, beads incubated with a normal brain sample that had a 
low concentration of complex when assayed b y ELISA; lane b, sample beads coated with anti-a- 
synuclein antibody (211) and incubated with a DLB brain sample that had a high concentration of 
complex; and lane c, recombinant a-synuclein.
The synuclein immunoblot displayed three bands (figure 5.5a). The protein was 
present in the normal brain tissue, and in the DLB brain sample. As these bands 
m igrated at the same rate as the recombinant protein, it could be surmised that this 
was the normal a-synuclein, not the larger aSp22. Parkin was not detected in normal, 
control brain tissue (figure 5.5b, lane a), but the band was present in the DLB sample 
tissue. The parkin must have co-precipitated with the a-synuclein. This data largely 
m irrored the data obtained from the plasma sample that gave a relatively high 
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Figure 5.6 Further immunoprecipitation experiments carried out on human
brain tissue
Brain tissue was obtained from a patient with DLB that gave a high A450nm reading of over 2.5 when 
assayed for the a-synuclein/parkin complex, and a normal, low reading ( A450 nm of near zero) control 
brain. Dynabeads were crosslinked to anti-parkin (N-18) antibody, and then incubated with the human 
brain homogenates. This was followed with detection by immunoblotting, either with anti-a-synuclein 
antibody (FL-140) (figure 5.6a) or anti-parkin antibody (PARK 11-S) (figure 5.6b).
Figure 5.6a
12.5% SDS-PAGE followed by immunoblotting with anti-a-synuclein antibody (FL-140). Lane a, 
beads coated with anti-parkin antibody (N-18) and incubated with a low complex concentration, normal 









12.5% SDS-PAGE followed by immunoblotting with anti-parkin antibody (PARK 11-S). Lane a, 
beads coated with anti-parkin antibody (N-18) and incubated with a high complex concentration DLB 
brain sample (A450 nm over 2.5); lane b, beads incubated with a low complex concentration normal 
brain sample (A450 nm of near zero); and lane c, recombinant a-synuclein.
The data reveals a band corresponding to parkin at 52 kDa, and a further 
imm unoreactive band at a higher molecular weight was detected.
5.4 Discussion
5.4.1 Confirmation of a functional relationship between parkin and a-synuclein
This study has confirmed a direct relationship between two proteins associated with 
PD, parkin and one o f its substrates, a-synuclein. The novel data identifies parkin in 
hum an blood plasma, and also an interaction in human plasma and brain that involves 
parkin and a-synuclein. However, the target for parkin does not appear to be the 
reported 22-24 KDa O-glycosylated isoform o f  a-synuclein, aSp22 (Shimura et al.
2001), but a form o f the protein that co-migrates with recombinant a-synuclein.
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5.4.2 In conclusion
The detection of a-synuclein, and/or of complexed or modified forms in plasma, could 
offer new opportunities for the development of a diagnostic test for PD or other 
related synucleinopathies. In this study, parkin was discovered in human plasma, 
apparently complexed to a-synuclein. The development of a good biomarker for these 
neurodegenerative diseases would dramatically accelerate research on these disorders. 
Biomarkers are biological substances that can be used to indicate the presence or onset 
of a disorder, in contrast to post-mortem diagnosis. A good biomarker should be 
precise and reliable, and distinguish between normal and disease states and different 
diseases. In addition to this, a biomarker could be used to track disease progression in 
diagnosed patients. However, although samples numbers are very small, this study 
suggests that the quantification of plasma a-synuclein, parkin, or a-synuclein/parkin 
complex is not a useful diagnostic biomarker for PD, or other synucleinopathies, given 
the variable amounts of the proteins in question found in both patient and control 
samples.
This study could suggest that a relatively high level of a-synuclein accompanies a 
high level of parkin and the a-synuclein/parkin complex results. It is possible that 
parkin is responsible for either (1) the ubiquitination of excess, damaged or misfolded 
a-synuclein to ensure it is degraded by the proteasome; (2) to ensure that the proteins 
are incorporated into inclusion bodies, or equally (3) to excrete the proteins from the 
cell by vesicular exocytosis. What role Lewy bodies play in the pathogenesis of PD is 
not yet understood. An interesting analogy can be drawn here. The absence of the E6- 
AP ubiquitin ligase in the neurological disorder spinocerebellar ataxia type 1 leads to 
a decrease in the amount of ataxin containing inclusions, and the clinical symptoms 
and neuronal injury are increased considerably (Cummings et al. 1999). It is possible 
that in PD, it is parkin that is responsible for the formation of Lewy bodies, a process 
that is impaired in ARJP where the parkin protein is mutated. It might be 
unconjugated (to parkin) a-synuclein, that would otherwise have been ubiquitinated, 
degraded or sequestered into Lewy bodies, that accumulates and leads to cell death.
Interestingly, it has also been shown that the human mutants of a-synuclein, A3 OP 
and A53T, demonstrate a decrease in the a-helical structure of the molecule (Li et al.
2002). If this is the case, it may potentially affect a-synuclein/parkin binding. It is
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known that patients with these mutations have an earlier onset of PD than sporadic 
cases (Polymeropoulos et al. 1997). This could be partially be due to a reduction in a- 
synuclein ubiquitination, leading to a reduction in its degradation by the proteasome 
and a decrease in the amount sequestered into inclusion bodies or secreted in vesicles. 
Also, the same may apply to the A46K a-synuclein mutation that has been illustrated 
to have effects on phospholipid binding capacity and filament formation when 
compared to wild-type protein (Choi et al. 2004).
The present study confirms previous work (Salem 2004) that has identified a- 
synuclein as a component of human blood plasma. Also, the data identifies parkin in 
plasma, and also a protein complex in human plasma that involves parkin and a- 
synuclein. Further to this, the levels of both proteins, both individually and complexed 
together, were investigated in blood plasma from patients with Parkinson’s and other 
neurodegenerative diseases. The results suggest that there is a correlation between the 
levels of expression of a-synuclein, parkin and the complex in individual plasma 
samples, but no clear relationship when comparing disease and control groups 
(although the number of samples analysed are small). At present, levels of these 
proteins would have to be investigated further, within much larger sample groups, to 
find if  they were to be useful as diagnostic indicators. However, the ability to track 
this complex, using the methods described, will be essential in future work to 
characterise a-synuclein and the a-synuclein/parkin complex in plasma.
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CHAPTER SIX- RESULTS
6 Isolation of the parkin/a-synuclein complex from human 
plasma by chromatography
6.1 Introduction
This study obtained substantial evidence to suggest that a-synuclein and parkin 
interact in human brain and in human plasma. The ELISA methods previously 
described give us the ability to track this complex, and would be essential in work to 
characterise a-synuclein and the a-synuclein/parkin complex in plasma.
This chapter describes the development of protocols for attempting the purification of 
the a-synuclein/parkin complex, as well as the two individual proteins, by utilising 
various chromatography techniques.
To determine the molecular weight (Mw) of the a-synuclein/parkin complex, and also 
the size of the individual proteins themselves, size exclusion chromatography is 
utilised.
6.2 Size exclusion chromatography
Size exclusion chromatography was used to determine the Mw of the immunoreactive 
parkin and a-synuclein, as well as any a-synuclein/parkin complex present in brain 
tissue. A Superdex 200 column was initially used in this study and was calibrated 
using a set of gel filtration molecular weight protein standards with Mw’s of 181 Da to 
669 kDa (Sigma), which gave a linear calibration on plot (figure 6.1).
94
y = -2.7549x + 6.0979 
R2 = 0.9922
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Figure 6.1 Calibration curve for Superdex 200
Graph presented as Kav to log MW (Kav=Ve-Vc/Vt-V0, where Ve = elution volume, V0 = void volume, Vt
= total column volume).
Initially, a O.lmg sample of recombinant a-synuclein was injected onto the column. 
This recombinant protein was frozen at -80°C immediately after purification from the 
E.coli lysate, and freeze thaw processes were avoided, to ensure that the protein was 
in its monomeric form. The peak at 13.77 ml (figure 6.2) gave a Kav of 0.45 and a Mw 
of around 72 kDa. It has previously been reported that synuclein runs at a high 










Figure 6.2 UV chromatogram showing application of recombinant a- 
synuclein and elution of proteins, from the Superdex 200 column
To find the Mw of the complex present in the brain of a DLB patient, we applied a 
200pl sample of filtered protein extract from brain tissue to the column, and the 
resulting fractions were collected. The UV chromatogram revealed a large peak as the 
tissue extract was applied, from elution volume A10-D10 (figure 6.3). Analysis of 
these fractions by ELISA, would reveal if the complex could be detected in the eluate 
from the column. This would give us the Ve for the complex, which would enable the 












Figure 6.3 UV chromatogram showing application of filtered brain tissue 
extract and elution of proteins, from the Superdex 200 column
The fractions eluted from the size exclusion column were assayed using the previously 
developed ELISA’s, to track where the a-synuclein, parkin and the complex elute 
from the column. The results showed that the proteins of interest had voided, i.e. they 
eluted with the void volume (data not shown). The Mw must have been larger than 600 
kDa for this to have happened. It is possible that the proteins of interest were 
interacting with the many other proteins and/or lipids within the brain tissue sample, 
which may not be representative of true interactions within the brain. It is also likely 
that the separation of proteins within blood plasma will be more successful, as there is 
a lower concentration of lipids present that may interact with a-synuclein.
An AD plasma sample (DA01) that gave a high absorbance reading for the a- 
synuclein/parkin ELISA’s, was centrifuged at 13000 rpm for 30 mins in a 0.45 pm 
filter, to remove any insoluble material. 250 pi of the plasma was applied to a 
Superdex 200 column using the previous method. The emerging 0.5 ml fractions were 
collected and assayed for a-synuclein and for the a-synuclein/parkin complex. Elution
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volumes 2-3 ml, which had no protein content (according to the UV chromatogram), 
weie used for the control/background wells on the ELISA plate. As can be seen on the 
UV chromatogram (figure 6.3), there are several large peaks as proteins are eluted 
from the column. Elution volume 5-26 ml were assayed by ELISA and the results 
show that, as with the brain tissue sample, both the a-synuclein and the a- 
synuclein/parkin complex elute in the same fractions (figure 6.4).
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Figure 6.4 To determine the molecular weight of the a-synuclein/parkin
complex
Plasma was applied to a Superdex 200 column and the fractions eluted were assayed by ELISA to 
determine the elution positions of the proteins. Both sets of data reveal that the proteins elute together
in the same fractions.
This could suggest several different scenarios. Either; a) all the a-synuclein is 
interacting with the parkin, b) the a-synuclein and the a-synuclein/parkin complex are 
both interacting with a separate molecular entity, or c) the protein and the complex
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elute independently in the same fractions. The proteins were eluted at approximately 
12 ml, which gives a Kav of 0.322 and a Mw of 162 kDa.
It was decided to attempt to confirm the Mw of a-synuclein using an alternative size 
exclusion column. Further chromatography under dissociative conditions, would then 
be attempted to separate and partially purify the two proteins of interest. The Superose 
6 size exclusion column was initially calibrated under the same method and 
associative running conditions as the Superdex 200 (figure 6.5).
6.5
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Figure 6.5 Calibration curve for the Superose 6 size exclusion column
The recombinant a-synuclein protein was run through the Superose 6 column, and the 
Kav calculated as 0.551, giving a Mw of 82 kDa (as opposed to the Mw of 72 kDa on 
the Superdex 200).
Again, the AD plasma sample that gave the high reading absorbance of over 2.5 for 
the a-synuclein/parkin ELISA’s, was centrifuged at 13000 rpm for 30 mins in a 0.45
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pm filter, to remove any insoluble material. 250pl of the plasma was applied to the 
Superose 6 column using the previous method. The emerging fractions were collected 
and assayed for a-synuclein and for the synuclein/parkin complex. Fractions 2-3 ml, 
that had no protein content according to the UV detector, were used for the 
control/background wells on the ELISA plate. As can be seen on the UV 
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Figure 6.6 UV chromatogram showing flow-through of plasma sample and 
elution of proteins from the Superose 6 column
Once again fractions 5.0 ml through to 25.0 ml were assayed by ELISA. The results 
(figure 6.7) show that, as with the brain tissue sample, both the a-synuclein and the 
synuclein/parkin complex eluted in the same fractions, although this time there are 














Figure 6.7 To determine the molecular weight of the a-synuclein/parkin 
complex plasma was applied to the Superose 6 column and the eluted fractions
assayed by ELISA
Using the calibration curve for this column, we can estimate the Mw of the “peaks” of 
the a-synuclein/parkin complex. The main peak at fractions 15.5-16 ml (figure 6.7) 
suggest that most of the complex is eluting at this position. We can use this to estimate 
a Mw of approximately 42 -  67 kDa. Figure 6.8 shows the calculated molecular 

















Figure 6.8 The previous graph is replicated along with the molecular weights
of the main peak fractions
The peak representing the a-synuclein/parkin complex (figure 6.8 in pink) is the 
“narrow er” o f the two peaks. The peak representing the a-synuclein (in blue) is much 
broader, and encompasses molecules o f MW from around 15 kDa to 298 kDa. This is 
a very large range in M w values. There is a “shoulder” in this trace (in blue) that 
follows the a-synuclein peak (in pink), which poses the question whether the right 
hand, lower M w peak is the a-synuclein that is together in a complex with parkin. The 
M W  o f  around 67kDa m ay point to that possibility. However, the left hand peak is at a 
larger M W  so could not be a-synuclein, unless it was in an oligomeric form or i f  it 
was interacting with other molecules. The main complication to this o f course, is that 
the recom binant a-synuclein ran at 82 kDa on this column under these elution 
conditions. W ith no explanation to why this is the case, it was decided that further 
investigations should be continued under dissociative conditions to attempt to 
m inim ise or eliminate any protein-protein interactions.
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The Superose 6 column was equilibrated in 4M guanidine hydrochloride and 
recalibrated under these dissociative conditions. Protein standards used to calibrate the 
column were denatured with 1M DTT to break any disulphide bridges, before being 
loaded onto the column.
6.5
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Figure 6.9 Calibration curve for the Superose 6 size exclusion column under
dissociative conditions
Again, the recombinant a-synuclein protein was run through the Superose 6 column, 
this time under dissociative conditions, and the Kav calculated as 0.591, giving a 
larger Mw of 102.5 kDa (as opposed to the Mw of 82kDa on the Superdose 6 under 
associative conditions).
The same AD plasma sample that gave the high reading absorbance for the a- 
synuclein/parkin ELISA’s, was once again prepared as before, and 250 pi of the 
filtered plasma applied to the Superose 6 column using the same method. The flow­
through fractions were again collected and assayed for a-synuclein and for the 
synuclein/parkin complex. As can be seen on the UV chromatogram (figure 6.10),
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there are several large peaks as proteins are eluted from the column. Once again 
fractions 5-25 ml were assayed by ELISA. On this occasion, the fractions were diluted 
three fold in PBS, as the running buffer conditions would otherwise have denatured 
the ELISA coating antibody, but unfortunately, only the a-synuclein capture, a- 
synuclein detection ELISA gave data. The results are presented in figure 6.11. This a- 
synuclein ELISA data revealed that the sensitivity of the assay was much reduced (see 















Figure 6.10 UV chromatogram showing flow-through from the plasma 














Figure 6.11 To determine the molecular weight of the a-synuclein in plasma, 
the tissue was applied to the Superose 6 column and the eluted fractions assayed
by ELISA
It was noted that there is hardly any difference between the elution properties of the 
proteins under associative or dissociative conditions (4M guanidine hydrochloride). 
The parkin ELISA’s did not give any data, probably due to the guanidine denaturing 
the coating antibody, and the actual protein being in such a low concentration within 
the diluted fractions.
After these investigations, the data was considered. The size exclusion columns 
provided estimations of the Mw of both recombinant a-synuclein and plasma a- 
synuclein, under both physiological and dissociative conditions (table 6.1).
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Table 6.1 Estimating the molecular weight of both plasma, and recombinant, a-synuclein using two 
size exclusion columns
MW recombinant a- 
syuclein (kDa)
MW plasma a-synuclein 
(kDa)
Superdex 200 72 162
Superose 6 42
Superose 6 (dissociative) 102 161
It was difficult to draw any conclusions from these data. Possible explanations could 
be such that the a-synuclein is interacting with itself, or with other protein molecules 
in the plasma, or with lipids in the fluid. It was decided at this point that other 
chromatographic techniques should be utilised to attempt to partially purify the 
proteins of interest from the plasma, before attempting to estimate their molecular 
weights. Other techniques that are not based on separation by molecular size might 
give useful information on the nature of any ‘complex’.
6.3 Ion exchange chromatography
Ion exchange chromatography is based on the binding of charged sample molecules to 
oppositely charged groups attached to an insoluble matrix. Substances bind when they 
carry a net charge opposite to that of the ion exchanger (the binding is electrostatic 
and reversible). When exposed to a pH below its isoelectric point, the molecule will 
carry a positive charge and would bind to a cation exchanger. At a pH above its pi, the 
molecule will be negatively charged and would bind to an anion exchanger.
Anion exchange chromatography with a Q Sepharose Fast Flow HiTrap column was 
chosen for the first round of the purification of a-synuclein, parkin and the a- 
synuclein complex, from the human plasma sample. This step was selected because of
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the isoelectric points of the proteins of interest. The isoelectric point (pi) is the point at 
which a particular molecule or surface carries no net charge. Amphoteric molecules 
called zwitterions contain both positive and negative charges depending on the 
functional groups present in the molecule, in this case the amino acids. They are 
affected by pH of their surrounding environment and can become more positively or 
negatively charged due to the loss or gain of protons (H+). Parkin has a pi of 6.71 and 
a-synuclein a pi of 4.67. Theoretically, both should adhere to an anion exchange 
column, by electrostatic interactions, run in a buffer of pH 8, and would be eluted with 
an increasing salt gradient. A continuous salt gradient is usually used. The Q 
Sepharose column was set with a flow rate of 1 ml/min, injecting 30 pi of high 
complex concentration plasma sample (approximately 2 mg total protein) diluted with 
an equal volume of buffer A.
The UV chromatogram at 280 nm showed a peak where proteins voided/did not 
adhere to the column, and a peak of proteins that were eluted by the salt gradient. The 
fractions from this run were analysed by ELISA to track where, in the progressing salt 
gradient, each protein of interest and the complex were eluted from the column. 
Analysis of the fractions showed that the proteins did not adhere to the column as 
expected (figure 6.12). However, 0.5 mg of recombinant a-synuclein, run under the 
same conditions, did interact with the column, eluting at a salt concentration of 0.35 












Figure 6.12 Q Sepharose FF HiTrap fractions from a plasma sample that 
assayed as containing a relatively high a-synuclein/parkin complex
The column was run under physiological conditions. Fractions were assayed in two separate ELISA’s 
to track where the a-synuclein and the a-synuclein/parkin complex elute from the column.
The a-synuclein ELISA (figure 6.12, in pink) reveals that most o f our protein is not 
binding to the column, although there is a small amount eluting around 10 ml, at 
around 0.25 M NaCl. The a-synuclein complex is also eluting with the void volume o f 
the column, although there is also a small amount eluting at 10 ml, there is also a 
small amount released from the column at 20 ml, around 0.75 M NaCl.
One explanation as to why the plasma a-synuclein and parkin did not adhere to the 
anion exchange column is that they are interacting with other plasma proteins or lipids 
w hich are altering the pi o f the whole protein complex to such an extent that it was not 
bound by the column. Therefore, it was decided to run the same anion column under 
the dissociative conditions o f 7M urea, in an attempt to separate any protein complex 
interactions.
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Recombinant a-synuclein eluted from the column under these dissociative conditions
at 0.3M NaCl (10.2ml) and similarly the plasma peaks also shift slightly in the same
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Figure 6.13 Q Sepharose FF HiTrap fractions from a plasma sample that 
assayed as containing a relatively high a-synuclein/parkin complex
The fractions were assayed in two separate ELISA’s to track where the a-synuclein and the a- 
synuclein/parkin complex elute from the column.
It was noted immediately that the strength of the absorbance readings is reduced for 
these assays, probably due to the urea denaturing the ELISA coating antibody. 
Although the urea should dissociate the protein interactions this does not seem to be 
the case. The a-synuclein is not binding to the column (Figure 6.13, in blue). If the a- 
synuclein was monomeric, it should all bind to the column and then elute at the same 
salt concentration as the recombinant protein. This is not the case. Also, the a- 
synuclein/parkin complex has not been dissociated, and it is not binding the column. It
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is possible that the complex has a pi greater than 7, and therefore would not bind an 
anionic column. One possible explanation to this scenario could be that as the N or C 
terminal of the protein is heavily negatively charged with aspartates and glutamates, 
and as this tenninus may be involved in the multimerisation, it may therefore be 
“masked”. The overall pi would increase and the protein would not bind to the 
column. If the protein was truncated at this end, or if the a-synuclein was a very stable 
multimer, with an overall higher pi than the monomer, this may explain it not 
adhering to the column. However, the problem with this reasoning is the fact that the 
epitope for the coating antibody (211) is amino acid 120-125. Therefore if the 
synuclein molecules had masked/truncated ends then the assay would not work. It was 
decided at this point to assay these same fractions from the Q FF Hitrap column, run 












Figure 6.14 Q Sepharose FF HiTrap fractions from a plasma sample that 
assayed as containing a relatively high a-synuclein/parkin complex
The fractions were assayed in another separate ELISA to determine whether the a-synuclein was in a
monomeric or an oligomeric form.
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The two assays mirror each other. This suggests that the total synuclein is in an 
oligomeric form. It may be the case that the “multimer” may be composed of just two 
a-synuclein molecules, together with many other proteins. It may not necessarily be 
aggregating with itself. However, the main question that arises here is why the a- 
synuclein is not binding the column. Is it urea stable? The protein complex is not SDS 
stable, as treatment allowed separation of the complex on analysis by SDS PAGE 
(Chapter 5). (The ELISA’s measuring oligomeric and monomeric a-synuclein, in the 
flow-through fractions, when the column is run under dissociative conditions gave no 
data. This is presumably due to the buffer denaturing the coating antibody.)
It follows that if the proteins of interest do not adhere to an anionic exchange column 
as expected, then they would be attracted to a cationic column, at the same pH. A 
cation exchange column, SP Sepharose FF HiTrap column was utilised. The same 
method was employed as before, with the identical buffers. Again, 150 pi of the 
plasma sample that gave a relatively high measured absorbance for the 
synuclein/parkin complex ELISA was diluted with 150pl of buffer A, 15min before 
application to the column. Two runs were completed, one in physiological conditions 
and one under dissociative conditions. Once again the fractions from both experiments 
were assayed by ELISA to track where the proteins of interest elute from the column. 
All the ELISA results, i.e. the total a-synuclein assay, the complex assay and the 
oligomeric assay, reveal that the proteins of interest do not bind to the cationic 
column, either under associative or dissociative conditions. They are eluted with the 
initial flow-through (data not shown).
The conclusion from these investigations is far from clear, a-synuclein with a pi of 
4.67, and parkin with a pi of 6.71, at pH 8 should carry a negative net charge and bind 
to an anion exchanger. This is not happening. Neither are they binding to a cation 
exchanger. An explanation as to why this may be the case could be the proteins are 
“shielded” by other molecules, for example in lipid micelles present in the blood 
plasma. With this scenario in mind, it was decided to repeat the experiments, but this 
time including the non-ionic detergent, Nonidet P-40, in the buffers, at a concentration 
of 1 5% NP-40 is used in many extraction protocols to solubilise membranes. It has a 
polar polyethylenglycol chain and a non-polar end, leading to the formation of lipids 
trapped in water-soluble micelles. The 150 pi plasma sample was incubated in 150 pi
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running buffer A, for 2 h at room temperature before the chromatography, to ensure 
any protein/lipid interactions had been dissociated. The fractions from this 
chrom atography were once again assayed by ELISA to detect the total a-synuclein, 
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Figure 6.15 Q Sepharose FF HiTrap fractions from the plasma sample run 
under associative conditions, with a non-ionic detergent, 1.5% NP-40
The fractions were assayed in four separate ELISA’s to track where the a-synuclein, the parkin and the 
a-synuclein/parkin complex elute from the anionic column.
For the first time, it appears that the proteins o f interest have bound to the anion 
exchange column. A proportion o f the proteins still did not interact with the anion 
exchanger, eluting straight through the column in elution volume 0-5ml, but then a 
significant amount have bound, eluting at around 0.25 M NaCl, in elution volume 6- 
10 ml. The a-synuclein, the parkin and the a-synucelin/parkin complex have eluted
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from the column in the same fractions. This could mean that that the proteins/protein 
complexes have a similar pi. Alternatively, it is possible that they are still interacting 
with each other. With the latter scenario in mind, it was decided that the fractions that 
contained the proteins that interacted with the column should be pooled and applied to 
the same anionic column, this time under the dissociative conditions of urea.
The previous run was repeated, and this time the fractions that contained the proteins 
of interest were pooled together (elution fractions from 6-9 ml, around 4 ml sample in 
total) and dialysed overnight in a Slide-a-lyser, Mw cut off of 3500 Da, in 4 M urea 
buffer. This was to achieve three objectives. The volume of the sample was reduced, 
the urea introduced into the sample was to initiate the protein dissociation and also the 
salt (NaCl) from the previous run was removed (thus allowing the proteins to adhere 
to the column). The dialysed sample was loaded onto the anionic Q Sepharose Fast 
Flow column using the previous method, and once again, the fractions collected were 
subjected to the tracking ELISA’s. Before the fractions were assayed, the urea was 
dialysed out so that it did not affect the ELISA coating antibody. The 1.5 ml 
Eppendorf tubes that were utilised to collect the fractions from the chromatography 
were adapted for overnight dialysis (figure 6.16).
o
Figure 6.16 The 1.5 ml Eppendorf tubes were adapted for dialysis
The caps were removed. A small piece of dialysis membrane (Mw cut off 3.5 kDa) that had been 
previously soaked in water, was placed in between the tube and the O-ring, and the tubes then 
suspended upside down in a large 3 1 beaker of distilled water, checking that the sample was in contact
with the membrane.
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The 46 tubes were suspended upside down in 3 1 of water, which was changed 3 times 
over the course of 24 hours. Following this procedure, the fractions were assayed. The 
results for each assay are showed in figures 6.17 to 6.19, with figure 6.20 representing 
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Figure 6.17 ELISA data for total a-synuclein
Analysis by a-synuclein capture, a-synuclein detection ELISA of the flow through fractions from the Q 
Sepharose FF HiTrap column, run initially in non-ionic detergent, followed by the dissociative 
conditions of 7 M urea. The peak elution volumes are shown and the NaCl gradient is represented. (It 
should be noted here that the peak at elution volume 16.0ml is a ‘real’ peak, as this cannot be easily














Figure 6.18 ELISA data for a-synuclein/parkin complex
Analysis by a-synuclein capture, parkin detection ELISA of the flow through fractions from the Q 
Sepharose FF HiTrap column, run initially in non-ionic detergent, followed by the dissociative 














Figure 6.19 ELISA data for total parkin
Analysis by parkin capture, parkin detection ELISA of the flow through fractions from the Q Sepharose 
FF HiTrap column, run initially in non-ionic detergent, followed by the dissociative conditions of 7 M 
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Figure 6.20 Comparison of ELISA data
The previous three individual plots (figures 6.17-6.19) are included to highlight the fact that although a- 
synuclein, parkin and the complex are eluting together in the same elution volume, they also are eluting
from the column separately.
As can be seen from the ELISA data, the proteins all interacted with the anion 
exchange column. The peak at fraction 9.5 ml represents the a-synuclein/parkin 
complex eluting from the column at around 0.35 M NaCl. It appears that the urea has 
dissociated some of the protein complex into the individual proteins. Parkin elutes at 
14.0 ml (0.6 M NaCl) and a-synuclein at the higher salt molarity at fraction 16.0 ml 
(0.7 M NaCl). By increasing the salt concentration, the molecule with the weakest 
ionic interactions (parkin) was disrupted first and elutes earlier in the salt gradient. 
The molecules that have a stronger ionic interaction (a-synuclein) require a higher salt 
concentration and elute later in the gradient.
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6.4 Overview of the isolation strategy
The isolation strategy for parkin, a-synuclein and the parkin/a-synuclein complex 
from human blood plasma, is outlined in Figure 6.21.





Collect flow-through (Elution volume 6-9 ml) 
t




Dialysis in water to extract urea
Figure 6.21 Flow-diagram outlining the strategy for isolating parkin, a- 
synuclein and the parkin/a-synuclein complex from human blood plasma
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6.5 Gel filtration chromatography repeated
The whole strategy was repeated. The peak from the last anion exchange column 
containing the a-synuclein/parkin complex, at elution volume 9-10.5 ml, was loaded 
on the Superpose 6 gel filtration column, under both associative and dissociative 
conditions. The information gained from doing this may suggest whether it was 
probable that the two proteins are; a) migrating together because they are interacting 
with lipid, or b) if they are interacting with each other. The above process was once 
more repeated and the resulting dialysed fractions were reduced in volume by vacuum 
centrifugation to around 50 pl/tube (total 150 pi). This sample was loaded onto the 
Superose 6 column, using the same method as before. However, before the sample 
was run, the Superose 6 gel filtration column is recalibrated for accuracy, giving an R 
value of 0.9552, and an equation to calculate the Mw of the unknown as y = -3.4393x 
+ 6.7419.
The sample was loaded onto the Superose 6 column. The UV chromatogram (at high 
resolution) reveals a small peak at 14.57 ml and another at 16.01 ml. The 0.5 ml 
fractions are assayed by ELISA to track when our proteins of interest are eluting from 
the column. Only two assays gave data; the total a-synuclein (figure 6.22) and the a- 












Figure 6.22 Total a-synuclein ELISA data from the protein isolation process 
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Figure 6.23 Total a-synuclein/parkin complex ELISA data for from the 
protein isolation process and subsequent Superose 6 gel filtration
chromatography
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The a-synuclein is detectable although the measured absorbtion value is much reduced 
(0 .025), the data revealing that the protein is eluting at 12.5-13 ml. The complex is 
also just detectable, and also eluted in these fractions. These fractions correspond to a 
peak on the chromatogram at 14.57 ml, and the calibration curve equation gives the 
molecular weight of the protein complex to be 156 kDa.
Recombinant a-synuclein was run through the column again, eluting at 15.69 ml, 
which corresponds to 77 kDa.
The Mw of the complex at 156 kDa is small and does not suggest a lipid interaction, 
rather a small number of units.
6.6 Discussion
Application of plasma to an ion-exchange chromatography column allows the 
separation of the complex and the individual proteins. The previously developed 
ELISA’s track the constituent proteins and the complex as they are eluted from the 
column. The large peak on figure 6.20 contains both a-synuclein and parkin, the 
proteins co-eluting as they interact to form a complex. The smaller peaks to the right 
are the elution positions of the individual proteins themselves.
The molecular weight of the complex was investigated using gel-filtration 
chromatography, and was estimated at 156 kDa. Parkin has a molecular weight of 53 
kDa and recombinant a-synuclein runs at 77 kDa, (although the protein is only 14.4 
kDa, it is known to run larger, as previously discussed). This data suggests that the 
complex is a single species with a simple molecular composition, for example a 1:1 
complex of a-synuclein and parkin.
Very recently, Kawahara et al. investigated whether a-synuclein accumulation might 
be involved in PD pathogenesis by interfering with the solubility of parkin (Kawahara
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et al. 2008). They concluded that a-synuclein and parkin co-immunoprecipitate in 
neuronal cell lines, and confirmed the association in neuronal cells by performing co- 
immunoprecipitation experiments. This was achieved by a-synuclein being 
immunoprecipitated from a neuronal cell extract with an anti-a-synculein antibody, 
followed by immunoblotting with an anti-parkin antibody, and then performing the 
experiment the other way around. The authors suggest that this evidence supports the 
possibility that interactions between a-synuclein and parkin lead to the formation of 
insoluble aggregates that could possibly damage the neuronal cytoskeleton, rather than 
impair the function of parkin. Unfortunately, the nature/size of the a-synuclein that 
interacts with parkin was not investigated.
To conclude, this work has confirmed that a-synuclein and parkin do interact in 
biological samples. For the first time, the existence of parkin and the complex has also 
been demonstrated in human plasma. These latter findings may prove to be useful as a 
method to attempt purification and full analysis of the nature and composition of the 
complex. It is of interest that these two molecules interact, and it is important to 
understand the roles of a-synuclein and parkin, and their interactions, in health and 
disease. It is possible these findings may be useful in the diagnosis of PD and other 
neurodegenerative diseases.
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CHAPTER SEVEN -  RESULTS
7 An ELISA method for detection for TDP-43
7,1 Introduction
In 2006 it was discovered that the TAR DNA binding protein (TARDBP), TDP-43, 
was the target protein in the ubiquitinated cytoplasmic inclusions in neurones of 
certain histological forms of frontotemporal lobar degeneration (FTLD), known as 
FTLD-ubiquitinated (FTLD-U), and also in motor neurone disease (MND) (Arai et al. 
2006; Neumann et al. 2006). Prior to this discovery, little was known of the function 
of this protein apart from it having a role in nuclear transcription in relationship to 
alternative splicing or exon skipping (Buratti et al. 2004; Wang et al. 2004). Now, the 
involvement of TDP-43 in the ubiquitinated lesions of FTLD-U and MND has been 
fully confirmed (Cairns et al. 2007; Cairns et al. 2007; Davidson et al. 2007; 
Mackenzie et al. 2007; Tan et al. 2007). Importantly, TDP-43 lesions are 
characteristically seen in patients who have inherited forms of FTLD, for example 
those with mutations in the progranulin gene (PGRN) (Boeve et al. 2006; Pickering- 
Brown et al. 2006; Snowden et al. 2006; Mackenzie 2007). Conversely, in those 
patients with other inherited fonns of FTLD, such as those with mutations in the tau 
gene (MAPT), or those with sporadic illness associated with Pick body type histology 
(where the underlying histology is based on aggregated tau proteins), no such TDP-43 
pathology is seen (Davidson et al. 2007). It is also of note that other studies have 
shown that TDP-43 pathological changes can also be present in around a quarter of 
patients with AD (Amador-Ortiz et al. 2007), and also prevalent in patients with DLB 
(Nakashima-Yasuda et al. 2007), or with parkinsonism-dementia complex of Guam 
(Hasegawa et al. 2007).
Therefore, it is conceivable that a pathological involvement of TDP-43 in 
neurodegenerative disease could far outstretch the confines of FTLD-U and MND. 
Clinically, around 70% of FTLD patients show behavioural and personality changes, 
which together are known as frontotemporal dementia (FTD) (Neary et al. 2005).
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Pathological studies, both prospective and retrospective, have suggested that around 
half of all FTD cases are either tau-positve, TDP-43-negative histology, the other half 
being ubiquitin-positive, TDP-43-positive (Lipton et al. 2004; Mott et al. 2005; Shi et 
al. 2005, Mackenzie et al. 2006; Davidson et al. 2007). At present, it is not possible to 
differentiate which group a patient with FTD would belong to, based on clinical 
symptoms alone. Only when a patient with FTD has inherited either a MAPT or PGRN 
mutation can tau or ubiquitin/TDP-43 based histology can be inferred. Theoretically, 
blood levels of TDP-43 may serve as a biomarker that could distinguish between 
histological subtypes of FTLD. This would be important in the future development of 
drugs aimed at preventing neuronal lesions in these diseases. To that extent, an 
ELISA-based assay has been developed to test whether TDP-43 can be detected in the 
blood of patients with FTD or AD.
7.2 Identifying suitable antibodies to detect TDP-43
An ELISA to detect TDP-43 was developed. Initially, suitable antibodies for detecting 
the protein in plasma were identified. The two available antibodies that were specific 
for TDP-43 were investigated in the roles of both capture and detection. Subsequently, 
the optimal conditions for a TDP-43 ELISA assay were investigated. The antibody 
concentrations used were the manufacturers’ recommended starting dilution for 
ELISA analysis. Anti-TDP rabbit polyclonal antibody was diluted to 1:100, and anti- 
TDP-43 mouse monoclonal diluted to 1:200. Recombinant TDP-43 protein was 
diluted to 0.05 pg/ml and 0.005pg/ml, and utilised in the investigation, along with 
PBS as a blank control. The combinations of the two antibodies, both in capture and 
detection, are shown in figure 7.1. (The PBS, which was used as a negative control, 
gave background absorbance that was deducted from the absorbance values from the 
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Figure 7.1 Optimisation of antibodies for TDP-43 ELISA
The results revealed that the best combination of antibodies for the TDP-43 detection 
assay was the monoclonal antibody for capture, and the rabbit polyclonal antibody as 
the primary antibody for detection (figure 7.1).
7.3 Optimising the antibody concentrations
Experiments were undertaken to determine the difference in ELISA detection/signal 
levels, when the capture antibody and the detection antibody are at different 
concentrations. The concentrations investigated were taken from the manufacturers’ 
recommended dilution ranges for ELISA’s. They were 1:100, 1:200, 1:1000, 1:10 000 
and 1:20 000. Recombinant TDP-43 at a concentration of 0.05pg/ml was captured 
then detected with the different combinations of the different antibodies. The optimal 
concentrations for each antibody giving the best signal to noise ratio, in both ELISA’s, 
are summarised in table 7.1.
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Table 7.1 Optimal concentrations of antibodies for an ELISA to detect TDP-43
Antibody C oncentration (Dilution)
C ap tu re  of TDP-43 Mouse monoclonal 0.2 pg/well (1:1000)
D etection o f TDP-43 Rabbit polyclonal 0.2 pg/well (1:1000)
7.4 Standard curve for ELISA measuring total TDP-43
The ELISA method to measure total TDP-43 was used to measure absorbencies at 
different concentrations of recombinant TDP-43 dissolved in PBS, ranging between 
0.001 (ig/ml and 2pg/ml. The recombinant a-synuclein was captured with mouse 
monoclonal anti-TDP-43 and detected with rabbit anti-TDP-43 antibody. This data 
was used to create a standard curve (figure 7.2).










Figure 7.2 Standard curve for the TDP-43 ELISA using recombinant 
TARDBP antigen (pg/ml) at known concentrations from 0.0003 pg/ml to 0.1
pg/ml
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The ELISA standard curve, polynomial (order 2), is relatively linear between the 
TARDBP antigen concentration ranges of 0.0003-0.1 pg/ml. At very low 
concentrations the assay is not accurate, and at values above 0.1 pg/ml the ELISA 
plateaus off as the assay starts to saturate. This standard curve will enable an 
estimation of the TDP-43 concentration in each blood plasma sample.
It was noted however, that these values may not be a true estimation of TDP-43 
concentration, as the recombinant TDP-43 is dissolved in PBS alone, i.e. not in the 
presence of other proteins. The other proteins present in plasma may have an 
inhibitory effect on the assay. A more biologically representative standard curve 
would be gained if the recombinant TDP-43 was assayed, dissolved in a plasma 
sample that had previously been determined as lacking TDP-43.
7.4.1 ELISA TDP-43 detection levels in PBS, and human plasma
To determine whether the other proteins in biological samples, for example blood 
albumins, effect the sensitivity of the measured ELISA absorbance value, known 
concentrations of the recombinant TDP-43 protein ranging from 10 pg/ml down to 0.1 
ng/ml were dissolved in PBS and assayed for TDP-43 as previously described. Each 
concentration was prepared in triplicate to calculate a standard error. Along side this 
experiment, the assay was repeated using TDP-43 dissolved in human plasma. The 
two sets of data can be compared to see if the high concentrations of other proteins 
affect the sensitivity of the assay.
The ELISA can detect protein levels as low as 0.001 pg/ml when the recombinant 
TDP-43 is dissolved in PBS alone. However, the sensitivity of the assay is slightly 
reduced when the recombinant protein is mixed with plasma (figure 7.3). It is possible 
that the detection antibody experiences a “masking” effect due to the presence of the 
other proteins present in the plasma. However, the sensitivity of the assay at higher 
concentrations above 0.01 pg/ml, the measured absorbance values are very similar. 
Therefore, it was decided that this time the plasma samples would not be assayed for
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protein content and concentration adjusted to a standard (as was the case when the a- 
synuclein/parkin ELISA’s were carried out).
3.5
□  TDP-43 in PBS 
■  TDP-43 in plasma
100 10 1 0.1 0.01 0.001 0.0001 0.00001 
TDP-43 concentration (|ig/ml)
Figure 7.3 ELISA to detect recombinant TDP-43 when dissolved in PBS, and 
also in a previously assayed plasma sample known to have very low TDP-43
concentration
7.5 Detection o f TDP-43 in human plasma
At present, there are no procedures, blood analyses or other in vivo tests, which can 
definitely specify a diagnosis of any dementia syndrome. Diagnosis of dementia is 
made by clinical, neuropsychological and radiological testing, and various levels of 
probability are ascribed (eg possible/probable AD) according to consensus guidelines. 
A biochemical assay that could detect differences between neurodegenerative 
diseases, including AD, FTLD, and the various subtypes of FTD would be of immense 
diagnostic value. A diagnostic test could be highly significant in the future 
development of therapeutic and preventative drugs aimed at removing or averting the
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intraneuronal inclusions of tau or TDP-43 proteins. Blood levels of TDP-43 could 
theoretically be such a biomarker.
Presently, it is not known if TDP-43 is actually present in plasma in either normal 
control subjects, or individuals with a neurodegenerative condition. If TDP-43 is 
detectable in plasma, then the relative amount of the protein might be associated with 
a particular disease state. These questions are investigated, using the developed 
ELISA-based assay, to observe any TDP-43 in the blood plasma of people with 
different neurodegenerative diseases and control subjects, and if  present whether this 
has any utility in discriminating between different diseases, or types of disease.
7.5.1 Measuring total TDP-43 in plasma from patients with neurodegenerative 
diseases, and control samples
The total amount of TDP-43 protein from 328 plasma samples was determined by 
ELISA (see table 8.2). 102 of the samples were from patients with a AD, 35 were 
from patients with FTD, 34 with LBD, 16 with MND, 12 with FTD + MND, 11 with 
PA, 11 with SD, 10 with PD, 7 with CBD, and 85 control subjects. The levels of 
absorbance when patient plasma was assayed, using the previously designed TDP-43 
ELISA, for patients in the different disease groups, can be compared to levels in 
control plasma samples from individuals with no neurological disease.
The TDP-43 standard curve could then have been utilised to estimate the TDP-43 
concentration in individual samples. However, it was decided not to calculate this, but 
rather use the “raw” absorbance data. There were two reasons for this. Firstly, it was 
known that the ELISA may not be very accurate at very low concentrations of protein, 
and secondly, the plasma absorbance readings above 2.1 are above the calibrated 
range and were saturated. Any calculation using a measured absorbance value of over
2.1 and the standard curve equation would have produced an inaccurate protein 
concentration. In order to achieve a more reliable estimation of TDP-43 concentration, 
those plasma samples with a high absorbance would have to be diluted down with 
PBS and assayed again. This was not carried out as the available residue plasma 
volumes were too small.
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Table 7.2 Demographics of neurological plasma and control samples examined in this study (n/a = not 
applicable, na* = data not available)
Dem entia Patients Disease Age of G ender;
G roups (n) D uration Onset M :F
(years) (years) %  : (n)
AD 102 2.90 ± 1.82 61.53 ±9.41 51.9:48.1 (53:49)
FTD 35 2.74 ±2.06 69.66 ±8.42 48.6:51.4(17:18)
MND 16 3.00 ±3.25 61.21 ± 10.12 80.0:20.0(12:03)
FTD + MND 12 4.81 ± 1.60 61.81 ±9.15 50.0:50.0 (06:06)
PA 11 5.72 ±2.57 64.00 ±9.31 54.5:45.5 (06:05)
SD 11 5.81 ±2.31 58.36 ±4.84 45.5:54.5 (05:06)
LBD/DLB 34 3.09 ±2.42 66.93 ± 8.59 73.5:26.5 (25:09)
VASC 3 3.66 ±2.08 61.66 ±2.51 66.7:33.3 (02:01)
CBD 7 3.71 ± 1.79 61.00 ±9.89 42.9:57.1 (03:04)
PD 10 na* na* 70.0:30.0 (07:03)
HD 2 3.50 ±0.70 59.50 ± 0.70 50.0:50.0 (01:01)
Controls 85 n/a n/a 43.5:56.5 (37:48)
The ELISA data for all groups (table 7.3) is shown in a chart in figure 7.4 a) and b), 
again as a box-whisker plot in figure 7.5.















o f samples 
over the 0.11 
“ norm al”
Controls 85 0.02 - 0.00 0.32 8.8%
AD 102 0.13 6.5 X 0.02 0.33 23%
FTD 35 0.260 13 X 0.11 0.52 46%
MND 16 0.090 4.5 X 0.03 0.15 31%
FTD+MND 12 0.24 12 X 0.03 0.43 33%
PD 10 0.06 3 X 0.01 0.12 20%
SD 11 0.09 4.5 X 0.09 0.12 36%
LBD/DLB 34 0.07 3.5 X 0.05 0.07 25%
VASC 3 0.04 2 X 0.01 0.07 n/a
CBD 7 0.08 4 X 0.05 0.08 n/a
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Figure 7.4 a) Dementia Group mean absorbance values. The line represents 
the 0.11 ‘cut o ff  point of ‘normal’ TDP-43 values; b) The percentage of patients 
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Figure 7.5 Box-whisker plots for the plasma ELISA results
The length of the box represents the interquartile range of the sample, the line drawn across the box the
median and outliers being denoted by dots.
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Regarding the ELISA data from the control plasma samples (see table 7.3 and figures 
7.4 and 7.5), on most occasions, TDP-43 is barely detectable with an average 
absorbance (OD) value of 0.02 (±0.32), with only 8 subjects (8.8%) having values 
exceeding 0.11. This value was chosen as an upper “cut o ff’ point of a “normal” range 
of TDP-43 values, as it corresponds to the 99% upper bound confidence interval for 
the mean.
TDP-43 was below “normal” values in 79 AD patients (78%), although 23 patients 
(22%) had values that exceeded this cut off. In FTD, 16 out of 35 patient plasmas 
assayed (46%) had an absorbance value in excess of 0.11. However, the proportion of 
patients with “high” TDP-43 values across each group (see table 8.3) differed 
significantly.
Mean absorbance values for control subjects compared with those of patients with a 
neurodegenerative disease revealed differences (see table 7.3).
All data were analysed using SPSS v 14.0. As the distribution of absorbance values 
was not normal, i.e. it was positively skewed according to Kolgomorov-Smimov test, 
non-parametric Kruskal-Wallis was employed throughout to compare groups. 
Kruskal-Wallis tests whether the means of two, or more, sets of unrelated 
measurements are different from each other. The post-hoc Mann-Whitney test was 
used when the results of the previous test revealed significant group differences. 
Mann-Whitney tests whether the medians of two unpaired sets of measurements are 
different from each other.
Table 7.4 Krustal-Wallis test for control subjects with other groups
Disease groups tested against controls x2 p value
All disease groups 6 6 .1 < 0 . 0 0 1
AD and FTD 53.2 < 0 . 0 0 1
AD and (FTD, 
FTD±MND, PA,SD)
57.8 < 0 . 0 0 1
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Controls and patients with FTD and AD were significantly different by Kruskal- 
Wallis test (% — 53.2; p<0.001). The differences were also significant when 
comparing the control group to both AD and FTD groups {£  = 53.2; p<0.001), and 
also when comparing AD with the disease groups pathologically associated with TDP- 
43.
Table 7.5 Post-hoc Mann-Whitney test
Disease group p value
Controls and AD < 0 . 0 0 1
Controls and FTD < 0 . 0 0 1
FTD and AD 0.037
Controls and FTD+MND 0 . 0 0 1
Controls and PD 0.008
Controls and SD 0 .0 0 1
Controls and LBD/DLB < 0 . 0 0 1
Post-hoc Mann-Whitney tests reveal that the median values for the AD, FTD, 
FTD+MND, SD and DLB groups are significantly different from controls (p<0.001). 
Differences between controls and the PD group are still significant (p = 0.008), with 
the median absorbance in FTD group being significantly greater than that in AD 
(0.037). However, if no correction was applied to these comparisons there would be a 
chance of 0.3017 (30.17%) of finding one or more significant differences in 07 tests. 
Bonferroni's adjustment of lowering the alpha (p value) for each test to 0.007 (at a 
mean correlation of zero giving the full Bonferroni adjustment), still allows five out of 
seven of the above tests to be significant.
Further statistical analysis was undertaken to investigate whether or not there was an 
association between the duration of disease and TDP-43 levels. Spearman’s Rank was 
employed to reveal any rank correlation between the two variables.
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Only the main groups were considered. Each disease group was analysed twice. First, 
all the cases were taken into account in the calculation, and secondly, only the values 
within each group that exceeded the 0.11 cut off were used.
Table 7.6 Spearman’s Rank Correlation data
To test whether there is a relationship between TDP-43 levels and duration of disease, for all samples, 
and then for only those values over the “normal” 0.11 “cut o ff’




Table 7.7 Spearman’s Rank Correlation data
To test whether there is a relationship between TDP-43 levels and age on onset of the disease, for all 
samples, and then only for those with a value exceeding the “normal” 0.11 “cut o ff’.




There is no clear association between duration of disease and TDP-43 levels, but there 
was a trend towards higher TDP levels with later age of onset in AD (Sig. = 0.090). 
This is interesting as it goes with tendencies for age of onset to be later in AD cases 
with TDP pathology compared to those without. Although this figure is not 
significant at the 0.05 cut off, it does suggest that there may be a chance of finding a 
significant effect with a larger sample size, which may be followed up on in the 
future.
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7.5.2 Immunoprecipitation of TDP-43 from human plasma
A hum an plasm a sample that gave a high absorbance reading when assayed with the 
TDP-43 ELISA, and also a sample that gave a very low signal, were added to beads 
cross-linked with rabbit polyclonal anti-TDP-43 antibody and incubated at 4°C 
overnight. Any captured protein was eluted from the beads by boiling in sample 
loading buffer. The eluted proteins were separated on SDS-NuPAGE 4-12%  gradient 
gels and transferred to nitrocellulose membranes. The m embrane was probed with 
m ouse monoclonal anti-TDP-43 antibody. Figure 8.6 shows the detection o f  a band at 
approxim ately 43 kDa in lane b that corresponds to full length TDP-43. This band is 
present in the elute from the high absorbance plasma immunoprecipitate, but is absent 






a b e d
Figure 7.6 Detection of TDP-43 in human plasma
Human blood plasma samples were incubated with magnetic Dynabeads crosslinked to anti-TDP-43 
polyclonal antibody and the resulting immunoprecipitates were fractionated on SDS-NuPAGE gels, 
transferred to nitrocellulose and probed with the monoclonal anti-TDP-43 antibody. Lane a, molecular 
weight markers (kDa); lane b, a high TDP-43 concentration plasma sample; lane c, empty lane; and 
lane d, a low TDP-43 concentration plasma sample.
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7.5.3 Detection of TDP-43 from human plasma by Immunoblotting
Plasm a samples from 3 patients with a neurodegenerative disease that gave a high 
absorbance reading when assayed with the TDP-43 ELISA, and also 3 samples that 
gave a very low signal, were prepared for immunoblotting. 3 pi o f plasma was boiled 
for 3 m in with 20pl LDS sample buffer and 2pl DTT, o f which 8pl was loaded onto 
SDS Nu-PAGE 4-12% gel. Recombinant TDP-43 was run as a positive control (the 
recom binant protein is a protein fragment with a GST tag, MW = 53.4kD).
A m em brane was probed with mouse monoclonal anti-TDP-43 antibody. Figures 8.7 
shows the detection o f a band at approximately 43 kDa that corresponds to full length 
TDP-43 and also bands at approximately 25 kDa that corresponds to TDP-43 
fragments. However, it should be noted that these bands are present in both the high 
absorbance plasma immunoprecipitate (figure 7.7, lane d,e,f), and also originating 









Figure 7.7 Detection of TDP-43 in human plasma
4-12% NuPAGE gradient gel showing analysis of plasma proteins by immunoblotting using anti-TDP- 
43 monoclonal antibody. Lane a, Magicmark molecular weight markers (Invitrogen); lane b, TDP-43 
antigen at MW = 53.4kDa as a positive control; lane c, empty; lanes d-f, human plasma samples that 
were high TDP-43 content; lane g, empty; lanes h-j, human plasma samples that were low TDP-43
content.
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This banding pattern is consistent with the immunoblot analysis performed on the 
brains of patients with FTLD-U (Arai et al. 2006; Neumann et al. 2006), revealing 
pathological TDP-43 immunoreacive bands at approximately 24, 26, 45 and high MW 
bands. From figure 8.7 it is clear that a band at 43 kDa is common to all plasma 
samples, although the 24/26 kDa bands are more prominent in the “high” TDP-43 
samples (lanes d - f )  than in the “low” samples (lanes h-j). The 24/26 kDa molecular 
weight bands may represent proteolytically cleaved fragments, or alternatively spliced 
isoforms of TDP-43. If the former, it is not clear whether these are generated from 
wild-type TDP-43 or from the hyperphosphorylated pathological 45 kDa protein (Arai 
et al. 2006; Neumann et al. 2006).
This immunoprecipitation experiments and plasma immunoblots identifiy and confirm 
the presence of TDP-43 in human blood plasma and further support and validate the 
ELISA data.
7.6 Discussion
In this study we have shown for the first time that the TAR DNA-binding protein can 
be detected within plasma of normal control subjects, as well as individuals with 
neurodegenerative diseases such as AD, FTD, DLB, MND and SD. The ELISA data 
indicates that TDP-43 is present at extremely low concentrations, or is absent, in the 
vast majority of normal people, and in these diseases there are substantial numbers of 
patients in whom TDP-43 is likewise barely present.
7.6.1 Possible methods of secretion of TDP-43
TDP-43 is a nuclear transcription factor, and so would be expected to normally be 
present within cell nuclei. Therefore its presence in neuronal nuclei in FTLD-U, like 
in other disorders is not surprising. However, it has been shown to be absent from
137
glial cell nuclei (Caims et al. 2007) suggesting that this protein only operates in 
neurones.
It has been suggested that pathological TDP-43 redistributes from the nucleus to the 
cytoplasm, producing the characteristic neuronal cytoplasmic inclusions (Neumann et 
al. 2006). However, it may be the case that the TDP-43 cannot cross the nuclear 
membrane, and therefore aggregates within the cytoplasm. The latter argument is 
consistent with the results of immunoblotting (Arai et al. 2006; Neumann et al. 2006), 
demonstrating that pathological TDP-43 is hyperphosphorylated, which could prevent 
it being able to cross through the nuclear envelope.
The mechanism(s) by which TDP-43 is secreted from the cell is unknown, but the 
reasoning as to why it is detected in plasma could be similar to the discussions 
presented in Chapter 4 with the case of a-synuclein.
7.6.2 Detection of total TDP-43 in human blood plasma
Group comparisons of ELISA absorbance levels reveal a highly significant increase 
(approximately 13-fold) in mean plasma TDP-43 levels in FTD compared to controls, 
whereas in AD the mean TDP-43 plasma level was about 6.5-fold increased (table 
7.3). The validity of the ELISA method is supported by the immunoblotting results 
(figure 7.7). In accord with the ELISA data, a single immunoreactive band migrating 
at 43 kDa, which corresponds precisely to the molecular weight of full-length TDP- 
43, was detected only in the high-reading plasma sample and not in the low-reading 
sample. This result not only confirms the specificity of the antibody pair employed for 
the sandwich ELISA, but also shows that the readout from the ELISA accurately 
reflects the levels of TDP-43 present in plasma.
Histological studies show that around 50% of patients with FTD have TDP- 
43/ubiquitin-based histology (Caims et al. 2007; Davidson et al. 2007). Therefore, it 
could be assumed that a similar proportion of patients would be present in the FTD 
sample group. If this histology was present in the brain, and there was secretion of 
TDP-43 into the plasma, then again, it may be expected that a similar proportion of
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patients would have “high” TDP-43 levels (i.e. readings above the 0.11 absorbance 
level corresponding to the 99% upper confidence interval for the control group). The 
proportion of FTD patients with “high” TDP-43 levels in plasma is 46% (table 7.3) 
which is comparable to the —50% seen at autopsy. Likewise in AD, it is identified that 
around 20-25% of patients with this form of dementia have TDP-43-based pathology 
(Amador-Ortiz et al. 2007), and therefore again it may be assumed that a similar 
proportion of AD patients in our group sample would have high plasma TDP-43 
levels. The proportion of such patients in our AD group was actually 23% which again 
mirrors what would be predicted from histological studies. Therefore, the proportion 
of patients showing high plasma TDP-43 levels in both FTD and AD closely match 
the proportions that would be predicted from histological studies.
Regarding the control group, the few elderly subjects with high TDP-43 levels 
(figures 7.3 and 7.5) may have high incipient neurodegenerative disease, most likely 
AD, since it has been shown that a very high proportion of mentally normally elderly 
subjects show at autopsy some degree of Alzheimer-type pathological changes in the 
brain, for example senile plaques and neurofibrillary tangles.
7.6.3 In conclusion
The proportions of patients with FTD and AD showing “high” TDP-43 plasma levels, 
and those displaying TDP-43 pathological changes at autopsy are statistically similar. 
Therefore it could be implied that plasma measurement of this protein could infer 
TDP-43 within the brain of that FTD or AD patient. However, it may be that these 
numerical associations are simply by chance. This relationship would be confirmed if 
autopsy follow-up of patients with AD or FTD with the high plasma levels were 
available. However, this may not be possible for several years, if at all, as the patients 
investigated here are mostly in the early stages of the disease. A different approach 
would be to compare plasma TDP-43 levels of FTD patients with the M A P I of PGRN 
mutations. It is known from histological studies that FTD patients bearing the MAPT 
mutation and tauopathy do not show TDP-43 pathological changes in their brains 
(Davidson et al. 2007), whereas those with PGRN mutations do (Baker et al. 2006;
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Boeve et al. 2006; Mackenzie et al. 2006; Pickering-Brown et al. 2006; Snowden et al. 
2006; Davidson et al. 2007). Unfortunately, there was only one bearer of the PRGN 
mutation within the present patient groups, and not one with the MAPT mutation, so 
this comparison was not possible.
The functional significance of the presence of TDP-43 pathology in the brains of 
patients with neurodegenerative diseases is not known. However, because brain TDP- 
43 levels could be predicted in such patients by this ELISA test, such knowledge may 
be of benefit in the future regarding the management or prevention of these diseases. 
This data suggests that measurement of TDP-43 protein levels in plasma may indicate 
those patients with TDP-43 pathology within the brain, as opposed to those with tau- 
based histological changes, even if it does not discriminate between clinical 
neurodegenerative diseases. With the advent of either tau-based or TDP-43-based 
therapies in the future, knowing who could potentially benefit from which treatment 




Neurodegenerative disorders pose a significant public health burden which will only 
increase as medical and technological advances ensure that the average life 
expectancy continues to increase. For example, the incidence and prevalence of PD 
increases with advancing years, occurring in about 1% of people over the age of 65 
years. Future demographic predictions project that the population aged over 65 will 
approximately double by the middle of the century, with the corresponding increase in 
individuals suffering from PD, not to mention all the other neurodegenerative 
disorders. The World Health Organisation expect that at this time, the number of 
individuals suffering from neurodegenerative disorders will exceed cancer as the most 
common cause of death (www.who.int/en/). Of course, the situation will be made 
worse if there are no treatments available to address the problem of progressive 
neurodegeneration, as the existing drugs are symptomatic at best with surgical 
therapies being only transiently effective. As of yet, the biochemical processes that 
underlie these diseases, and result in the formation of protein aggregates, are not fully 
understood. Therefore it is clear that the nonnal and the pathological processes of the 
brain should be fully investigated, and the functions of the implicated proteins 
identified, as these may provide potential therapeutic agents, or be useful as 
biomarkers for the disease.
The a-synuclein “self-aggregation hypothesis”, proposes that the soluble, unfolded 
protein oligomerises to form various structured intennediates, seeding aggregation to 
form insoluble, amyloid-like fibrils. These small intermediates, the soluble oligomers 
in the aggregation process, can confer synaptic dysfunction, whereas large, insoluble 
deposits may function as “reservoirs” of the bioactive oligomers. The distinct protein 
aggregates that are found in AD, PD, HD and prion diseases are implicated in these 
disorders. The “self-aggregation hypothesis” was exemplified on the discovery that a 
fibrillar form of the presynaptic protein is the major component of LB’s, in the 
insoluble inclusions characteristic of PD. This emerging concept may also apply to 
AD where A0 oligomers adversely affect synaptic structure and plasticity. The same
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hypothesis could be proposed for TDP-43, which is the major protein present in the 
insoluble inclusions seen in FTLD-U. An array of environmental factors, plus three 
gene mutations associated with familial PD that result in amino-acid substitutions in 
a-synuclein (A30P, A53T and E46K), have been shown to accelerate the process in 
vitro and in transgenic animal models of PD. It is therefore widely accepted that 
aggregation of a-synuclein is central to the pathogenesis of PD, even though the toxic 
form of a-synuclein and its mechanism of neurotoxicity remain unknown. In the TDP- 
43 proteinopathies (including cases of sporadic and familial FTLD-U, FTD/MND and 
sporadic MND) the scenario is different in that it is a mutation in the progranulin 
gene that is, on the whole, thought to be responsible for the disease, although the 
protein that aggregates is not the progranulin protein, but TDP-43. It is possible that 
abnormal metabolism mediated by progranulin may play a pivotal role in 
neurodegeneration. Again, the toxic form of TDP-43, the method of aggregation and 
the mechanism of toxicity are unknown. Research into other neurodegenerative 
diseases indicates that a broadly similar process of neuronal dysfunction is induced by 
diffusible oligomers of misfolded proteins.
The self-aggregation hypothesis does not explain why ubiquitous proteins such as a- 
synuclein aggregate specifically in dopaminergic neurones of the substantia nigra in 
PD, or why TDP-43 aggregates in either cytoplasmic, neuritic, or nuclear inclusions in 
FTLD-U. Why age is a risk factor for these disorders is not clear, although there are 
several lines of evidence that suggest elevated oxidative stress is an issue, and 
oxidative damage to biomolecules in the SN in PD is involved. This has led to the 
proposal that oxidative stress may contribute to the death of neuronal cells in PD, with 
dopaminergic neurones being particularly susceptible due to high levels of pro­
oxidants such as dopamine. Oxidative stress in the brain increases with age as a result 
of the accumulation of redox-active metals such as Fe and Cu (Morita et al. 1994; 
Takahashi et al. 2001; Maynard et al. 2002). This indicates that a breakdown in metal 
homeostasis could predispose to oxidative stress and age-related neurodegenerative 
diseases.
ELISA’s were developed using different antibodies for capture and detection, to detect 
a-synuclein, the a-synuclein/parkin complex, the parkin protein and TDP-43. More
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extensive clinical studies will be required to investigate whether the ELISA’s would 
be useful as a diagnostic tool or whether it could be utilised to track the disease 
progression, e.g. in drugs trails. It would be interesting to determine if there was a 
correlation between detection of oligomers and the severity and/or stage of the 
disease. Studies on blood samples from familial cases or from transgenic mouse 
models would be useful for validating the ELISA as an early diagnostic method. It is 
possible that medication taken by patients, especially dopaminergic medication taken 
by PD patients, could influence the data (Conway et al. 2001). Studies on newly 
diagnosed patients who are not yet taking medication could indicate whether the drugs 
had any confounding effects. Moreover, the principle of the ELISA could be 
developed for other sensitive diagnostic tests, for the presence of other forms of 
protein aggregates, such as ubiquitinated TDP-43 or a-synuclein. Diagnosis of AD has 
been based on detection of phosphorylated tau protein (Vandenneeren et al. 1993) 
and Ap peptides (Seubert et al. 1992) in biological fluids, especially plasma and CSF. 
This has led to development of a commercial assay for tau protein (INNOTEST hTAU 
Ag by Innogenetics, Belgium) and also the CSF-A42 test from the same company. 
The combined use of CSF-tau and CSF-A42 markers results in some sensitivity and 
specificity for AD versus normal aging, and other neurodegenerative diseases.
Research is still in the early stages of understanding the processes of how 
neurodegenerative diseases develop, but it is apparent that a new classification of 
neurodegenerative disorders, the TDP-43 proteinopathies, has emerged, and this will 
have significant implications for the diagnosis and treatment of FTDs and ALS. This 
is understandable based on similar earlier advances in recognising mechanisms of tau, 
Ap- and a-synuclein-mediated neurodegeneration in AD and other tauopathies, as well 
as in PD and related a-synucleinopathies. In this thesis, an assay was developed to 
monitor the levels of normal TDP-43 in plasma. Further assays could also be 
developed to monitor levels of pathological TDP-43 and could lead to the 
development of diagnostic tests to distinguish TDP-43 proteinopathies from other 
clinically similar neurodegenerative disorders. Moreover, the development of imaging 
ligands, that facilitate the detection of TDP-43 neuropathology in living individuals, 
would provide a powerful tool not only for diagnosis but also for following the 
response of patients with a neurodegenerative TDP-43 proteinopathy to disease- 
modifying therapies. However, more importantly, the recognition that TDP-43
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pathology underlies and links several neurodegenerative disorders will be a significant 
driving force towards efforts to develop more effective therapies for these diseases.
Efforts have been underway over the past few years to find biochemical, 
neuropathological and genetic biomarkers for neurodegenerative diseases. This would 
enable the disease to be diagnosed at earlier stages of the disorder, often when the 
currently available treatment is more effective. The neuropathological diagnosis is 
currently the only firm diagnosis, but of course is done after autopsy. It would be 
much more preferable to have a firm diagnosis at early stages. Patients may then have 
the opportunity to receive early treatment which may slow down the progression of 
the disease. Moreover, a biomarker could not only be used to help in predicting the 
onset, or diagnosing the diseases, but also to help in overseeing the rate of 
progression, or in responding to treatment. A biomarker would be required to 
distinguish normal aging individuals experience with advancing years from dementia, 
one disorder from another with dementia, as well as to help in identifying the exact 
cause of a dementia. Therefore, the biomarkers for PD, AD, FTD and other 
neurodegenerative diseases such as ALS and HD, must be reliable and specific, and 
they should be useful in guiding clinicians to make more accurate diagnosis and better 
treatment of the disease in question.
Two biochemical markers have been very helpful in detecting the onset of PD. The 
loss of the dopamine transporter detected by PET imaging and the presence of the a- 
synuclein protein located in the Lewy body lesions, are both characteristic of PD. 
Several other biochemical markers in blood and CSF have also been proposed. A 
recent study in our laboratory has recognised decreased levels of a-synuclein in the 
CSF of aged individuals and subjects with PD (Tokuda et al. 2006). The validity of 
these markers in clinical applications is currently under investigation. The present 
study confirms previous work (Salem, 2004) that has identified a-synuclein as a 
component of human blood plasma. We investigated whether a-synuclein can be used 
as a biomarker for PD. Other work in our laboratory has been to develop a novel 
ELISA method that detects only oligomeric "soluble aggregates" of alpha-synuclein 
(El-Agnaf et al. 2006).
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The data presented in this thesis identifies parkin in plasma, and also a protein 
complex in human plasma that involves parkin and a-synuclein. In this thesis, the 
levels of two proteins implicated in PD, a-synuclein and parkin, both individually and 
complexed together, were investigated in blood plasma from patients with PD and 
other neurodegenerative diseases. The results suggest that there is a correlation 
between the levels of expression of a-synuclein, parkin and the complex in individual 
plasma samples, but no clear relationship when comparing disease and control groups 
(although the number of samples analysed is small at present). At present, levels of 
these proteins would have to be investigated further, within much larger sample 
groups, to find if they were to be useful as diagnostic indicators. However, much 
larger sample groups were assayed when investigating TDP-43 levels across control 
and disease groups. The proportions of patients with FTD and AD showing “high” 
TDP-43 plasma levels, and those displaying TDP-43 pathological changes at autopsy 
are statistically similar. Therefore it could be implied that plasma measurement of this 
protein could infer TDP-43 within the brain of that FTD or AD patient. Although the 
functional significance of the presence of TDP-43 pathology in the brains of patients 
with neurodegenerative diseases is not yet known, brain TDP-43 levels could be 
predicted in such patients by this ELISA test, and such knowledge may be of benefit 
in the future regarding the management or prevention of these diseases. The data in 
this thesis suggest that measurement of TDP-43 protein levels in plasma may indicate 
those patients with TDP-43 pathology within the brain, as opposed to those with tau- 
based histological changes, even if it does not discriminate between clinical 
neurodegenerative diseases. With the advent of either tau-based of TDP-43-based 
therapies in the future, knowing who could potentially benefit from which treatment 
could potentially be of importance.
Rapid progress towards understanding the molecular mechanisms of 
neurodegenerative disorders, such as PD and FTLD, will revolutionize drug discovery 
for these conditions. The development of models for these disorders is accelerating 
efforts to translate insights from neurodegenerative mechanisms into disease- 
modifying therapies. However, there is an urgent need for biomarkers to accurately 
diagnose neurodegenerative disorders early in their course, when therapy is likely to 




Further work could be focused on the full characterisation of a-synuclein in plasma, as 
well as investigating the molecular composition of the a-synuclein/parkin complex 
and determining the precise nature of the interaction. Initially, the presence of parkin 
in blood plasma could be confirmed by mass spectrometry, and concentrations of the 
parkin protein could be determined when the recombinant protein becomes available, 
to enable the construction of a standard calibration curve.
The pathogenic mechanisms underlying a-synuclein/parkin pathology in the various 
neurodegenerative diseases remains elusive. The normal and pathological functions of 
the interaction between a-synuclein and parkin should be investigated, along with 
histopathological studies, and also studies as to whether the targeted 
disruption/promotion of this interaction could provide a novel approach to the 
treatment of PD.
Further biomarker studies could focus on oligomers of a-synuclein, the a- 
synuclein/parkin complex, as well as phosphorylated and ubiquitinated forms of the 
proteins.
8.1.2 FTLD-U
The pathogenic mechanisms underlying TDP-43 pathology in the various FTLD-U 
cases remain elusive; with questions regarding its presence both in the cytoplasm and 
the blood plasma remain unanswered. Previous studies of granular glial inclusions 
which were ubiquitin negative but TDP-43 positive (Caims et al. 2007) suggest that 
the pathogenic mechanisms initially involve the modification of the TDP-43 protein, 
followed by ubiquitination. Developing an ELISA method to detect ubiquinated TDP- 
43 in plasma, and/or brain tissue and comparing this data with the TDP-43 results, 
may give a better insight into the pathological processes involved in FTLD-U.
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As mentioned previously, the relationship between individuals who have “high” TDP- 
43 plasma levels, and those who show TDP-43 in the brain at autopsy could be 
followed up; however, this may not be possible for several years, as the patients 
investigated here are mostly in the early stages of the disease. A different approach 
would be to compare plasma TDP-43 levels of FTD patients with the MAPT of PGRN 
mutations, draw comparisons with the frequency of APO E e4 allele, and compare the 
age of onset of disease with plasma levels, the duration and severity of disease.
The presence of high TDP-43 levels in a good proportion of AD cases (~20%), (which 
matches the FTLD-U type TDP-43 pathology in AD), has raised the possibility of 
concurrent FTLD-U in these cases, which extrapolates into a large number of cases of 
AD worldwide being unrecognised mixed AD/FTLD-U cases (Amador-Ortiz et al. 
2007). Demographic parameters such as duration of disease or the APO E genotype 
may account for these differences. However, it may be the case that the large number 
of cases diagnosed with AD could possibly have the mixed pathology, which in turn 
may account for differences in the age of onset of disease, duration, and so on. Such a 
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